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Kurzzusammenfassung 
 
Enzymatische Untersuchungen von isolierten funktionellen Domänen aus 
iterativen Pilz-Polyketidsynthasen 
  
Der von Pilzen hergestellte Naturstoff Squalestatin S1 wird von zwei verschiedenen iterativen 
Polyketidsynthasen erzeugt, einer Hexaketidsynthase (SQHKS) und einer Tetraketidsynthase 
(SQTKS).  
Der Fokus dieser Arbeit liegt auf der chemischen und biologischen Untersuchung der 
isolierten Dehydratase (DH) und Enoylreduktase (ER) von SQTKS. Die Untersuchungen der 
ER konzentrierte sich auf eine mögliche Programmierung des Enzyms. Hierzu wurden 
verschiedene Moleküle synthetisiert, mit denen das Enzym untersucht wurde. Es wurde 
erwartet, dass diese Programmierung von anderen katalytischen Domänen, die in SQTKS 
involviert sind, unabhängig ist. Um diese Hypothese zu prüfen wurden mehrere 
Pantetheinverbindungen synthetisiert und in in vitro Versuchen getestet. Die Pantethein-
verbindungen imitierten verschiedene Zwischenprodukte der ER und das Endprodukt von 
SQTKS. In dieser Untersuchung war es möglich, Informationen über die Selektivität und 
Inhibierung des Enzyms zu erhalten. Für die Messung von kinetischen Daten wurde eine neue 
Analysemethode entwickelt.  
Für die Untersuchung der DH von SQTKS wurde das erste natürliche Substrat als 
Pantetheinverbindung synthetisiert und ebenfalls in einem in vitro Versuch bezüglich seiner 
Aktivität und Kinetik getestet. Für analytische und kinetische Messungen wurden die Methoden 
LCMS und UV-Spektroskopie verwendet. Eine mögliche Inhibierung der DH wurde ebenfalls 
getestet und analysiert.  
In einem weiteren Projekt wurde die mögliche Interaktion der isolierten ER und DH untersucht. 
Hierzu wurden verschiedene Methoden (SPR, ITC) verwendet. Außerdem wurden 
Wechselwirkungen mit Substraten geprüft, die Zwischenprodukte anderer Domänen von 
SQTKS nachahmten. Die Oberfläche von SPR-Chips wurde mit diesen Substraten modifiziert 
und mit den isolierten Enzymen gespült. Auf diese Weise konnten Interaktionen von 
verschiedenen Substraten mit der ER oder der DH gemessen werden. 
Im letzten Projekt wurde die Selektivität einer Acyl-Transferase (AT) untersucht, die im letzten 
Schritt der Squalestatinbiosynthese aktiv ist. Hierzu wurden verschiedene Vorstufen von 
Squalestatin S1, sowie verschiedene Reaktionspartner hydrolysiert. Die enzymatische 
Untersuchung und die Synthese von neuen Squalestatinderivaten bilden den Abschluss dieser 
Doktorarbeit. 
  
 
 
Abstract 
 
Enzymology of Isolated Functional Domains from Iterative Fungal Polyketide 
Synthases 
The fungal secondary metabolite Squalestin S1 is produced by two different highly 
reducing iterative polyketide synthases (HR-iPKS), a hexaketide (SQHKS) and a 
tetraketide (SQTKS) synthase. The main investigation of this thesis is focussed on the 
chemical selectivity of the isolated dehydratase (DH) and enoyl reductase (ER) domains 
of SQTKS. The isolation of these domains was performed in previous work.  
Investigations of the ER domain focused on possible mechanisms of 
programming. This programming was expected to be independent of other catalytic 
domains involved in SQTKS. To test this hypothesis several pantetheine substrates were 
synthesized and tested in vitro. Pantetheine substrates should mimic intermediates and 
the final product, squalestatin tetraketide, of SQTKS. In this investigation, it was 
possible to get information about the selectivity and inhibition of the enzyme. A new 
analysis method was developed to measure kinetic data. 
In further investigation the DH domain of SQTKS was investigated. The first 
natural substrate was synthesized as a pantetheine compound and activity of the enzyme 
was tested in vitro. Analysis methods by LCMS and UV were performed to measure 
kinetic data. Inhibition assays of the DH domain similar to the ER domain were tested 
and analysed. 
In the next project interactions of the isolated ER domain and DH domain with 
each other were tested. Also, interactions with substrates that mimic intermediates of 
other domains of SQTKS were investigated. A synthesis was developed to create 
pantetheine glycine substrates which were used to modify analytical chips for use in 
surface plasmon resonance (SPR) to develop a standard protocol to measure protein-
substrate interactions. The results of this investigation showed that the DH and ER 
domain are not specifiic to the known chemical motifs and can also interact with other 
chemical motifs which are substrates for keto-reductase (KR) or C-methyltransferase 
(C-MeT) domains. 
Finally the selectivity of an acyl transferase (AT) enzyme which acts as the last 
step of squalestatin biosynthesis was investigated using various squalestatin precursors 
synthesised by degradation of squalestatin S1 itself. This allowed the synthesis of new 
squalestatin analogues. 
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Abbrevations and Units 
 
ACP   Acyl carrier protein 
AT    Acyl-transferase 
BSA   Bovine serum albumin 
CDI   N, N’-carbonyldiimidazole 
DCM   Dichloromethane 
C-MeT  C-Methyltrasferase 
CoA   Coenzyme A 
COSY   Correlation spectroscopy 
Da   Dalton 
DH   Dehydratase 
DMAP  4-Dimethylaminopyridine 
DTT   Dithiothreitol 
EDCI   1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ER   Enoyl reductase 
FAS   Fatty acid synthase 
His-tag   Histidine tag 
HMBC   Heteronuclear multiple bond correlation 
HSQC   Heteronuclear single quantum correlation 
HPLC   High performance liquid chromatography 
HRMS   High resolution mass spectrometry 
IPTG   Isopropyl -D-1-thiogalactopyranoside 
KM   Michaelis-Menten constant 
KR   -Ketoacyl reductase 
KS   Ketosynthase 
LC   Liquid chromatography 
LCMS   Liquid chromatography mass spectrometry 
MS   Mass spectrometry 
NAC   N-Acetylcysteamine  
NADPH  Nicotinamide adenine dinucleotide phosphate 
NMR   Nuclear magnetic resonance 
PANT    Pantetheine 
PCC   Pyridinium chlorochromate 
PCR   Polymerase chain reaction 
 
 
PKS   Polyketide synthase 
ppm   Parts per million 
SNAC   S-N-acetyl cysteamine 
SQTKS  Squalestatin tetraketide synthase  
TE   Thiolesterase 
TFA   Trifluoro acetic acid 
THF   Tetrahydrofuran 
UV   Ultra violet 
VMax   Maximum rate of a reaction 
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1. Introduction 
 
Polyketides are one of the major groups of natural products. They are not essential for 
their producers and classified as secondary metabolites. Producers of polyketides are 
bacteria, fungi and plants.
[1]
 The functions of many of these compounds are currently 
unknown. However, since polyketides occur widely it is assumed that they give their 
hosts some advantage. It is hypothesised that these compounds are used for defence 
against other organisms or as signal substances for communication with other 
organisms. They might have an advantage as effect to get new living environment for 
example.
[1]
 
 Polyketides have a high structural diversity. They include aliphatic, cyclic, 
acyclic, and aromatic compounds and macrocyclic lactones. The structural diversity of 
these compounds is the reason for their biological activity. Representative examples are 
tetracycline 1 and erythromycin B 2 (Figure 1).
[1-2] 
 
Figure 1: Structure of tetracycline 1 and erythromycin B 2. 
 
1 is an antibiotic isolated from Streptomyces aureofaciens that is used against Gram 
negative and Gram positive bacteria.[3-5] 2 was first isolated from Streptomyces 
erythreus. In contrast to 1, 2 is only active against Gram positive bacteria. It is used 
against bacteria that have a resistance against -lactam antibiotics and is used as a 
replacement for penicillin.
[6]
 Other polyketides are known that are candidates for use as 
antiparasitic, antifungal and cholesterol lowering drugs.
[7-8]
 
 The reason for the diversity of polyketides is their different functionalization. 
Despite their chemical diversity all polyketides are produced by enzymes known as 
polyketide synthases (PKS). The PKS are encoded by genes, and usually PKS genes are 
found clustered in the genome with genes which encode enzymes which perform post-
PKS modification of the polyketide.
[9,10]
 These are known as tailoring steps. 
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1.1 Biosynthesis of Polyketides 
 
Polyketides and fatty acids are biosynthesised in the same way. Both are built by 
megasynthases composed of several different catalytic enzymes. The structural diversity 
of polyketides is a result of the programming of the megasynthases. A polyketide is 
formed by a PKS, which is responsible for forming a backbone of carbon atoms. The 
starter unit in most cases is acetyl CoA 3, although other starter units are known. More 
uncommon starter units are propionyl CoA 4 and benzoyl CoA 5 (Figure 2).
[11,12,13]
 
 
Figure 2: Starter units of a PKS. 
 
PKS consists of several catalytic enzymes or domains.
[11,12,13]
 Most PKS have an acyl 
transferase (AT), a ketosynthase (KS) and an acyl carrier protein (ACP). The KS 
performs the key carbon-carbon bond-forming reaction and is essential for all FAS and 
PKS. The process starts with the loading of a starter unit onto the KS domain 
(Scheme 1). For this the AT catalyses the reaction with an activated acyl unit, which is 
usually a CoA thiolester. The ACP has a phosphopantetheine group which is covalently 
bound to a strictly conserved serine residue. Acyl groups are bound as thiolesters to the 
terminal thiol of the phosphopantetheine.
[11,12,13]
 
 
Scheme 1: Loading of the KS domain with the starter unit. 
 
For elongation of the carbon chain, an extender unit is loaded onto the ACP. A typical 
extender unit for a PKS or FAS is malonyl CoA 6. This process is also catalysed by the 
AT domain. The starter unit and the extender unit then react in a condensation reaction 
similar to a Claisen condensation by loss of carbon dioxide (Scheme 2).
[14]
 This 
formation of the carbon-carbon bond is catalysed by the KS domain.
[15,16]
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The extension is performed with an inversion of the configuration at the malonyl 
carbon. In most cases this inversion is not directly observed since the extender unit is 
without substituent in the -position (Scheme 2).[15,16] 
 
Scheme 2: Extension of the carbon chain without any modification. 
 
After the chain extension it is now possible to modify the ACP-bound molecule by 
enzymatic reactions at the -carbonyl. A different catalytic domain is responsible for 
each modification step. The modifying domains are the C-methyl transferase (C-MeT, 
not present in FAS), ketoreductase (KR), dehydratase (DH) and the enoyl reductase 
(ER, Scheme 3).
[15]
 These reactions are known as the -modification cycle. In FAS the 
cycle is always completed to give a -methylene; but in PKS the cycle can be 
shortened. 
Scheme 3: The -modification cycle.  
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Nearly every functionalization requires a cofactor. In some fungal PKS the first 
modification of the carbon chain is catalysed by the C-methyltransferase (C-MeT). The 
C-MeT can transfer a methyl group to the acidic -position of the polyketide. A 
deprotonation of this position results in an enolate, and a nucleophilic SN2 reaction 
follows in which the -carbon attacks the methyl group of S-adenosyl methionine 
(SAM) 12 (Figure 3). At the methylation stage, and in the two subsequent reductions, 
new stereocenters are formed, therefore R- and S-isomers of the different PKS 
intermediates are possible. The absolute configurations of the stereogenic centers are in 
some cases predicted by different amino acid residues of the active site of the protein.
[17] 
 
 
Figure 3: Known cofactor for methylation reactions: S-adenosyl methionine 12. 
 
The KR domain acts after the C-MeT and reduces the -carbonyl moiety to a -hydroxy 
intermediate. Cofactors that are used during this process are nicotinamide adenine 
dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) 13 
(Figure 4). Both are known for a hydride transfer and can be used in the reduction 
step.
[17]
  
 
Figure 4: Essential structural part of NADH and NADPH 13. 
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During the reduction two stereocenters are predicted by the KR domain; the carbonyl 
can be reduced stereoselectively to L--hydroxyl- or D--hydroxyl groups. The 
stereochemistry of substituents in the -position is determined by the domain after the 
reduction. In total four different stereochemical outcomes are possible.
[18,19,20] 
The next modification step is performed by the DH domain which eliminates the 
-hydroxyl group. Both configurations (cis and trans) of the resulting double bond are 
known. The stereochemical information that was introduced in the previous (KR) step is 
lost by this elimination.
[21,22]
 Finally, reduction of the  olefin is catalysed by the ER 
domain. The carbon-carbon double bond is reduced in the presence of the cofactor 
NADPH 13. The enzyme can introduce two new stereocenters similar to the KR 
domain.
[22]
  
 After each -modification cycle the newly functionalised chain is passed back to 
the KS for further extension. Extensions and -modifications are continued until the 
chain reaches its predetermined length. Finally, the elongated carbon chain is cleaved 
from the PKS. This is usually achieved by a thiolesterase (TE), although other types of 
release mechanisms, including reductive methods, are also known.
[23,24]
 Intramolecular 
macrocyclisation is a common release mechanism. In this release an internal hydroxyl 
group or amino group performs the nucleophilic attack.
[24]
 Examples are 
10-deoxymethynolide 15 and narbonolide 16 (Figure 5) which are the precursors of the 
antibiotics methymycin and pikromycin respectively.
[25,26]
 
 
Figure 5: Structures of 10-deoxymethynolide 15 and narbonolide 16.
 
 
The mechanism of TEs involves initial transfer of the polyketide to a catalytic serine 
residue to form an intermediate ester. This is then attacked either by water (to form a 
carboxylic acid), or by an internal nucleophile to form a macrocycle (Scheme 4).
[26,27]
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Scheme 4: Proposed mechanism of the thiolesterase.
[27] 
 
1.2 Architectures of FAS and PKS 
 
The architecture of FAS is well studied, and some FAS molecules have been fully 
crystallized and investigated. Two architectures of FAS are known, and these are 
classified as Type I and Type II systems. In Type I systems the catalytic domains are 
covalently linked to form one or two very large single molecules. In Type II systems the 
catalytic domains are separate proteins, but it is very likely that they assemble via non-
covalent interactions to form functional complexes which are similar to the Type I 
systems.
[28] 
 Investigations of PKS structures are further behind the studies of FAS. It has not 
yet been possible to crystallize a complete PKS. Some single domains have been 
successfully crystallized and investigated. Compared with FAS the same domains, 
active residues, and cofactors are observed, and PKS are classified in the same way as 
FAS, into Type I and II systems.
[21,28,29] 
 Type I PKS are found in bacteria and fungi. They consist of large multi domain 
megasynthases. The domains are covalently bound together.
[1,30]
 Type I PKS usually 
form dimers. Type I PKS are further subdivided into iterative and modular types (see 
below for details). The iterative Type I PKS are further sub-divided into non reducing 
(NR-PKS), partially reducing (PR-PKS) and highly reducing PKS (HR-PKS) types. 
Modular Type I PKS can be broadly divided into cis-AT and trans-AT types.
[2,11,31]
 
 
7 
 
 Type II PKS are mono domain enzymes that come together and form a non-
covalent complex which functions iteratively. This complex consists of five to ten 
individual enzymes. The synthesized polyketides normally have a chain length of 16 to 
24 carbons. In most cases the chain length is controlled by the KS domain. Different 
amino acid residues seem to be important for chain length control. Type II PKS have 
only been found in bacteria, to date.
[32,33,34]
 A typical compound produced by a Type II 
PKS is actinorhodin 17 (Figure 6).[11]
 
 
Figure 6: Structure of actinorhodin 17.
 
 
Type III PKS are simple enzymes, an example is the chalcone synthase. Structurally 
this Type of PKS is completely independent from the other two forms. They are simple 
homodimers of ketosynthases that do not use an ACP or AT. They react directly with 
CoA-bound substrates in a decarboxylative Claisen condensation. Usually aromatic 
compounds like p-coumaroyl-CoA 18 are the starter units, but malonyl-CoA 6 can also 
be used as a starter unit. Type III PKS enzymes act in an iterative way and produce 
small aromatic metabolites like the chalcone 19 (Scheme 5) by a PKS Type III.
[11,35,36]
 
 
Scheme 5: Extension of like p-coumaroyl-CoA 18 by 6.
[36]
 
 
1.2.1  Modular Type I Polyketide Synthase 
 
Modular PKS form an assembly line with several active modules (Scheme 6). A module 
contains all required extension and -processing domains for a single round of 
biosynthesis. It is possible to read these mPKS like a book and to get all information 
about the several extension and reducing steps. One of the most investigated synthases 
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is the PKS of 6-Deoxyerythronolide B 20 (DEBS), the backbone of 
erythromycin B 2.
[37,38,39]
 DEBS has three large proteins (DEBS1- DEBS3) that can 
each be divided into two or three modules.  
 
Scheme 6: Biosynthesis of 6-Deoxyerythronolid B 20 and erythromycin B 2. 
 
Each module has a certain set of domains that are responsible for the catalytic reactions. 
The starter unit propionyl CoA 4 is loaded onto the synthase by a specialised AT-ACP 
didomain which makes up the initial loading module. This is passed on to module 1 
which loads a methyl malonyl extender unit (AT), catalyses carbon-carbon bond 
formation (KS) and then reduces the -ketone (KR). As is usual, the intermediates are 
attached to the ACP.
[37,38,39]
 The programming of -processing is controlled by the 
presence or absence of -processing domains in each module. Only DEBS module 4 has 
a complete set of domains to reduce the keto function to a methylene. The final module 
containes a thiolesterase which catalyses the release of the polyketide by formation of a 
macrocycle.
[37,38,39]
 The observation that each module catalyses a single round of 
extension and -processing which corresponds to a single 'ketide unit' of the product is 
known as the colinearity rule.
[40] 
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After the polyketide is released from the PKS, post-PKS-modifications take place by 
hydroxylases, methyl-transferases and glycosyl transferases to form the final compound 
2 which is an important member of the class of macrolide antibiotics.
[41] 
There are some modular PKS known that do not follow the co-linearity rule. For 
example the iterative use of modules during chain extension is known. Another form of 
mPKS uses trans-AT domains. In contrast to the integrated AT domains (Scheme 6) the 
AT domain is free standing (Scheme 7).
[42,43] 
 
Scheme 7: Modular arrangement of  trans- and cis- AT domains.
[43] 
 
1.2.2 Iterative Type I Polyketide Synthases 
 
In contrast to modular PKS, iterative Type I PKS only have a single set of catalytic 
domains. These domains are used in different combinations during the -modification 
cycle and the extent of -modification can have a large variation between the different 
extensions. This makes it much more difficult to predict the chemical programme of the 
PKS.  Which protein components control this diversity is still unknown. Iterative Type I 
PKS are often found in fungi and rarely in bacteria.
[44,45]
   
 Iterative Type I PKS are divided into different subclasses based on the domains 
present in the enzyme, and the overall chemistry carried out. The simplest systems are 
known as non-reducing PKS (NR-PKS) and these perform no reductive modifications 
during chain construction; slightly more complex are the partially reducing PKS (PR-
PKS) which usually perform a single programmed reduction; and the most complex are 
known as highly reducing PKS (HR-PKS).
[46]
 Currently there are no reported structures 
of complete fungal iterative Type I PKS systems. 
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1.2.3 Non Reducing PKS (NR-PKS) 
 
Non reducing PKS have no reducing domains that are involved in the -processing of 
the polyketide - they lack KR and ER domains. Starter units are transferred to the PKS 
by an N-terminal starter unit acyl-carrier transacylase (SAT) domain which is unique 
to this class of PKS. The KS, AT and ACP are responsible for forming a poly--keto 
acyl ACP (Scheme 8) in the usual way. The cyclisation of the chain appears to be 
controlled by another unique domain known as a product template (PT) domain.
[47,48]
  
PT domains are required because poly--keto intermediates have acidic protons and 
keto functions that make the polyketide intermediate very unstable. Spontaneous 
cyclisations are possible, and the PT domain some-how prevents these reactions. In 
most cases backbone cyclisations, as well as the chain length of the product, are 
controlled by the PT domain.
[47,48]
 
  
Scheme 8: NR-PKS of orsellinic acid 22.
[49] 
 
A typical example of a NR-PKS is that involved in orsellinic acid 22 biosynthesis 
(Scheme 8). Sequence analysis of the orsellinic acid PKS (orsellinic acid synthase, 
OAS) shows the expected domains SAT, KS, AT, PT and ACP.
[50]
  
A variety of different domains are known to be present downstream of the ACP 
in NR-PKS. For example in OAS there is a thiolesterase (TE) which releases the mature 
polyketide from the PKS.  
 
Figure 7: Structure of citrinin 23. 
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For some products of NR-PKS a C-MeT can also be found at this position. The 
production of citrinin 23 involves, for example, the addition of two methyl groups to the 
growing carbon chain (Figure 7).
[51]
 Final release of the PKS products can be catalysed 
by several different domains. Currently reductive releases (R domains), TE domains or 
Claisen cyclases (CLC) are known.
[52]
 
 
1.2.4 Partially Reducing PKS (PR-PKS) 
 
Partially reducing PKS are known in bacteria and fungi. The PKS consists of KS, AT, 
KR, and ACP domains. Known examples of PR-PKS produce mellein 25 and 
6-methyl salicylic acid. In comparison to NR-PKS some functionalization of the 
polyketide chain is possible by PR-PKS. Diversity in the chain-length of the produced 
polyketide can be attributed to the C-C-bond forming catalytic domains. In most cases 
the chain length is controlled by the substrate-binding pocket of the KS domain. 
Cyclisation, (Scheme 9), is not catalysed like the ones in the NR-PKS by PT domains, 
but the positions of the keto and hydroxyl groups determine the cyclisation pattern. The 
reducing step is clearly programmed because not every keto functionalization gets 
reduced.
[50,53,54,55,56]
  
 
Scheme 9: Mellein biosynthesis. 
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1.2.5 Highly Reducing PKS (HR-PKS) 
 
HR-PKS are an enigmatic group of multidomain enzymes that can control chain-length 
and -processing reactions in a programmed way. How this programming works, 
however, is unclear.
[44,45,57]
 HR-PKS are large multifunctional enzymes which act in an 
iterative way. The domain set is the same as mammalian FAS (mFAS, section 1.3) with 
KS, AT, DH, C-MeT, ER, KR and ACP domains. The KS, AT and ACP must be active 
in each extension cycle, but the other domains can be active or inactive during each 
cycle of -processing. Different combinations of the -processing domains are active 
after each different extension cycle, and this results in structurally complex 
compounds.
[57]
 The use of HR-PKS is known mostly in fungi and rarely in bacteria.
[57] 
 The biosynthesis of the fungal metabolite lovastatin 26 is a good example of 
HR-PKS, and also illustrates two different classes of HR-PKS. In the lovastatin diketide 
synthase (LDKS) the ER domain plays an essential role as it is present and active 
during biosynthesis. For the lovastatin nonaketide synthase (LNKS) the original ER 
domain that is found in the PKS is inactive. In this system a trans-acting ER performs 
the reduction of the olefin during -processing. This ER is encoded by a separate gene 
and works in addition to the PKS (Figure 8).
[58] 
 
Figure 8: Iterative modules of LDKS and LNKS. ER* is inactive. 
 
Brefeldin A 28 is an antibiotic isolated from the fungus Eupenicillium brefeldianum and 
is also the product of a HR-PKS.  It is used as protein-transport inhibitor and has 
antiviral, antifungal and antitumor activities. 28 probably arises from the highly 
functionalised C16 precursor 27 and shows the high level of programming possessed by 
HR-PKS (Scheme 10).
[59,60]
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Scheme 10: Structure of brefeldin A 28 and its likely biosynthesis from a C16 hydroxy triene product of an 
HR-PKS. 
 
The switching between active and inactive domains during -processing is shown in the 
contrast between full reduction (position 4) and partial reduction (position 2). The DH 
appears to be inactive during the first cycle, but active elsewhere, and the ER appears to 
be inactive during cycles 3, 6 and 7, but active in cycles 2, 4 and 5.
[59]
  
 
1.3 Structure of mammalian FAS 
 
Currently there are very few crystal structures of isolated PKS modules available. 
However, PKS (especially HR-PKS) have strong end-to-end sequence similarity to 
mammalian fatty acid synthases (mFAS) and it is hypothesized that they are similar and 
have closely related structures. The structure of mFAS has been elucidated by 
crystallization studies (Figure 9).
[61]
  
 mFAS is a homodimer with a roughly anthropomorphic shape. The central body 
is determined by the KS, DH and ER domains. The arms and legs are shown by AT and 
KR. Two non enzymatic domains are attached at the top of mFAS. One of these 
domains is homologous to the methyltransferase family and is called a pseudo-
methyltransferase (MeT). The other non-functional domain dimerizes with the 
catalytic active KR domain, and is named pseudo-ketoreductase (KR).[61] 
Unfortunately the mFAS structure does not show the position of the ACP, or of its 
terminal TE domain. 
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Figure 9: Structure of mFAS.
[61]
 
 
Two sets of every catalytic domain are found in the dimeric structure. It can be divided 
into the elongation and in the -processing part. The elongation section is determined 
by the domains of the KS and MAT. Both are important for the extension steps 
(Figure 10). The remaining domains are used for the -modification cycle. The crystal 
structure of mFAS is very highly organized with only 9% of the whole sequence being 
linker region.
[61]
 
 
Figure 10: Different parts of Type I FAS and PKS. 
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1.3.1 Intersubunit and Interdomain Connections of mFAS 
 
The dimerized mFAS polypeptides have an interface which is created by the contacts 
between the different domains. In total an interface of 5400 Å
2
 exists. Nearly 150 amino 
acid residues are involved at these interfaces.
[28]
 Most of the interfaces are contributed 
by the homodimers of KS and ER domains (2600 Å and 1600 Å/ 74 and 47 amino acids 
respectively). Other contacts are formed by the DH domains (800 Å/ 27 amino acids) 
and smaller contacts between MAT, DH and KS domains (400 Å).
[62,63]
 
The elongation and -modification parts of mFAS are connected by a small 
linker (20 amino acid residues). Due to the fact that mFAS and fungal HR-PKS show 
end-to-end sequence homology it seems highly likely that HR-PKS are structurally 
similar to mFAS. Thus the structure of mFAS gives information about how the protein 
structure of an HR-PKS could be.
[61]
 
KS and MAT domains make up the elongation part. The KS domain exists as a 
homodimer with an interface of the two monomers and is located in the centre. This 
dimer is surrounded by the DH and MAT domains. The KS and MAT domains are 
connected by a linker, which is built up of 70 amino acids. Direct interactions of KS and 
MAT domain are prevented by -helices and -sheets. Also a connection between 
MAT and DH domain is known. A linker connects the KS domain with the DH domain 
and thus elongation and modification part.
[61,62,63]
 
The -modification part of the protein is formed by five domains. DH, ER, KR, 
KR and (C-MeT domains are involved in the different modification steps. In mFAS 
the DH domain exists as a homodimer. It shows weak connections to the ER domain, 
which also exists as a homodimer. An interface between the subdomain of the DH and 
KR domain of 800 Å was found. The second hot dog subdomain of the DH is the part 
that interacts with the KR.
[61]
 
The KR domain is the central domain of the modifying part and has an interface 
to all modifying and noncatalytic domains (DH, ER, KR and MeT). KR and KR 
form the main interface. This interface has a size of 1100 Å
2
. The size of the interface 
between KR, KR and MeT is 200 Å2.[61] 
 Analysis of the non-catalytic domains shows some special structural 
modifications. The KR is half the size of the active KR domain, but it forms an 
important structure which supports the catalytically active KR.
[61]
 The second non-
catalytic domain of mFAS, the MeT, is a relic of an S-adenosyl-methionine dependent 
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methyltransferase. Its inactivity is due to the loss of the binding motif for the cofactor 
SAM 12, as well as several peptide deletions when compared to active C-MeT domains, 
for example those of HR-PKS.
[64]  
 
Figure 11: Possible position for ACP domain for interaction with elongation and modification part. 
 
The final important domain is the ACP. It was not possible to crystallize the ACP as a 
part of the FAS structure. This could be explained by the high flexibility of the domain. 
However it is observed that the entries to the active sites of the cataltic domains appear 
to line the large cavity formed by the MAT, KS, DH, KR and MeT domains. The 
anchor point for the ACP may lie in the center of this modification area. Structurally the 
ACP consists of a four helix bundle. This is the usually found structure for ACPs. One 
of the helices is very important for the docking process to the different domains. The 
docking process leads to electrostatic interactions (Figure 11).
[61,65] 
 
1.3.2 Structural Relationship of mFAS and PKS 
 
At the moment very few structures of mPKS have been reported. Production of crystals 
of a complete PKS is usually not possible because of instability of the enzymes.
[63]
 
However, progress has been made in crystallising isolated domains and didomains of 
PKS enzymes. Several crystallisation experiments of isolated mPKS fragments were 
successful.  
 
KS-AT-didomain 
Tang and coworkers reported the isolation and crystallisation of a KS-AT fragment of 
the DEBS5 module.
[62]
 It has a size of 194 kDa and is homodimeric. The full length of 
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KS and AT domains and additional linkers were crystallised. The orientation and 
organisation of KS and AT domains were very similar to mFAS. Homodimeric KS 
domains seems to be centered on a 2-fold rotational axis. AT domains are located at the 
edge of the KS domains. The active sites of both domains have a distance of 80 Å 
(Figure 12).
[62]
 
 
 
Figure 12: Orientation and organisation of KS-AT didomain of DEBS5.
[62] 
 
Comparison of the linker regions of mPKS and mFAS also shows similarities. Linker of 
KS to AT regions fits well. A contrast was recognized for an N-terminal linker. This 
could be reasoned to the transfer of the growing polyketide chain that is transferred by 
this linker. However, the linker is missing in the mFAS sequence.
[61,62,63]
  
 
KR domains 
Other domains that have been investigated very frequently are KR domains from 
modular PKS. Two examples are EryKR1 and TylKR1. Both are structurally related to 
the KR domain of mFAS. Interfaces of this domain were found with ER- and DH 
domain. In agreement to the structure of mFAS is that the isolated KR domains are 
monomeric.
[61,66]
 The catalytic KR domain consists of two structural subdomains. One 
contains the known Rossman fold which forms the cofactor binding site, the other one 
(known as KR) is a subdomain that has lost the dinucleotide binding site and its main 
role is the stabilization of the KR domain.
[66,67]
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DH domains 
Crystal structures of several isolated DH domains of modular PKS are available. All 
reported structures shows that the DH domain exists as a dimer. This is similar to the 
reported structure of mFAS. Also for mPKS only a small interface is observed.
[68-70] 
The DH domain of DEBS DH4 is similar to the mFAS DH and is composed of 
two subdomains, each is a hot dog fold. The “bun” is formed by a seven-stranded 
antiparallel -sheet. A central helix is orientated in this fold and makes up the "sausage" 
of the “hot-dog” (Figure 13). 
 
Figure 13: Structure of the hot dog fold of cur F.[71] 
 
Several catalytic residues are conserved between the mFAS and DEBS DH4. In 
particular, the HXXXGXXXXP motif is distinctive for DH domains. The glycine is 
necessary to allow a turn in the structure. Several other motifs that are conserved are 
“GYXYGPXF” and “LPFXW”. More detail is discussed in section 3.5.[68-70]  
The proposed mechanism of DH starts with a deprotonation at the -position by 
a histidine residue (section 3.5). Elimination of water occurs via an E1cb mechanism, 
with overall syn stereochemistry. Further details of the mechanism are discussed in 
section 3.5.
[68-70]
 
 
ER domains 
Different structures of ER domains from modular PKS are known. For example the 
structure of the ER-KR didomain of Spn2 from the spinosyn mPKS has been reported. 
The ER domain of Spn2 belongs to the medium-chain dehydrogenase/reductase family. 
Two subdomains are found for this class (section 2.2). In contrast to mFAS the ER 
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domains of the PKS do not exists as dimers. In the case of the trans-acting ER domain a 
loop prevents the dimerisation.
[70] 
 
Figure 14: Orientation of ER-KR domains in Spn2 (a) and mFAS (b).
[72] 
 
Crystallisation of the ER-KR didomain fragment of the spynosyn synthase module 2 
shows an interface of both domains. This interface is larger than the known one of 
mFAS. Nonconserved hydrophilic residues in the subdomain (KR) and substrate 
binding domain (ER) seems to be responsible for this interaction. Additional linkers 
increase this interface (Figure 14).
[72]
 This is in contrast to mFAS.
 [61]
  
 
Types of proposed protein structures of modular PKS 
Zheng et al. proposed, based on several crystallisation experiments, a different possible 
structure for modular PKS. This structure has a similar elongation part to mFAS but a 
differently organised -processing part. Differences are shown by the organisation of 
the domains.
[72]
  
 
Figure 15: Proposed domain organisation by Zheng et. al. 
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Difference between the mPKS and mFAS exists in this model in the -processing part. 
The organisation of DH, KR and ER shows a monomeric behaviour for the ER domain. 
Zheng et al. showed the structural relation between ER domain and KR domain by the 
crystallisation of the didomain of the modular PKS Spn2. In contrast to mFAS the ER 
domain is not located in the center of the protein. The result is a more open structure of 
the protein (Figure 15).
[61,72]
   
 Since it was not possible to create a complete crystal structure of a PKS other 
methods for structural analysis have been developed. One of these is cryo electron 
microscopy. Dutta and coworkers worked with this method to visualize module 5 of the 
pikromycin modular PKS which consists of KS, AT, KR, ACP domains. A completely 
different domain organisation was found in contrast to mFAS.
[61,73,74]
 The domains are 
shaped like an arch. The KS domain exists in this architecture as a homodimer. An 
additional connection to the AT domains is observed. The AT domain is connected on 
the other side to the KR domain. Positions for the ACPs were found near to the AT and 
KR domains in a reaction chamber which is faced by the KR and AT (Figure 16).
[73]
  
 
Figure 16: Domain organisation of PikAIII (a and b).
[74] 
 
This configuration is very near to the one that was proposed by Staunton et al. 
(Figure 16, Structure c)),
[75]
 Structural relationship to KS-AT didomains or mFAS do 
not exist.
[62,73]
 Every AT domain in PikAIII is rotated by 120° in comparison to mFAS. 
An interface between KS and AT domains is observed. In mFAS the connection 
between both domains exists by a linker.
[61]
 This orientation of the AT forms, in 
connection with the KR a reaction chamber in the center of PikAIII.
[75]
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Fungal HR-PKS 
No structures of any of the core components of a fungal HR-PKS, either as single 
domains or as multidomains, are known. However there is overall end-to-end sequence 
homology between mFAS and HR-PKS, with active sites located in the same positions 
and showing very high levels of amino acid conservation. This includes both active and 
inactive domains, and even includes the inactive C-MeT domain of mFAS, which is 
active in many HR-PKS. It is therefore hypothesised that the mFAS structure is likley to 
be a good model for that of HR-PKS. 
 
1.4 Programming in Fungal HR-PKS 
 
The programming in highly reducing iterative polyketide synthases has been rarely 
investigated. One of the biggest problems is that in an iterative PKS the extension steps 
are cryptic. The structure of the polyketide cannot be predicted by sequence analysis. 
How is the chain length determined? Where does a methylation take place? Which 
reductive domains are active? So far very little information has been gathered about 
how these programming steps are controlled. However, the biosynthesis of a few 
polyketides has been investigated in considerable detail and some information is 
beginning to be discovered. In particular the cases of lovastatin 26 and tenellin 47 have 
revealed key information about programming. 
 
1.4.1 Biosynthesis of Lovastatin 
 
One of the most investigated and understood highly-reduced polyketides is the 
cholesterol lowering drug lovastatin 26 (Figure 17) obtained from the filamentous 
fungus Aspergillus terreus and also identified in Monascus ruber as Monacolin K.
[76-78]
 
Due to inhibition of (3S)-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 26 is 
used as a cholesterol lowering drug, and also for the inspiration for the development of 
many semi-synthetic analogues.
[77-80]
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Figure 17: Structure of lovastatin 26. 
 
Lovastatin 26 is built up by two different iterative polyketide synthases.
 
The polyketides 
are linked together by an acyl transferase to form an ester linkage. The lovastatin 
nonaketide synthase (LNKS / lovB) is responsible for the production of the lovastatin 
precursor dihydromonacolin L 29 (Figure 18). This PKS contains KS, AT, DH, C-MeT, 
ΨKR, ER*, KR, ACP, C domains. The terminal C (condensation) domain is a relic from 
a now inactive NRPS module - the C domain is thought to be inactive.
[79] 
 
Figure 18: Structure of precursor dihydromonacolin L 29. 
 
In vitro studies showed that LovB as a stand alone synthase is not able to produce 29 
since its ER domain is inactive (demnoted ER
*
). During the production of 29 the 
required ER is encoded by lovC. This ER is a separate protein and is known as a trans-
acting ER.
[77-80]
 
The side chain of 26 is synthesized by a second PKS known as Lovastatin 
diketide synthase (LDKS/ lovF) which shows the following domain organisation KS, 
AT, DH, C-MeT, ΨKR, ER, KR, ACP. No release domain was found and further 
investigations showed that the offloading of this domain is performed by protein-protein 
interactions with LovF and LovD (AT domain involved in the transfer of LDK to 
LNK).
[77-80]
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Scheme 11: Biosynthesis of lovastatin 26. 
 
Several intermediates of the biosynthesis of 26 are known (Scheme 11). The synthase 
starts with acetyl CoA 3 which is elongated by malonyl CoA 6. After the first two 
elongations only the KR and DH modification enzymes are active (intermediates 30 and 
31). After the third elongation all domains are active, including the C-MeT and trans-
acting ER with consequent full reduction to form compound 32. Similar modifications 
operate during the fourth step, but without methylation to give 33. After another 
elongation with active KS, KR and DH domains, the formed hexaketide 34 is 
transferred into the bycyclic compound 34 by a Diels Alder reaction.
[77-80] After further 
elongation to 36, 37 and then 29 the carbon chain is cleaved by a thiolesterase 
(TE/LovG) to release 38 as the first enzyme-free intermediate. 
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By later modifications the precursor 38 is oxidized twice by a P450 enzyme (LovA) to 
introduce the second olefin and a hydroxyl group. In the last modification step the AT 
domain encoded by lovD forms 26 with the addition of α-S-methylbutyrate that was 
produced by LDKS. Further details of LovD activity are discussed in chapter 5.1.
[77-80]
 
 Tang and coworkers showed another example of programming in iterative PKS 
in 2015. Specifially the methyltransferase domain of lovastatin was investigated.
[85]
 
After the third elongation, the C-MeT works directly after the ketosynthase, and it is the 
only time the C-MeT domain is active. This methylation is important because without 
it, it is not possible for the ER domain to work. The substrate cannot be recognized 
(Scheme 12).
[81]
 
 
Scheme 12: Third elongation step of LNKS. 
 
To investigate the behaviour of the C-MeT domain several SNAC-substrates were 
synthesized, which were different in chain length. The first four elongation substrates of 
LNKS were synthesized with an SNAC-residue. For enzyme assays the iterative 
enzyme LovB was expressed and a mutation in the DH was introduced to stop further 
modifications (designated LovB
*
, Scheme 13).
[81]
  
 
Scheme 13: Enzyme assays of several -keto-acyl-SNACs. 
 
Different enzyme assays were set up. First the natural tetraketide substrate 43 was 
assayed with LovB
*
 in the presence of SAM. The activity of the enzyme with this 
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substrate was observed by LCMS. Also the diketide, triketide and pentaketide mimics 
were analysed but the diketide and pentaketide were not substrates, and the triketide 
was methylated very slowly (Scheme 13).
[81]
 
 Comparing the kinetic results of the tetraketide with the triketide analogue the 
catalytic efficiency slows down by a factor 2500, also the kcat and KM each change by a 
factor of 50. Additional substrates based on tri- and tetraketides, that had saturated 
carbon chains showed slow activity with LovB, but again an increase of KM was 
detected, which shows the high substrate specificity of the lovB C-MeT domain for its 
natural substrate.
[81]
 
 After analysing the C-MeT assays, the same investigations were performed with 
the KR domain. Since the KR is active in every extension, in contrast to the C-MeT, a 
much higher spectrum of different substrates would be expected to be processed. In the 
evaluation of the different assays of tri- and tetraketides it seemed not to have an effect 
to the enzyme if a methyl group is added to the -keto-ester or not. Also the chain 
length does not affect the KR domain.
[81]
  
 In final competitive assays of lovB
*
 in the presence of the corresponding 
cofactors 12 and 13, different substrates were tested with the DH-mutated enzyme 
(Scheme 14). The assays showed clearly that the triketide has a higher affinity to the 
KR than the C-MeT. Only a small amount of the methylated version was found in the 
LCMS chromatogram.
[81]
 
 
Scheme 14: Competitive enzyme assays of KR and C-MeT domains. 
 
The competitive assay of the tetraketide showed a high affinity to the C-MeT. No 
reduced product of the KR was observed. This shows again the much higher catalytic 
efficiency of the C-MeT to the natural tetraketide. Since there is not much control by 
the KR domain, the substrate specificity of the C-MeT seems to be important for the 
programming and the synthesis of the correct substrate, which are necessary in the 
following elongation steps. 
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The programming of the second extension step is programmed in a competitive step of 
C-MeT and KR. Both enzymes compete for the release product of the KS domain. In 
every elongation without the second one, the KR is favour against the C-MeT. The 
second elongation in contrast to the other ones shows the high selectivity of the C-MeT 
to the tetraketide.
[81]
  
 After the sixth elongation step a bicyclic system is formed via a biological Diels 
Alder reaction. LNKS catalyses an intramolecular endo cyclisation. It seems likely that 
LNKS controls the conformation of 34 so as to bring the atoms to the correct distance 
for the cyclisation (Scheme 15) but it is still not known exactly how this is 
achieved.
[82-83] 
 
Scheme 15: Diels-Alder reaction after the sixth elongation. 
 
1.4.2 Biosynthesis of Tenellin and Desmethylbassianin 
 
The fungal metabolites tenellin 47 and desmethylbassianin (DMB) 48 are 
biosynthesized by hybrid PKS-NRPS systems, and have also been investigated to 
determine the origin of PKS programming. The PKS is a HR-PKS and the NRPS adds a 
tyrosine to the resultant polyketide chain and catalyses a Dieckmann cyclisation. For 
both compounds a trans-acting ER domain is used (Figure 19). Tenellin 47 is built up 
by four different proteins: the iterative HR-PKS (TenS) which works with the trans-
acting enoyl reductase (TenC) and two cytochrome P450 mono oxygenases (TenA and 
TenB).
 [84,85]
 
Figure 19: Structure of tenellin 47 and desmethylbassianin 48. 
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The biosynthesis of 47 starts with acetyl CoA 3 which is elongated four times with 
malonyl CoA 6. After the first elongation all -processing enzymes are active. 
Complete reduction is performed by the TenC trans ER domain. This trans ER domain 
is inactive after the next elongation cycles so an unsaturated carbon chain is formed. 
The methyl transferase only works after the first two cycles and is then silent. The KR 
is functional after the first three rounds of extension, but inactive after the fourth. After 
the fourth extension the polyketide is fused with a tyrosine residue to form 
pretenellin A 49 (Scheme 16). The two P450 oxidases work in a post PKS modification 
to form 47.
[84,85]
  
 
Scheme 16: Biosynthesis of tenellin precursor pretenellin A 49. 
 
DMB 48 is similar to 47 and is also built by a PKS-NRPS known as DMBS which 
requires a trans ER (DmbC). Examination of the structure of 48 indicates that it has one 
more extension cycle than 47. In contrast to 47, 48 has one less methylation. To 
investigate a possible role of programming the trans ER domains were investigated. 
The trans-ER proteins of 47 and 48 biosynthesis were interchanged but this did not 
show any significant changes or possible reprogramming by these proteins.
[84,85]
 
 Comparison of the two biosynthesic gene clusters shows very high homology 
between the different genes and proteins. The two clusters have a 90% sequence 
identity of the genes and also the same orientation of the open reading frames. The very 
 
28 
 
high level of protein similarity allowed fusion proteins to be formed by genetic 
engineering in which different domains from DMBS are inserted into TENS 
(Scheme 17).
[86-88]
 
 
Scheme 17: Fused chimaeras of DMBS and TenS. 
 
Interestingly after replacing the elongation part and the dehydratase (KS, AT, DH) of 
TENS with the ones of DMBS no change in the polyketide chain was observed. The 
product was still 47. This means that the chain length cannot be programmed by these 
three domains. In the next experiment C-MeT and KR from DMBS were swapped 
into TenS. With this fusion two new products were observed. 
Desmethyl-pretenellin A 53 and prebassianin 54 were isolated as major and minor 
products. The methylation pattern changed for the major product to a double methylated 
compound, but has the same chain length as 48. For the minor product the chain length 
was the same as 47. In contrast to this, the methylation pattern was this time different. 
Only one methylation was observed which corresponds to the side chain of 48.
[86-88]
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Including in the next domain swap the keto reductase of DMBS, changes the product 
proportion to the predesmethylbassianin A 55. More precise swaps of DMBS (C-MeT-
KR) showed a high titer of 54. Also a small amount of 47 was detected. These results 
suggest that the methylation pattern is controlled by the C-MeT-KR (Figure 20).[88] It 
seems, that the C-MeT must be programmed on its own. The DMBS C-MeT seems only 
to recognize diketides, but the TenS C-MeT can recognise both diketides and 
triketides.
[88] 
 
Figure 20: Structure of predesmethylbassianin A 55. 
 
The use of domain swaps became a useful tool and was also used in further 
investigations of NR-PKS. An exchange of the SAT domain in NR-PKS showed that it 
is possible to control/ influence the chain length of the final products.
[89]
  
 
1.5  Squalestatin S1 
 
Squalestatin S1 56 (SQS1), also known as zaragozic acid A, is produced by Phoma 
species of fungi.
[90-95]
 It is an inhibitor of mammalian squalene synthase and thus a 
potential inhibitor of cholesterol biosynthesis. SQS1 56 was discovered in the early 
1990s and investigated independently by Glaxo and Merck and is potentially a lead 
structure for the development of a cholesterol lowering drug.
[90-95]
 
There are several derivatives of the squalestatins/ zaragozic acids known (e.g. 57 and 
58). All compounds have a very polar 4,8-dioxabicyclo[3.2.1]octane core which is the 
result of post polyketide modifications (Figure 21).  
At position 6 of the core of 56 is attached a tetraketide side chain (Side chain B 
in Figure 21). This position can be substituted by many different side chains.
[93-100]
 The 
side chains have a high diversity in the chain length, methylation pattern and 
methylation positions. Also the reduction pattern of the side chains can differ. This 
diversity could be an indication of a broad substrate tolerance of an acyl transferase 
which combines both polyketides. The origin of the heavy atoms of 56 was elucidated 
by feeding experiments using 
13
C, 
2
H and 
18
O labelled precursors.
[93,96,97]
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Figure 21: Structure of target compound squalestatin S1 56 and known derivatives.
[92] 
 
SQS1 56 is is built up by two different polyketide synthases similar to lovastatin 26 
biosynthesis. The core of 56 and side chain A are synthesized by a hexaketide synthase 
(known as squalestatin hexaketide synthase, SQHKS) and the very uncommon 
benzoate 5 starter unit. This starter unit is extended five times by malonyl CoA 6. The 
different methyl groups are derived from SAM 12. Four oxygens (O*) are derived from 
atmospheric oxygen 59.
[97]
 
Scheme 18: Biosynthase of 56 with corresponding starter units. 
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After that, several modifications take place to form the final 
4,8-dioxabicyclo[3.2.1]octane core. Four carbon atoms are derived from citric acid 60 
and attached by condensation reactions at the hexaketide chain. The gene cluster 
encoding SQS1 biosynthesis was identified using full genome sequencing by Beate 
Bonsch (Scheme 18), but the exact chemical steps leading to the formation of the 
4,8-dioxabicyclo[3.2.1]octane core are still unknown.
[97]
  
Knockout experiments of the identified tetraketide synthase gene (phpks1) 
showed the loss of 56, but formation of 56 lacking the B side chain 61 suggested that 
the tetraketide is probably added late during the biosynthesis.
[98]
  
The squalestatin tetraketide 61 is constructed by the squalestatin tetraketide 
synthase (SQTKS, Scheme 19). Cox et al. found the 8 Kb gene (phpks1) that encodes 
SQTKS in 2004. SQTKS consists of KS, AT, C-MeT, KR, KR, DH, ER, and ACP 
domains. Alignments with mFAS and LDKS showed 26% and 59% similarity 
respectively.
[98]  
 
Scheme 19: Iterative module producing SQTK. 
 
The biosynthesis of 61 starts with the starter unit acetyl CoA 3. 61 and is elongated in 
three extensions with malonyl CoA 6. In the first two cycles all domains are active. The 
PKS chain is methylated and fully reduced at the -keto moiety to a methylene. After 
the final extension step the C-MeT and ER are inactive. The methyl group in the 
-position is missing (Scheme 19). Also a double bond in the -position of 61 exists. 
Finally the tetraketide gets released from the PKS. As there is no TE domain contained 
within SQTKS it is currently unknown how 61 is released from the PKS. Possibly 
another gene in the gene cluster is responsible for this step.
[98]
 
Finally both individual side chains are combined by an acyl transferase (AT) to 
build up the target compound 56. For 56 it was proposed that two different ATs work 
separately and individually.
[97]
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1.6 Aims of the Projects 
 
The tetraketide side chain of squalestatin S1 56 is produced by SQTKS, but the 
programming mechanisms of the PKS is unknown. Analysis of 61 shows that the ER 
and C-MeT domains of SQTKS are inactive after the last extension. The crucial 
questions of the project are how is 61 formed, how is its biosynthesis programmed and 
what is the mechanism for controlling the programme? 
 
Figure 22: Possible points that can control the programming of SQTKS. 
 
The programming could be performed either by substrate-recognition or by kinetic 
selection, but this is unclear. Previous investigations have shown that some domains, 
such as C-MeT, appear to be individually programmed.
[88] 
Programming of recognition 
could be connected to the methylation pattern, methylation position but also to the chain 
length of each indicidual substrate (Figure 22). However, other domains such as KR 
control chain-length and this is counter-intuitive. 
 Previous work in the Cox group has succeeded in isolating several domains of 
SQTKS which are involved in the synthesis of 61. An individual analysis of single 
domains could be performed.
[100,101]
 In the following thesis, the focus is on the 
investigation of the ER and DH domains of SQTKS. These domains appear to have 
contrasting programming: the DH works after all three rounds of extension; but the ER 
does not work after the second round of extension. Previous work (Doug Roberts in the 
Cox group, unpublished) also showed that the isolated SQTKS-ER domain cannot 
properly control the stereoselectivity of the reduction - it releases racemic products in 
contrast to complete SQTKS which releases enantiopure products.
[100]
 A problem could 
be the expressed protein but also the reaction rate could be too slow. Protonation could 
be completed by water. Also in the previous work acyl substrates were based on SNAC 
compounds and only a small part of the ACP was mimicked in that way.
[100]
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Figure 23: Structure of Coenzyme A 62. 
 
The current project is based on the use of pantetheine substrates which mimic more of 
the acyl ACP natural substrate of PKS domains (Figure 23). This longer chain should 
result in more interactions between the domain under study and its acyl substrate. A 
higher reaction rate should be observed in the reduction process. Possible interactions of 
the DH and ER domains will also be analysed by biophysical methods such as surface 
plasmon resonce (SPR) and isothermal calorimetry (ITC).  
 Finally, acyl transfer of squalestatin tetraketide 61 to the squalestatin core will 
be investigated. Possible precursors are necessary for the enzymatic investigation. The 
focus will be on the synthesis of three possible candidates that could be involved in the 
biosynthesis. The counterparts to the squalestatin cores will also be prepared. Substrates 
with pantetheine and CoA residues will be synthesized. Possible differences between 
these substrates will be investigated and analysed. 
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2.0 Project 1: Investigation of the Programming of the Isolated ER 
Domain of the Squalestatin Tetraketide Synthase 
 
Fungal iterative HR-PKS show distinct and often complex programming. It is clear that 
systems such as SQTKS can build polyketides which possess a similar level of 
structural complexity to those synthesised by modular PKS, but the use of a single 
iterative PKS module makes the fungal PKS highly efficient. However, the mechanisms 
of programming of these types of PKS are not clear. For modular systems the 
programme is controlled by: the number of modules (i.e. chain length); the presence or 
absence of -processing domains within modules (i.e. extent of functionalisation at each 
-position); and individual domain selectivity, for example by the AT domains, which 
controls the selection of extender units (i.e. the methylation pattern). Furthermore, 
modular PKS can control the stereochemistry of each - and -position, and this is 
usually controlled by the selectivity of the KR domain (-hydroxyl positions) and the 
ER domain (-alkyl positions). 
The only one of these programming methods which is available to fungal PKS is 
individual domain selectivity. Some evidence has been collected to-date to support the 
idea that the individual domains might control their own programming. For example the 
Cox group have shown through in vivo domain swaps that the tenellin PKS C-MeT 
domain appears to control its own 'programme' (section 1.5); while the Vederas group 
have shown that isolated catalytic domains of LNKS also have distinct selectivity 
preferences for different polyketide intermediates (section 1.5). Since SQTKS itself is 
too large to express as a single protein, we planned to use in vitro studies of isolated 
domains from SQTKS to determine their substrate- and stereo-selectivities. 
The chemical programme of SQTKS can be inferred from the structure of 
squalestatin tetraketide 61 itself (Scheme 20). All -processing domains are functional 
after the first two extension cycles, but the C-MeT and ER are inactive after the third 
extension, and the KS also does not act again after the third extension. There must also 
be a cryptic off-loading step which removes the polyketide from SQTKS at the end of 
biosynthesis, but it is not known how this happens. 
 Since the ER also sets the stereochemistry of the two asymmetric centres of 
SQTK 61 we decided to start our studies by investigating it, and we thus planned to 
produce the isolated ER domain and study its interaction with various substrates. In 
addition we planned to investigate its setereoselectivity. 
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Scheme 20: Different extension steps of the squalestatin tetraketide synthase (SQTKS).
[98] 
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2.1 Previous Studies of ER domains from FAS and PKS 
 
The ER domain is the final enzyme of the modification set of enzymes that can be 
active in the -processing cycle of a polyketide synthase. It belongs to the medium 
chain NADPH-dependent dehydrogenase/ reductase family (MDR). The enzyme is built 
of two structural subdomains: a substrate binding and a co-factor binding domain 
combined by a linker region. The stereochemistry of the -position is determined by 
this enzyme e.g. the 2R or 2S configuration (Figure 23). The stereochemistry is 
controlled by the face-selectivity of the reprotonation at the -position. Which amino 
acid residues are necessary or important is currently unclear.
[22,101,102] 
 
Figure 23: Possible stereochemical outcomes of the ER domain. 
 
Only a few studies have been performed to determine the possible catalytic residues in 
the active site of an ER domain. The mechanism most likely involves transfer of a 
hydride to the -position of the reacting substrate, to create an intermediate enol(ate) 78. 
  
Scheme 21: Proposed mechanism of the ER domain. 
 
The collapse of 78 and its reprotonation at the -carbon sets the stereochemistry, but 
residues involved in activating and orienting the substrate, and in stabilising the 
intermediate and actively reprotonating 78 have not been conclusively identified 
(Scheme 21).
[103] 
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Figure 24: Proposed catalytical triad involved in the reduction process. Distances in Å.
[104] 
 
The crystal structure of the Mycobacterium tuberculosis FAS ER-ACP didomain was 
obtained in complex with NAD
+
 82 and an acyl-substrate (Figure 24). The trans double 
bond is positioned near to the nicotinamide (4.8 Å). The p-hydroxyl of a tyrosine 
residue 80 can interact by hydrogen-bonding with the substrate carbonyl oxygen 
(3.7 Å). It is proposed that this interaction stabilizes the enolate during the reducing 
step. NAD
+
 82 interacts with two other amino acids. It is speculated that 
phenylalanine 79 is involved to ensure that the hydride for the transfer is in the correct 
distance to the -carbon of the substrate. How the final reprotonation works is unclear, 
and residues possibly responsible for this step are not identified.
[104] 
 
Further investigations were performed using mPKS ERs by Leadlay's group in 
Cambridge. To elucidate important residues that predict the stereochemistry of the final 
product, mPKS were sequenced and divided into two groups that produce R and S 
products. ER domains of the fourth module of erythromycin (Ery-4) and module 13 of 
rapamycin (Rap-13) were used in recombinant model PKSs. The modules were inserted 
into DEBS1 and combined with the TE domain of DEBS3 and to produce triketides.
[105]
  
 These chimeric PKSs produced a 2-methyl triketide lactone that is completely 
reduced at C-3. Studies showed that for the erythromycin hybrid the 2S-methyl product 
83 is observed and for the rapamycin hybrid PKS the 2R-product 84 is produced 
(Scheme 22).
[103,107-108]
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Scheme 22: Chimeric PKS of DEBS1-TE with DEBS 4 or RAPs 13. 
 
It was found that one single amino acid shows good correlations with the configuration 
of the polyketide product. For S-configuration a tyrosine at position 52 (Tyr52) seems to 
play an essential role. If this residue is not present, the R-configured product is found 
(Scheme 22). For the R-configuration the three amino acids valine, alanine or 
phenylalanine were found at position 52. Module-4 of DEBS has a tyrosine at 
position 52, which is missing in module-13 of RAPS and replaced with valine. 
Replacing tyrosine by valine in the erythromycin module resulted in a 2R-configured 
final product 84.
[103,107-108]
 
In a later study Leadlay and coworkers then replaced the valine in the rapamycin 
module by tyrosine, but surprisingly this resulted in no change in the final product. 
Compound 84 was still produced. Position 52 seems to be an important point in the 
active site but there must be some additional residues that are involved in controlling 
the -position stereochemistry.[103,107-108] 
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Further analysis showed that ER positions 46, 47, 52 and 53 are possible key 
residues for predicting the stereochemistry of the -position. In the ER which produces 
the 2S-configured triketide lactone 83, positions 46 and 47 contain leucine or 
isoleucine; proline is present at position 53. The 2R-configured product 84 is produced 
by an ER which has valine (46, 47) and proline (53) residues in these positions. 
Mutations of RAPS module-13 at these positions produces a small proportion of the 
2S-methyltriketide lactone 83 (Scheme 22).
[103,107-108]
 
 
Scheme 23: Prediction of chemical outcomes of the ER domains. 
 
A possible explanation is as follows: The hydride of NADPH 13 attacks the -position 
of the double bond forming an enolate intermediate. After that a protonation at the 
-position takes place either at the re- or si face. The results of Leadlay and co-workers 
showed that often a tyrosine residue is the proton source in the re- face that yields in an 
S--substituent. In the absence of this tyrosine the protonation occurs from the other 
side which results in a R--substituent. Which residue is the source of the proton in this 
case is unclear (Scheme 23). 
 
Another example of these essential amino acid residues in ER enzymes was published 
by Erb and coworkers who also highlighted a tyrosine residue at position 79 as the 
cryptic proton donor. In contrast to Leadlay, Erb investigated a yeast mitochondria 
reductase which was a pro-2-R specific ER domain. A replacement of the tyrosine and a 
tryptophan residue was performed. A redesigning of the active site was expected to 
change the stereochemistry. These residues were replaced with phenylalanine and 
glutamic acid respectively. A pro-2-S specific ER was generated by the mutation. This 
was in contrast to the original active site.
[109]
  
 
 
40 
 
Whether these investigations by Kwan, Leadlay and Erb can be transfered from modular 
to iterative PKS enzymes is not clear. The SQTKS-ER could also use residues like 
tyrosine in the active site that act as a proton donor. Sequence alignments between 
SQTKS-ER and EryER4 and RapER13 showed more than 35% identity to the PKS ER 
domain. Comparison of the yeast sequence with the modular PKS enzymes showed at 
position 79 always a tyrosine. This position in the SQTKS-ER is occupied by leucine 
and the other specific residues from Leadlay's study show no similarity to those in the 
ER of SQTKS. 
 There are several tyrosine residues in the sequence of SQTKS-ER but only the 
amino acids around the tyrosine at position 152 showed some identity in SQTKS, 
RapER13 and EryER4 (Figure 25). This tyrosine residue is placed in the binding site of 
NADPH. 
 
 
Figure 25: Sequence alignment of SQTKS, RapER13 and EryER4. 
 
Other parts where a high similarity is shown between the three ER domains is within 
the amino acids from 57 to 76. These amino acids are a part of the substrate binding 
site. Position 56 has a tyrosine residue in SQTKS but it seems very unlikely that this 
residue is important for the stereochemical outcome. This residue is far away from the 
reduction position in the model of SQTKS-ER (section 2.4).  
None of the tyrosine residues found in SQTKS-ER align with the tyrosine 
residues of EryER4 (position 78) and the valine residue of RapER13 (position 78) that 
are (possibly partly) responsible for the stereochemical outcome of their PKS enzymes. 
In the sequence of SQTKS-ER a leucine residue is placed at this position. If tyrosine is 
the important residue, in SQTKS-ER the amino acids should be similar to the one of 
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other PKS enzymes. If the tyrosine is not the essential residue, there must be other 
residues responsible for the stereochemical outcome. They must be positioned on the 
other site of NADPH and near to the double bond. Arginine and aspartic acid are two 
possible candidates for this protonation. 
In contrast to most modular polyketides the spinosyn PKS module two 
(SpnER2) has an ER domain that acts as a monomer, confirmed by size exclusion 
chromatography. This is in contrast to the experimental analysis of SQTKS-ER. 
Sequence alignment of SpnER2 and the SQTKS-ER shows an identity of 34%.
[72]
 The 
crystal structure of SpnER2 shows the residues lysine (position 264) and aspartic acid 
(position 288). They are possible candidates for stabilizing the reduction intermediates 
or directly involved as proton source. Both residues are found in the active site at a 
distance of 6 Å away from the nicotinamide hydride. These residues are potential 
candidates for taking part in the protonation and stabilizing the substrate or possible 
intermediates. The alignment of the sequences show that for the SQTKS-ER both 
residues are available, only separated by 22 amino acids. The distance to the highly 
conserved pyrophosphate binding motif (GGVGMA) is 84 amino acids. This is similar 
to the distance based on the crystal structure of SpnER2.
[72]
 
 
2.2 Aims of the project  
 
To get more information about the programming of iPKS, investigations of the isolated 
ER domain of SQTKS were performed. The focus of the investigation was the 
stereocontrol and the substrate selectivity of the isolated protein. The ER domain should 
be programmed since it sets two stereocenters in the final tetraketide 61 and cannot 
reduce the teraketide intermediate.  
Programming could be controlled by substrate recognition,
[100,101]
 and this could 
be tested by small molecules that vary in chain length, methylation pattern or the 
geometry of the double bond. Testing the programming using acyl-ACP substrates 
would be very difficult, due to the size of the ACP. Historically the ACP was mimicked 
by SNAC substrates
[100]
, but since investigations of the isolated ER with these 
substrates gave poor results in previous studies it was decided to produce pantetheine 
substrates here. The pantetheine substrates mimic more of the phosphopantetheine link 
to the ACP. We hoped that they may interact more strongly with the isolated ER 
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domain. If this is the fact, then the double bond should be reduced faster than in the 
equivalent SNAC compounds.  
The synthesis of structurally different pantetheine substrates is the first aim of 
this project. The substrate library will be include compounds with different chain 
length, methylation patterns and the geometries of the double bond. The second aim is 
the enzymatic investigation of the isolated ER domain with these pantetheine substrates. 
A stable kinetic enzyme assay has to be develop to analyse the different acyl 
pantetheine substrates. The third aim is the investigation of pantetheine substrates in the 
presence of 61. Is there any influence of 61 on the isolated ER domain and is the effect 
of 61 in enzyme assays detectable. It is possible that 61 may act as an inhibitor of the 
ER. 
 
2.3 Results  
2.3.1 Isolation of the Single ER Domain of SQTKS 
 
In order to investigate the programming of the ER domains from SQTKS the phpks1 
gene was reconstructed using cDNA and optimised for E. coli expression. The 
reconstructed gene was used as a template for PCR so that several single domains 
coding regions could be isolated. A separate investigation by David Ivison led to the 
production of 22 different soluble protein constructs, including single domains. David 
Ivison produced soluble protein of 22 different constructs.
[100,101]
 
The generation of soluble protein was achieved by heterologous expression of a 
plasmid contributing the domain coding region of interest. The expression plasmid was 
transformed in E. coli Rosetta II cells. The expression vector pET28a(+)_ER was 
constructed (Figure 26) in previous work by David Ivison to express the ER domain in 
E. coli.
[100,101]
 
 
Figure 26: Plasmid in pET28a(+)_ER which was transferred in E. coli. 
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In this project pET28a(+)_ER was transformed into the bacterial producer strain E. coli 
BL21. A successful transformation of the plasmid into E. coli was confirmed by colony 
PCR amplifying the DNA insert coding for the ER domain. A PCR product of 906 bp 
was generated, which is the same size as the PCR product from SQTKS producer 
Phoma sp. (Figure 27). 
 
 
Figure 27: Colony PCR control of the fresh transformed cells. Lanes A1, A3 and also A5 and A6 show in 
comparison to the control the successfull transfer. The size of 1 kb confirms the expected result. 
 
Strains positive for the SQTKS-ER domain were grown in a starter culture of 2TY-
medium. This starter culture was incubated over night. After that it was diluted 1:100 in 
2TY-medium (1-2-litre). The protein production was induced with 
iso-propyl β-D-1-thiogalactopyranoside (IPTG) at an OD600 of 0.6 and at 16 °C. After 
incubation over night the cells were harvested by centrifugation. The cells were broken 
by sonification and the resulting lysate was purified by a Nickel NTA column. The final 
protein was expressed as a His6-tagged fusion protein and isolated by affinity column in 
the first step.  
 
Figure 28: SDS-page of NiNTA and gelfiltration purification of the ER domain. 
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In the second step of the protein purification, the protein was purified by gel filtration to 
remove final impurities. Finally the resulting protein was analysed by SDS page 
(Figure 28). The purified protein matched the expected size (38.7 kDa). Isolation of 20 
to 25 mg of protein (Bradford) per expression was typical.
[101]
 
The ER domain forms a discrete dimeric protein when analysed by calibrated gel 
filtration (Figure 29). This is consistent with the structure of mFAS in which the ER 
domain appaers to have a large dimerisation surface.
[61]
 This contrasts to some other 
PKS ER domains, such as from the spinosyn modular PKS, which show monomeric 
behaviour.
[72]
 
 
 
 
Figure 29: Purification chromatogram of ER domain. 
 
For the calibration of the gel filtration column the three enzymes, Carbonic anhydrase 
(28 kDa, 3), BSA (66 kDa, 2) and Apoferritin (443 kDa, 1), were used. The resulting 
UV FPLC run of the calibration is shown (Figure 30). This calibration made it possible 
to investigate the isolated enzyme between their behaviour about oligomerization. The 
calibration run was performed in the same buffer as the size exclusion purification of 
SQTKS-ER.
 
 
Figure 30: Size-exclusion chromatogram of calibration enzymes. 
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2.3.2 Investigation of Programming by holo-ACP Mimics  
 
To determine the programming rules within the ER domain, a substrate library of 
several ER substrates was synthesized. Since ER proteins usually process ACP-bound 
substrates, perfect synthetic substrates should be ACP-bound. Some examples are 
known from the literature of the use of acyl-ACP substrates in kinetic assays.
[110]
 
However since ACP-substrates are hard to produce and analyse, we decided to use acyl 
pantetheines and acyl SNACs (Figure 31) which are widely used as acyl-ACP 
mimics.
[111,112]
 
 
Figure 31: Structures of used substrate residues. 
 
In addition to the natural substrates (85, 93 and 102), this library includes a broad range 
of unnatural substrates, e.g. with modifications in chain length; methylation pattern; 
methylation position; olefin stereochemistry; and even ethyl-substitution (Figure 32).  
We also included compound pairs such as 93/94 and 102/104 to test whether the 
ER is sensitive to stereocentres further away from the reaction centre. Previous 
investigations by Doug Roberts were made with SNAC compounds.
[100]
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Figure 32: Table of synthesized pantetheine substrates. 
 
In early work in this project SNAC and pantetheine substrates were directly compared 
using purified ER protein. Assays were set up which contained the ER protein, the 
SNAC or pantetheine substrate at identical concentration, and NADPH 13 which is the 
ER's preferred cofactor. As substrate is reduced, 13 is oxidised and this is observed 
spectro-photometrically at 340 nm. The rate of consumption of 13 is thus directly 
related to the reduction of the substrate. A similar method was developed by 
Kapoor et al.
[113] 
 The reduction of tigloylpantetheine 85 and tigloyl SNAC 107 were directly 
compared (Figure 33). To observe significant data in the SNAC assay, five times more 
enzyme was required than for the pantetheine to get comparable data. The pantetheine 
substrate is reduced twelve times faster than the SNAC substrate. The differences in the 
assays are caused by the structure of the two substrates. It seems that the 
pantetheine must interact with the active site of the ER domain. Based on this early 
assay we decided to use only acyl pantetheines as substrates.  
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Figure 33: Enzyme assay of tigloylpantetheine 85 and tigloyl SNAC 107. 
 
Preliminary experiments in previous work showed that it is possible to synthesize small 
pantetheine compounds. For this, commercially available pantethine dimer was cleaved 
with DTT to give the free thiol, and addition of acyl chlorides 108-111 generated the 
corresponding pantetheine thiolesters 113, which were then purified by HPLC 
(Scheme 24).
[72] 
 
Scheme 24: First method for synthesis of pantetheine substrates. 
 
For diketides this reaction worked well, but for longer substrates it was not effective. 
One problem was the low solubility of the pantetheine dimer in organic solvents which 
limited possible acyl coupling reactions.
 
Small acids and acid chlorides were 
commercially available and were used directly as shown in scheme 24.  
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2.3.3 Synthetic Route of Pantetheine Substrates 
 
For longer and modified substrates an alternative synthetic route was developed. This 
starts with carboxylic acids that are coupled to a protected pantetheine residue which 
can be easily handled in organic solvents and purified. The final step is deprotection and 
purification by mass-directed HPLC. 
The required acids were created in the following different ways. Knoevenagel 
reactions were used for unmethylated -unsaturated acids (Scheme 25). For this 
reaction, different aldehydes 114 were dissolved in pyridine in the presence of malonic 
acid. The elongated intermediate of the reaction was then decarboxylated in an 
additional reflux reaction at 115 °C. Finally, acidification and extraction resulted in the 
formation of products in high purity (>95%) and acceptable yield (40 to 50%). In this 
way it was possible to create 2-hexenoic- 116, 2-heptenoic- 117, 2-octenoic- 118 and 
2-decenoic 119 acids.
[115,116] 
 
Scheme 25: Knoevenagel reaction of different carboxylic acids. 
 
Wittig reactions were used to create the -methylated unsaturated carboxylic acids. 
Aldehyde 114 was used as the starting material for elongation by Wittig salts. Both 
starting materials were stirred in CH2Cl2 at RT for 18 hours and were finally purified by 
flash column chromatography. The corresponding esters 120 were cleaved by potassium 
hydroxide in a mixture of ethanol and water. After three hours under reflux the mixture 
was acidified and extracted to isolate the final -methyl-unsaturated acids 121. The 
produced substrates imitated tri-, tetra- and pentaketides (Scheme 26).
[116,117] 
 
Scheme 26: Synthesis route of -methylated carboxylic acids. 
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In the third method a reaction route was developed to synthesize -ethylated carboxylic 
acids. Triethyl-2-phosphonobutyrate 122 was deprotonated by potassium tert-butoxide 
in THF at 0 °C and then 114 was added to give the corresponding ethyl esters 123 and 
124. In this reaction both geometries of the double bond (E and Z ratio 2:1) were 
synthesized. Finally, the esters were cleaved again with potassium hydroxide to the 
corresponding carboxylic acids 125, 126. Ethylated hex-2-enoic 127, hept-2-enoic 128 
and oct-2-enoic 129 carboxylic acids were created using this method. The E- and 
Z-isomers were then coupled to pantetheine resdues and used in the enzyme assays 
without separation (Scheme 27).
[118]
 
 
Scheme 27: Synthesis route of -ethylated carboxylic acids. 
 
Several different carboxylic acids were prepared using a fourth route. A one pot 
reaction is shown for this synthesis in literature that combines oxidation and 
olefination.
[119]
 An example is the synthesis of 7-methyloct-2-enoic acid 132 and 
6-methylhept-2-enoic acid 135 (Scheme 28). 4-methylpentanol 130, 5-methylhexanol 
133 were oxidised (PCC) to form the corresponding aldehydes in a one pot reaction, 
which was followed by TLC. The aldehyde was then treated in situ with a Wittig salt to 
give the corresponding methyl esters 131 and 134. The addition of celite and 
magnesium sulphate was used to bind the reduced chromium salts and aid removal by 
filtration.
[119,120]
 After purification by flash column chromatography the resulted esters 
can be cleaved on the usual way. The acids could be isolated in a yield around 
70%.
[118,121]
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Scheme 28: Synthesis of 7-methyloctenoic acid 132 and 6-methylheptenoic acid 135. 
 
A racemic version of SQTK 136 was synthesised (Scheme 29). This began with racemic 
2-methylbutyraldehyde 137. A Wittig-reduction-Wittig strategy was used to obtain 142 
as a racemic mixture of diastereomers. At the starting point of the investigation, no 
enantiopure version of SQTK was available. Parts of this synthesis were performed by 
Adeline Kongtso during the supervision of her Masters Thesis.
[122,123,124]
 
 
Scheme 29: Synthesis of racemic version of SQTK 136. 
 
The enantiopure tetraketide 61 was synthesized using Squalestatin S1 56 as starting 
material. 56 was cleaved with potassium hydroxide. The final solution was extracted at 
pH 11 with sodium hydrogencarbonate. After that it was acidified to pH 1 and extracted 
with ethyl acetate. Compound 61 was obtained without by-products in a yield of 86% 
(Scheme 30).
[118] 
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Scheme 30: Synthesis of enantiopure SQTK 61. 
 
Once the carboxylic acids had been synthesised we then set out to find good methods to 
couple them to pantetheine. Townsend and coworkers published a method to synthesize 
a possible precursor for pantetheine in 2013. First pantothenic acid hemi-calcium salt 
143 was protected in actone at 25 °C in the presence of p-toluensulfonic acid to give the 
acetal 144. After that, a coupling with CDI and cysteamine in THF was used to generate 
the pantetheine dimethyl ketal 145. The yields of 84% for 145 are similar to the ones 
described by Townsend et al.
[49]
 
 
Scheme 31: Synthesis route of pantetheine substrates. 
 
The protection changes the solubility of the pantetheine so that 145 is soluble in 
CH2Cl2, EtOAc and MeCN. It was now possible to do an EDCI coupling, followed by 
deprotection and purification by HPLC, to get the final pantetheine substrates 147 
 
52 
 
(Scheme 31). In total, it was possible to synthesize twenty two pantetheine substrates 
which had differences in the methylation pattern, chain length, the isomerization of the 
double bond, and the methylation position. Yields and purity of the pantetheine 
dimethyl ketal substrates are not described in literature. Compared with other EDCI 
reactions for example the procedure of Carroll et al. that was used in the previous work 
by Doug Roberts the yield of 70 to 80% is in the expected area.
[100,125]
 Several 
advantages are known in contrast to the synthetic route that was performed by 
Zheng et al. (section 2.3.2, Scheme 24). The pantetheine dimer and monomer are highly 
hydroscopic. A sticky oil is formed on air. In contrast to the pantetheine dimethyl ketal 
it is also only soluble in water, THF, methanol, and acetonitrile.
[72,100] 
The pantetheine substrates included the three natural substrates and 19 different 
unnatural substrates designed to probe the selectivity of the ER. For example, an ethyl 
group in the -position should give information about the size of the ER active site at 
this position. This substrate library of diketides, triketides, tri and a half ketides, 
tetraketides and pentaketides completes the chemical part of the project.  
 
2.3.4 Enzymatic Investigation and Substrate Selectivity 
 
Kinetic investigation of the synthesized substrates described in section 2.3, should give 
further information about the selectivity of the ER and we hoped to be able to link this 
to the observed programming of the ER during the biosynthesis of squalestatin 
tetraketide 102. We planned to measure VMax/KM values (known as the specificity 
constant) for each of the different substrates. In that way a quantitative, detailed 
comparison of the different substrates and the enzyme selectivity should be possible. 
Differences in the selectivity of the enzyme should be revealed by different substrate 
structures of the compounds. 
 
Several early experiments were conducted to show that the reduction of the double bond 
can in fact be catalysed by the isoltated SQTKS-ER domain. These assays involved 
incubation of the ER enzyme with an SNAC or pantetheine substrate, such as 85, and 
NADPH 13 in buffer at 25 ˚C. The reactions were followed by HPLC and the product 
148 is clearly produced (Figure 34). However discontinuous HPLC-based assays are not 
convenient for measuring kinetic parameters. In order to obtain good initial rate data a 
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continuous assay is required. We developed a method based on the wavelength of the 
used cofactor 13 (340 nm). During the reaction the concentration of 13 decreases and 
this can be observed continuously at 340 nm.
[100,113]
 
 
Figure 34: Analytical enzyme assay of tigloylpantetheine 85. 
 
We first tried to set up in vitro UV assays at 200 L scale using 96 well plates.[100] 
However, no reproducible data was obtained.
[100]
 The formation of air bubbles was 
observed in the wells, which severely influenced the absorbtion. Absorption gets 
measured from the bottom to the top in the instrument. Changing the buffer conditions 
to reduce the amount of glycerol did not show a significant effect. Much better data was 
obtained when the enzyme assays were performed in cuvettes. The volume was scaled 
up from 200 L to 400 L to reach the minimum required volume. The absorption was 
measured from the side so that formation of air bubbles was limited or had no effect on 
the assay. It was possible to collect reproducible data. Assays were performed with 
50 mmol TRIS, 150 mmol NaCl and 20% glycerol buffer (Figure 35). 
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Figure 35: Reaction of the enoyl reductase in the present of NADPH 13. 
 
The enzyme requires the cofactor NADPH 13 to function, so this was added to the 
buffer in a 0.25 mmol concentration. Detection of NADH was not successful and 
showed no turn-over. Every substrate was measured in three technical replicates in 
substrate concentrations from 0.0625 to 0.625 M (Figure 36). 
 
Figure 36: Absorption curves (A,B,C) of the three replicates of tigloylpantetheine 85 at 0.0625 M. 
 
Enzyme activity was standardised under constant conditions using ethyl-hex-2-enoyl 
pantetheine 95, so that in every assay the same activity of the enzyme was used 
(SQTKS-ER, 0.08 U/µl). In the assays the absorption curve of consumed 13 was 
followed. After calculating the initial rates of the different substrates by Microsoft 
EXCEL the rate data were plotted with the software Curve Expert. In that way, it was 
possible to generate a nonlinear fit of initial rates in triplicate by direct fit to the 
Michaelis Menten equation (Figure 37).  
Finally the curve gives information about the Michaelis Menten Constant KM 
and the rate VMax, and these values allow the comparison of the different substrates with 
each other. Although separate values can be obtained the value of VMax/KM (the 
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specificity constant) is the best way to directly compare the different substrates 
(Figure 38). 
 
Figure 37: Michaelis Menten curve of 85, substrate concentration against the rate. 
 
The comparison of the different values shows that a methyl or ethyl group in the 
-position seems to fit very well in the active site and be reduced very fast. This is 
visible for example by the results of compound 91 and 95. It seems that at this position 
the shape of the active site has enough space to accept several different substituents in 
the - or -position. If the methylation is present at another position in longer carbon 
chains, the initial rates and VMax/KM values are much lower in comparison to 
-methylated or -ethylated substrates (compounds 92, 93, 94). It was also possible to 
show that both E- and Z-isomers of the diketides 85 and 86 could be reduced 
successfully. 
The fact that Z-olefins could be reduced by the enzyme is another indication of a 
broad substrate specifity. This shows that the ER domain is not selectively programmed 
to E-isomers, which are the naturally expected substrates.  
 The chain length of the substrates has some influence as well. For the diketides 
the substrates 85 to 88 could be reduced. Only the tetra-substituted form 89 shows no 
conversion to the reduced product. Triketides seems to be good substrates for the ER 
domain, which results in higher VMax/KM values (compounds 90- 95). The kinetic results 
of the tri and a half- and the tetraketides (96- 104) show a smaller VMax/KM value than 
the di- and triketides. Also surprising are the enzyme assays of the pentaketides 105 and 
106 that shows that they can be reduced by the ER domain. 
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Figure 38: VMax/KM values of the different pantetheine substrates. 
 
Interestingly, the result of the 4S-2-dimethylhex-2-enoyl pantetheine 93 showed a 
higher rate of conversion to the reduced product than the racemic version of this 
substrate 104. From this result, it is not clear what effect the stereocenter at the 
-position plays, which is in one assay clear determined and in the other assay in a 
racemic form. The role of this position cannot be confirmed without testing the pure 
4R-substrate 149 (Figure 39). In comparison with the racemic version, the assay using 
compound 93 ran 1.5 times faster. Therefore it might be expected that 149 should work 
similarly to an inhibitor and block the active site. Whether blocking is reversible or 
irreversible is not known at this time and needs to be further investigated. If this 
position is important, it should also be recognized in the enzyme assay of a stereo 
controlled 4S-methylated triketide. 
 
Figure 39: Structure of 4R-methylhex-2-enoyl pantetheine 149. 
 
Another example of the influence of the stereochemistry is the natural 4S,6S –
tetraketide 102, which is not measurably reduced by the ER in our kinetic studies. 
However the 4RS,6RS mixture of stereoisomers did show measureable reduction, so at 
least one stereoisomer of the tetraketide must be recognised and reduced.  
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Figure 40: Enzyme assay of 4S-6S-dimethyloct-2-enoyl pantetheine 102. 
 
It seems that the ER domain is sensitive against 4S,6S dimethyloct-2-enoyl pantetheine 
102. Which of the three other stereoisomers can be reduced was not further investigated.  
Since the kinetic assay runs only for a time period of twenty minutes we tested in an 
analytical assay over a time period of 24 hours a possible conversion of 102 into the 
reduced product. Also in this assay no conversion was obtained (Figure 40). 
 
2.3.5 Inhibition Test of SQTK  
 
The kinetic results suggested that some compounds could not be reduced, but do not 
show if this is because the compounds cannot access the active site at all, or if they can 
enter the active site but not form a productive conformation for reaction. We tested 
these possibilities by setting up inhibition assays. If compounds can act as inhibitors it 
means that they can enter the active site. 
 The substrate 85 was incubated with the ER enzyme in the presence of different 
concentrations of 102 under same conditions as used previously. The rate of the reaction 
of 85 is lower (Figure 41) in the presence of the tetraketide 102. It can be concluded that 
the tetraketide 102 can enter the active site of the ER domain but cannot be reduced, 
presumably because it cannot reach a productive conformation. 
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Figure 41: Enzyme assay of 85 in the present of different 102 concentrations. 
 
Since there is still a reduction process of 85, a reversible inhibition must take place. The 
fact that longer unmethylated pantetheine substrates can be reduced, as well as other 
stereoisomers of 102 shows that the ER is very sensitive to the methylation position and 
stereochemistry, and this presumably is the reason why 102 cannot be reduced by 
SQTKS in vivo. 
 
2.3.6 Stereoselectivity of the Isolated ER Domain 
 
The reduction of the double bond by NADPH 13  been studied in several investigations 
reported in the literature. In general, the 4-pro-R hydride of 13 is transferred and few 
exceptions are known. During the reduction four stereochemical outcomes are possible 
for the substrate and all of them are known in ERs from different FAS systems. 
Previous investigations were performed by isotope labeling experiments. By specific 
known dehydrogenases the position of the isotopic label was decided 
(Scheme 32).
[126-128] 
 
Scheme 32: Investigation of the hydride transfer of 13 to 150. 
 
The final product of SQTKS is released as 4S,6S dimethyl oct-2-enoic acid 61.  Since 
the ER catalyses the last -modification step of the synthase, it must be responsible for 
the determination of the stereochemistry in the molecule. In addition to position C-2 
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also the hydride transfer of 13 to C-3 could be investigated. The two possible hydrides 
of 13 are available for this process. 
The stereoselectivity of the isolated SQTKS-ER domain was investigated in 
previous work by Doug Roberts using Parker`s in situ NMR method for the 
determination of chirality of -substituted carboxylic acids. The ER product                 
2-methylbutyric acid 151 was used. By adding 1R,2R-1,2-diphenylethylenediamine 152 
to the NMR sample, resonances for the methyl groups of 151 are shifted 
enantioselectively, meaning the R and S enantiomers of 151 are resolved in the 
1
H NMR 
spectrum (Scheme 33).
[129,130] 
  
Scheme 33: Stereoselective investigation of C2-position. 
 
If a single enantiopure compound was generated from the ER reactions, only a single 
set of resonances for 2S-2-methylbutyric acid 151 would be expected. Tigloyl-
pantetheine 85 was incubated with the ER domain and 13 for 24 hours. Then the 
reaction product was isolated and hydrolysed. After that the mixture was acidified and 
extracted into CDCl3 and two equivalents of 152 were added. It was shown that both 
product stereoisomers are formed and thus the isolated ER is not able to control the 
stereochemistry of the substrates in the -position.[99,129,130] 
 It was possible to show the transfer of the 4'-pro-R-hydride of 13 to the substrate 
85. The transfer of the hydride was elucidated by several isotope labelling experiments 
using stereoselectively deuteriated NADPD. The different forms of NADPD (4'-R and 
4'-S) were synthesized by known enzymatic procedures.
[130]
 Both forms were incubated 
overnight with the ER domain and 85. After incubation of the ER domain with both 
isomers of NADPD and 85, the hydride transfer were analysed by LCMS.
[129]
  
 
Scheme 34: Enzymatic reaction of 13 with a pantetheine substrate to determine the stereocontrol of the -
position. 
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In the corresponding assays it was clearly determined that the 4'-pro-R-hydride is 
transferred. The rate of reaction using the labelled 4'R-NADPD was slower than the rate 
of the 4'S-NADPD reaction, presumably due to a primary kinetic isotope effect.
[129] 
 
 
Scheme 35: Synthesis of corresponding S-mandelate esters to investigate the stereoselectivity of the 
-position. 
 
The resulting deuterated products from the enzyme assays were hydrolysed and coupled 
to S-methylmandelate 148 and analysed by NMR and LCMS. The results of these 
assays again confirmed that the products were racemic at the -position. However 
transfer of deuterium from 4'-R-NADPD was highly stereoselective at the -position 
(Scheme 35).
[129]
 
 
2.4 Discussion 
 
To investigate the programming of the ER domain a library of different pantetheine 
substrates was created. Several different methods had to be developed for the synthesis 
of the carboxylic acids. These acids were then converted successfully to the 
corresponding pantetheine thiolesters. The pantetheine synthesis was also significantly 
improved by using the acetal-protected pantetheine reported by Townsend for the 
coupling reactions.
[49] 
Pantetheine substrates showed a much better solubility and 
reproducibility in the final in vitro enzyme assays than the previously investigated 
SNAC substrates. The successfully synthesized library included substrates with 
different structural features to test the selectivity and programming of the isolated ER 
domain. 
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Comparing the different SNAC and PANT substrates with each other showed 
the different results. For SNAC substrates the best diketide is tigloyl- followed by 
angelic- and crotonyl- SNAC. For PANT substrates the order is crotonyl- 87, 
angelic- 86, tigloylpantetheine 85. Other variations of diketides were not synthesized as 
SNAC substrates. The best substrates are the triketides: 91 and the natural substrate 93 
(93 was not made as an SNAC). A substituent in the -position seems to increase the 
rate of the reaction. Possibly the methyl group favours the orientation of the double 
bond to the catalytic residues of the active site. After that the unmethylated triketide 
follows which can rotate more freely in the active site. At least the racemic 
4-2-dimethylhex-2-enoyl substrate 94 follows. The additional methyl groups decreases 
the rate. This is for PANT and SNAC residues the same. The 4(S)-2-dimethylhex-2-
enoyl substrate 93 is in contrast to 94 enantiopure. It shows a higher VMax/KM value than 
94. This is in agreement with the expected results, since 93 is the natural precursor of 
the tetraketide 102. Unfortunately the second enantiopure compound 149 could not be 
synthesized but it is expected that its VMax/KM should be lower than that of 94.
[100] 
Other important information was elucidated for the tetraketides. The best 
tetraketide is the -methylated form 100, followed by 99 and 104. This is surprising 
since the SNAC version of 104 showed no conversion to the fully reduced compound. 
Possibly the reduction process is too slow for the SNAC version. Enantiopure 
compound 102 as the PANT substrate showed no conversion in contrast to 104. Longer 
carbon chained SNAC compounds showed a low water solubility (8-10 carbon atoms). 
Addition of DMSO was necessary to ensure their solubility. The use of PANT 
substrates had no limits for longer substrates containing this number of carbon atoms. 
Also different methylation patterns had no significant effect to the solubility. For both 
residues a reduction of mimicked pentaketides could be measured.
[100] 
In comparison to the previous results of SQTKS-ER with SNAC compounds, a 
faster reduction was observed. Large errors were measured for the reduction of the 
SNAC substrates, also was it difficult to tell if a reduction happen for the slowest 
substrates or not. The faster determination of the kinetic data with the pantetheine 
substrates prevents the enzyme from precipitation. A typical enzyme assay of a PANT 
substrate took 10 to 15 min. Enzyme assays for SNAC substrates required nearly a day. 
For the PANT substrates three replicates of measurements were performed to minimize 
the errors.
[100] 
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The ER domain of SQTKS shows broad substrate selectivity as a stand-alone enzyme. It 
was possible to reduce almost all the synthetic pantetheines. Another investigation of 
programming of iPKS by Tang (section 1.4) showed, in contrast to this, the high 
selectivity of the C-MeT domain of LNKS. This enzyme is highly selective to one 
compound which was shown in competition assays with the KR domain of LNKS. In 
contrast to the performed investigation of the ER domain of SQTKS, the C-MeT 
domain was investigated by SNAC compounds. The analytical method that was used 
was different. Tang et al. analysed their enzyme assays by LCMS.
[81]
 This method was 
not possible to establish for the ER domain of SQTKS. Another difference is the used 
enzyme. In the case of SQTKS we used an isolated ER domain excised from the 
complete PKS, while Tang et al. used a mutated version of the complete LNKS PKS 
protein. A mutation in the DH domain of LNKS stopped the reaction after the KR 
reaction. In that way the information of the stereochemistry of the first two -processing 
steps was determined. 
 The isolated ER domain seems not to control the stereochemistry in the -
position. The problem of the racemisation at the -position could not be solved by 
changing from SNAC to pantetheine substrates. First, it was speculated that possibly the 
low reaction rate of SNAC compounds was the reason so that a protonation by water 
could take place.  
A catalytically active form of the ER domain was expressed but the loss of 
stereoselectivity at the -position was thought to be due to a problem with protein 
folding. It is also possible that the fragment of the ER domain is catalytical active but 
some essential amino acid residues are not included in the expressed protein.
[129]
 
Taillorin et al. published a theory that could influence the stereochemical outcome of 
the ER domain in our investigations. The paper focussed on the interactions of the ACP 
with the isolated ER domain. The target of the investigation was the inhibition of the 
Escherichia coli Type II FAS ER domain (FabI).
[131]
 It seems possible that a part of the 
ACP is necessary for the closing process of the ER's active site. Another possibility is 
the interaction with other PKS domains around the ER.     
In contrast to the -position, the stereochemistry of the -position could be 
elucidated by Doug Roberts. The hydride transfer of NADPH to the substrate is 
controlled.
[129] 
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2.5 Conclusion 
 
The tested structural factors with the subtrates synthesized in section 2.3.2 showed 
several information about the programming of the ER domain. Use of acyl PANT 
substrates gave useful kinetic data in combination with the isolated ER domain. Two 
analytical methods could be established. One that showed the reduction process by UV, 
the other one by LCMS. 
The in vitro assays were also significantly improved. The change of the system 
from 96 well plates to cuvettes gave significant improvements. The different substrates 
were measured in triplicate for each concentration, and this gave consistent data sets 
with low variation. The rate data was then used to create the Michaelis-Menten curves 
that were used to create the VMax/KM values for each substrate.  
The results show that the isolated ER domain of SQTKS has remarkably broad 
substrate selectivity, with almost all synthesised substrates showing measurable activity. 
The substrates included assumed intermediates as well as others which are unlikely 
intermediates (the Z-isomers) and those which cannot be intermediates (e.g. ethyl-
substituted, incorrectly methylated, and compounds with odd carbon chain-lengths). 
This suggests that the active site of the SQTKS-ER domain must be quite large and 
flexible. Another information that could be required is the relation between the C-MeT 
and ER domain. Further investigations showed that SQTKS-ER exists as dimer. Since 
there is a high end to end homology between vFAS and the fungal HR-PKS this 
confirmed the expected data.
[61,101]
  
In vitro assays showed that the isolated ER domain is not possible to predict the 
stereochemistry of the -position. All substrates were produced as racemates. None of 
the enantiomers was preferred. This position is very rare investigated in mPKS and 
iPKS. Some investigations of this position are mentioned in section 2.1. Catalytic 
residues were highlighted but none of these informations could be transferred to 
SQTKS. It is possible that the ACP is involved in the process, but this can not yet be 
confirmed as the SQTKS-ACP has not yet been cloned and expressed. Catalytical 
activity was shown without the ACP but maybe the active site needs to be docked by 
the ACP. Otherwise it could be flooded by water. An uncontrolled protonation could 
result in the entrance of water. 
 In contrast to this the stereochemical investigation of substrate-position C-3 was 
successfull. The transfer of the hydride could be investigated. It seems that the 
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orientation of the substrate in relation to the cofactor may be more important. 
Investigation of possible protein structural features that could be important is necessary 
to further investigate this point. The production of protein crystals was attempted by 
previous workers, but this was not successful.
[100]  
However previous workers were able to generate a structural model of the 
isolated ER domain, based on the crystal structure of the vertebrate fatty acid synthase 
(2vz9) as template.
[129]
 The three main features of the model are the N-terminus, which 
forms a globular domain, the middle section, which forms a cofactor binding domain 
containing a Rossmann fold and finally the C-terminus that forms part of the active site 
around the cofactor and substrate binding regions.
[129] 
A tunnel is indicated by the model that shows the active site with the possible entry of 
the substrate and the underlying cofactor. The active hydrides of the cofactor are 
positioned at the end of the tunnel (Figure 42).  
 
Figure 42: Pocket of the active site of the ER domain. 
 
Only the nicotinamide 4'-pro-R hydrogen is freely available in the pocket during the 
reduction process while the 4'-pro-S hydrogen points towards the wall of the pocket. 
Specific contacts of the NADPH are observed with residues S2072, K2055, G2029, 
I2119 and V2144.
[129]
 This is in agreement with vFAS. It is known that the 4'-pro-R 
hydrogen of NADPH is added at C-3 to the substrate similar to the stereochemical 
investigation of SQTKS-ER.
[129]
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Docking pantheine substrates into this model showed a parallel orientation of the 
substrate to the cofactor for 4S-2-dimethylhex-2-enoyl pantetheine 93. For the 
 unsaturated moiety a s-cis conformation is observed. The distance between the 
substrate -carbon and the active hydride of NADPH is 3.6 Å. The model also offers an 
explanation for the faster reaction of pantetheine substrates as compared to the SNAC 
substrates. The two methyl groups at the end of the pantetheine residue interact with the 
hydrophobic area of the pocket at the entry of the tunnel.  
This area is constructed by the residues C2097 and L2098. In the full PKS it is 
assumed that the ACP would be located at the entrance to the tunnel, which is in 
agreement with the model. Another contact outside the tunnel between ACP and ER 
domain is suggested. Analysing the position of the - and -positions of the substrate 
shows that the model and experimental data are consistent with respect to to the hydride 
transfer. Stereochemical in vitro assays with 85 showed the selective hydride transfer to 
the Re-face of C-3. Additionally the resulting enol(ate) must be reprotonated. In the 
case of SQTKS-ER this is expected from the Re-face of C-2 to create the known 
stereochemical outcome. As shown in section 2.1 there are some catalytic residues 
known that could be involved in this process. Leadlay highlighted tyrosine and valine 
residues. For vFAS and SQTKS a leucine residue is found at this position. But the 
reprotonation is different between vFAS and SQTKS-ER. For vFAS the enolate 
reprotonated Si and not Re like the investigated ER domain. However, analysing the 
area at the -carbon in the model shows that no residue or proton source is available 
that can predict the stereochemistry at this position.
[129]
 
Docking experiments of the tetraketide substrate 99 were in agreement to the 
triketides. Orientation and location of the acyl group of 99 to cofactor NADPH 13 was 
still the same. Only the carbon chain is now located deeper in the active side of the 
tunnel. In contrast to the previous s-cis confirmation now a s-trans confirmation is 
observed. For the docking process of 102 this confirmation is twisted. This time also the 
location of the substrate is different to 99. Reasoned to the additional methyl groups 102 
is located on top of the active site.
[129] 
This also explains why the natural tetraketide 102 works as an inhibitor. It is 
possible for 102 to enter the active site, as shown in the inhibition assays, but it cannot 
reach a suitable conformation for reduction. Significantly, the racemic mixture of 
stereoisomers of 104 was slowly reduced showing that at least one of the four isomers 
can reach a productive conformation for reaction. This suggests that interactions 
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between the tail of the polyketide, and in particular its methyl groups, with the walls of 
the active site can control the positioning of the reacting olefin.
[129]
  
 
2.6 Future Work 
 
For the future the analysis of the active residues that are involved in the reducing step 
would be helpful. From previous studies with other ER enzymes and domains no 
residues have so far been found which have been conclusively shown to be involved in 
the reprotonation step. Two ways are possible for the analysis. First the creation of a 
crystal of the ER domain could show the correct distances and also the real active site. 
From this crystal also active residues could be hypothesised and this could lead to 
investigation of the active site by point mutations. Also on that way possible active 
residues could be identified. Changing amino acids which form the walls of the 
substrate-binding pocket could open or extend the active site. In that way the reduction 
of longer chained pantetheine substrates should be possible. Possible amino acids for 
these investigations are phenylalanine (F280), leucine (L269) and isoleucine (I270). 
Also mutation of the amino acids that hinders 102 to get in the correct distance to the 
catalytic residues could be performed. The assumption of the theory based on the model 
of SQTKS could be tested. 
 
Figure 43: Different stereoisomers of 102. 
 
For the natural SQTK 102 the synthesis and enzyme assays were performed and 
analysed. The enantioselective synthesis for the other three isomers has to be developed 
also corresponding enzyme assays have to be performed. The different isomers are 
known by literature (Scheme 36).
[132-141]
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Scheme 36: Synthesis to form the precursor 165 of 4R,6R-isomer  156. 
 
Starting with commercial available (2S,4R)-5-hydroxy-2,4-dimethylpentyl acetate 160 
and additional protection of terminal hydroxyl group results in the protected compound 
161. Additionally the acetate group can be hydrolysed to an alcohol by sodium 
methanolate. In the next step a good leaving group is created by a tosylation with tosyl 
chloride of the terminal alcohol in the presence of triethylamine and DMAP. The 
following reactions are a nucleophilic substitution of the tosyl residue by a Gilman 
Cuprate to form the protected alcohol 162, which gets deprotected in the next step by 
tetra-butyl-ammonium fluoride (TBAF). Finally, the known methods of previous 
reactions can be used to form the carboxylic acid 165 that is used in the final coupling 
reactions. For all steps yields of 80% and more are reported.
[132-141]
 Synthesis of 
precursors of the carboxylic acids or esters for isomers 155 and 157 are also 
known.
[141,142,143]
  
Synthesis of 171 starts with the Evans auxiliary (S)-hydroxymethyl 
pyrrolidinone 166. Reaction with (S)-(+)-1-iodo-2-methylbutane 167 with additional 
removal of the auxiliary with 10% HCl and reduction of the carboxylic acid results in 
the alcohol 168. Oxidation by TPAP and N-methylmorpholine N-oxide results in the 
aldehyde 169. By additional Horner-Emmons reaction 169 is transferred in the ester 
170. This could be cleaved with potassium hydroxide to the desired product 171 
(Scheme 37). The fourth isomer could be synthesized by the alkylation of the 
oxazilidone amide 171 with the (R)-2-methylbutyl trifluoromethanesulfonate 172. The 
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resulting product 173 is reduced to the alcohol 174 by LiBH4. Further steps of the 
synthesis of 177 are described by the production of 171 (Scheme 37).
[116,142-145]
  
 
Scheme 37: Synthesis of precursors 171 and 177 of the 4R,6S-isomer 155 and 4S,6R-isomer 157. 
 
Another investigation can focus on the interactions between the pantetheine arm and the 
amino acid residues of the ER domain. The comparison between SNAC and pantetheine 
substrates showed a high difference in the reduction process. For the reduction of the 
tigloyl moiety a factor of 12.5 was measured. The further analysis of the interactions 
between the pantetheine arm could be performed by an exchange of several 
heteroatoms. Since the addition of the second amide group has a significant effect 
several atoms could be replaced to get a better understanding about which parts of the 
pantetheine arm interacts with the active site. For example a possible candidate is the 
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nitrogen atom of the amide group that could be replaced by an oxygen to form the ester 
178. Possible compounds are shown (Figure 44). 
 
 
Figure 44: Synthesis of modified tigloylpantetheine structures. 
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3.0 Project 2: Investigation of the SQTKS-DH Domain 
 
A second domain that is found in the -modification part of PKS is the DH domain. It is 
well understood and investigated in mPKS. Several crystal structures from mPKS and 
FAS are available and these highlight residues which are involved in the dehydration 
process. However, DH domains from iPKS have not been previously investigated. 
The DH domain acts after the KR and directly before the ER domain in the 
-processing cycle. The DH catalyses the loss of water from the alcohol 180 formed in 
the previous step by the KR domain to give an unsaturated thiolester 181 
(Scheme 38). The olefins formed by DH domains are in most cases trans configured, 
but the cis configuration is known in some cases.
[17] 
 
 
Scheme 38: Basic reaction of the DH domain. 
 
3.1 Previous Structural and Stereochemical Investigations  
 
Recent structural studies have shown that DH domains, in most cases, form dimers in 
solution. Each monomer consist of a double hot dog fold. An -helix shows the 
structure of the “sausage” that is surrounded by a curved -sheet, which forms the "bun" 
of the hotdog (Figure 45).
[71]
  
 
Figure 45: Structure of the double hot dog fold of the CurF DH domain.[71] 
 
The active site of the DH is formed by a His-Asp “catalytic diad” system. The histidine 
is located at the N-terminus of the hotdog, while the aspartate is at the C-terminus. The 
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active site is located at the bottom of a V structure formed by both hot dogs. The 
substrate tunnel is located at the bottom of the V. This structural relation was found for 
several DH domains including those from CurF and CurK and also Ery DH4 and 
mFAS.
[17,21,61,71] 
 
Figure 46: Structure of the dimer of double hot dog folds of EryDH 4.[21] 
 
Formation of the homodimeric structure is necessary for the catalysis process 
(Figure 46). Every active site is formed by two identical monomers. For the DH domain 
itself hydrophobic residues are found that have potential in interfaces with other PKS 
domains (Section 1.3.2).
[21,71] 
X-ray crystal structures for several DH domains of 
modular PKS enzymes have been reported.
[16]
 These DH crystal structures show a high 
similarity to the ones of the animal fatty acid synthases.
[17, 61]
 
 
 
Figure 47: Sequence alignment of SQTKS-DH to EryDH4, CurK and CurF DH domains.
[71] 
 
One example is the crystal structure of EryDH4. For this enzyme a double-hotdog fold 
for the structure was found. A loop connects two pseudosymmetric halves of the DH 
monomer. One of these halves posses the catalytic active histidine (residue 45) as part 
of a conserved HXXXXXXX(Y/F)PG motif.
[21,71]
 Comparing this sequence with the 
 
72 
 
one of the DH of SQTKS, CurK and CurF showed that this motif is clearly conserved 
(residues 45 to 55). Comparing all four sequences an identity of 15 to 20% was 
observed (Figure 47).
[21,71]
 In Type I PKS an aspartic acid residue is also involved in the 
mechanism of the DH. This residue is found at position 236 of the sequence alignment 
that contributes in all four PKS enzymes. Analysing the sequences showed that at this 
region again a high similarity is observed (Figure 47).
[21,71]
 
The glutamine at position 240 of EryDH4 is highlighted as it is also conserved in 
many PKS DH enzymes, but can be substituted by histidine in some DH proteins. The 
crystal structure of EryDH4 shows that this residue is connected via hydrogen bonds to 
an invariant tyrosine residue at position 180 (present in SQTKS-DH, EryDH4, CurK 
and CurF).
[21]
 Another tyrosine residue, ten amino acids away, is found in the 
GYXYGPXF motif. This tyrosine is located close to the active site histidine and 
aspartic acid. In the crystal structure of EryDH4 water is bound by this residue and 
directly coordinated to the catalytic aspartic acid. This motif is also found in the DH 
sequence of SQTKS but the tyrosine is replaced by histidine (Figure 47). For the other 
PKS this tyrosine is conserved.
[21, 71]
 
How much information of the crystal structures can be transferred to the aligned 
sequences of SQTKS-DH is unclear. It shows only that the residues that are involved in 
the catalytic process are found in modular and iterative PKS. It is not known if these 
residues have the same task in iterative PKS. Also several motifs were found in all four 
PKS. 
 
Scheme 39: His-Asp catalytic dyad mechanism of the DH domain. 
 
The proposed catalytic mechanism involves removal of the proton in the -position of 
the substrate 9a by the active site histidine. An enol(ate) intermediate 9b is formed 
which is stabilised by hydrogen bonding and alignment of the polar C-O bond with the 
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hotdog helix dipole. Then, aspartic acid protonates the -hydroxyl group and water is 
the leaving group (Scheme 39). The overall mechanism corresponds to an E1cb process. 
Almost all known DH catalyse an overall syn removal of H2O to form a trans 
olefin 9c.
[17]
  
 
3.2 Aims of the project 
 
To get more information about the programming of SQTKS a second domain should be 
investigated. The DH domain was chosen. There was some information from previous 
investigations by the Cox group available about this domain. For example the 
stereochemistry of the substrate for this domain is known.
[146] 
A synthetic route for an 
acyl pantetheine substrate of the DH is planned as the first aim of this project. It is 
expected that the pantetheines should be faster substrates than the corresponding SNAC.
 
For final enzymatic investigations it is planned to express the isolated DH domain of 
SQTKS. This includes the transformation of a plasmid in a bacterial producer strain, the 
development of the fermentation system of the bacterial strain and the development of a 
purification protocol for this protein. Following the expression enzymatic investigations 
of the DH and the synthesized compound is planned. Also is it necessary to develop a 
suitable method for the enzymatic investigation.
 
The final aim of this project is the 
investigation of the pantetheine substrate in the presence of 61. Is there any influence of 
61 to the isolated DH domain and an effect of 61 in enzyme assays detectable. It is 
possible that 61 has an inhibitory effect on the DH enzyme.  
 
 
3.3 Results and Discussion 
3.3.1 Isolation of the Single DH Domain of SQTKS 
 
To investigate the kinetic reaction, activity and the stereochemistry the dehydratase 
domain of SQTKS was expressed as a soluble protein. The domain boundaries were 
chosen by sequence alignment with known DH domains from mFAS. In the mFAS 
structure the DH- and ER domains are bound covalently by a linker and by interfaces of 
amino acids to each other. Further investigations of this thesis were orientated on 
interaction between the two isolated domains of SQTKS (Chapter 4). It was suggested 
that maybe the DH domain could be involved in influencing the stereochemistry at the 
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-position during the ER reaction. Previous work (Chapter 2) had shown that in the 
isolated ER the stereochemistry at this position cannot be controlled as it is in the full 
SQTKS. 
To express the single DH domain, the plasmid construct pOPINF-DH (produced 
by David Ivison) was transformed into the producer strain E. coli BL21 and also in 
E. coli Top 10 cells (Figure 48).
[101]
  
 
Figure 48: Plasmid in pOPINF_DH vector. 
 
A single colony of the producer strain E. coli BL 21 was transferred in 2TY-media to 
produce a starter culture and incubated over night. The starter culture was diluted 1:100 
in 2 litres of 2TY media separated into 20 flasks. After an optical density of OD600 0.6 
was reached, the cells were induced at 16 °C with IPTG (injection of 50 L of a 
1 M stock solution). Cultures were cultivated for a further 16 hours and then cells were 
harvested by centrifugation and lysed by sonification.  
 
Figure 49: Chromatogram of the re-buffering of the DH domain to remove imidazole. 
 
The resulting lysate was purified by NiNTA chromatography and the final protein was 
purified similar to the ER domain with a fused His6-tag. Purified expressed protein was 
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re-buffered with imidazole-free buffer, since it was confirmed that the protein has a low 
tolerance to imidazole (Figure 49, Lines D1 and D2). 
Finally, the resulting protein was analysed by SDS-page which showed the 
unexpected mass of a 27.8 kDa protein. The expected size was 38.1 kDa. Since there 
was no visible fragmentation on the gel, further analysis was necessary to confirm the 
protein (Figure 50). 
 
Figure 50: SDS-page analysis of DH expression. 
 
A problem in the SDS-page analysis could be the amount of glycerol (10%) in the 
purification buffer. It is possible that the protein was not completely unfolded. To 
confirm this, the protein sequence was analysed by MALDI.  
 
Figure 51: MALDI-analysis of the DH domain. Green bars show the high identity of the observed 
fragments in comparison to the known amino acid sequence of SQTKS-DH. 
 
The results of the MALDI experiment showed that the expected protein was expressed 
and that the SDS page did not show the correct size. An identity of 100% was observed 
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for the obtained fragments. The previous assumption that the protein was not 
completely unfolded is correct. The His6-tag as starting point and the final amino acid 
sequence were found. The gaps that in the sequence from the MALDI analysis most 
likely correspond to peptide fragments which did not ionise in the experiment 
(Figure 51).  
It was possible to express the isolated DH domain in a scale of 30 mg. A similar 
expression and purification system was used that was successful in previous work for 
the expression of the ER domain. The change of the expression medium from LB to 
2TY resulted in an upscale of isolated protein. Changes of the induction point had also a 
positive effect.  
 
Figure 52: Size-exclusion chromatogram of isolated DH domain in solution. 
 
Analysis of the purified DH domain by size-exclusion chromatography showed two 
peaks in the chromatogram. Only a small amount of the enzyme forms a dimer in 
solution, peak at 190 mL. The peak at 210 mL shows that most of the DH domain was 
eluted as a monomer (Figure 52). The investigation was performed in the same buffer 
like the ER domain since for this enzyme a calibration of three different enzymes was 
available.  
A reason for the monomeric DH domain could be the amount of glycerol (20%) 
that was used in the buffer. It is possible that the glycerol forms a surface around the 
enzyme, which makes it impossible that an interaction between the monomers take 
place. In general the interface between DH monomers is quite small and formed by 
highly complementary and hydrophobic surfaces. The result is in contrast to several 
other DH domains of mPKS and mFAS where it is known that they form dimers in 
solution.
[71]
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3.3.2 Synthesis of Pantetheine Substrates for the DH Domain 
 
To test the DH domain for its activity a pantetheine substrate was synthesized. The 
same synthetic route was used as described previously; EDCI coupling of 
corresponding acids with the pantetheine acetone acetal. Further tests showed that the 
DH domain recognises only one stereochemical orientation of the hydroxy group. These 
investigations were performed by another PhD student of the Cox group with SNAC 
compounds, which were also in this topic poor substrates.
[146]
 To test the enzymatic 
activity, a enantiopure pantetheine compound with the known accepted stereochemistry 
was synthesized.  
The synthesis started with the commercially available 3R-hydroxybutanoate 
methyl ester 182 (Scheme 40). This ester was deprotonated by two equivalents LDA in 
the first step. In the second step 182 was methylated with iodomethane. This type of 
stereospecific methylation is called the Frater-Seebach alkylation and is known to give 
the 2R,3R stereoisomer in this case. Next, the product of this methylation 183 was 
protected by reaction with tert-butyldimethyl-silyl triflate in dichloromethane. The ester 
184 was cleaved in the presence of lithium hydroxide in aqueous medium to generate 
the carboxylic acid 185 which was coupled to pantetheine dimethyl ketal using standard 
EDCI conditions. This was performed in a similar way to the previously described ER 
substrates (section 2.3.2).  
 
Scheme 40: Synthesis route of (2R, 3R)-3-hydroxy-2-methylbutyl pantetheine 187. 
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Finally the deprotection of the pantetheine residue and also of the hydroxyl group was 
achieved using TFA. The final product had an ee of 97%.
[147-149]
 The substrate was 
generated during the supervision of the Bachelor Thesis of Sandra Johannsen with the 
topic “Synthesis of substrates for the SQTKS Dehydratase” (Scheme 40).[150] 
 
3.3.3 Enzymatic Investigation of DH Domain 
 
Analytical scale assays were performed in a total volume of 120 L at 30 °C in TRIS 
buffer pH 8.5 containing 0.5 mmol substrate and a final concentration of 0.5 mg/ mL 
enzyme. The assays were analysed by LCMS (Figure 53). The substrate 187 was 
converted cleanly to the expected product 85.  
 
Figure 53: Chromatogram of an enzyme assay of the DH domain. Dehydration of 187 to 85. 
 
Problems in this case were to measure the initial rate and to get the final KM and VMax 
values. Again the LCMS assays were discontinuous and difficult to make reproducible.  
It was not possible to establish a calibration curve for one of the substrates. The 
measured initial rates also showed a high variance.  
Since the LCMS data could not give an accurate kinetic rate, the UV profile of 
starting material and product was analysed. As the product of the reaction, 
tigloylpantetheine 85 has an absorption maximum at 260 nm, which the starting 
material does not have. Again investigations by UV were performed (Scheme 41). 
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Scheme 41: Dehydration process of 3R-Hydroxy-2R-methyl butanoyl pantetheine 187 with UV profiles of 
85 and 187. 
 
With this information the assay condition were changed. Similar to the assays of the ER 
domain the reaction was analysed continuously by UV to create a new method for DH 
domain analysis using in cuvettes since it was not possible to get good quality data by 
96 well plates. 
 
Figure 54: Absorption curve of 85 in the performed enzyme assays. 
 
In this method the total volume of the assay was 400 L and performed with 330-
365 L of 50 mmol TRIS buffer (pH 8.5), 150 mmol NaCl and 10% glycerol buffer. 
The substrate was measured in three technical replicates in substrate concentrations 
from 0.0625 to 0.625 M. In contrast to following the cofactor concentration in the ER 
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assays, this time the formation of product 85 was followed directly (Figure 54). This 
assay gave reliable initial rate data with low variability. Initial rate data was collected in 
triplicate and plotted vs substrate concentration to obtain the Michaelis parameters 
(Figure 55). 
 
Figure 55: Michaelis Menten Curve of the DH enzyme assay. 
 
The Michaelis Menten Curve was plotted and the corresponding values were calculated 
by the calculation program Curve Expert. For KM a constant of 1.34 M was calculated.  
The resulting VMax/KM value of 87.3 min
-1
 is again in the same area like the analysis of 
the ER domain (Figure 55). The calculated kcat value was 117 min
-1
. A value of 
87.3 M-1min-1 was reached for kcat/KM. 
In literature several investigations are shown to determine the stereoselectivity of DH 
domains. ACP bound species are the natural substrates of iPKS and FAS DH domains, 
but it is normal to assay these enzymes in vitro using acyl-SNACs.
[146,151]
 During the 
investigation of the SQTKS-DH domain by Emma Liddle in the Cox group, SNAC 
substrates were used.
[146]
 For the SNAC analoque of 187 a kcat value of 0.063 min
-1
 and 
a KM of 4.5 mM was calculated.
[146] 
The resulting conversion to the dehydrated 
compound was very slow in this case. But these results show that the acetyl 
pantetheines are effective substrates, similarly to the previous work with the ER domain 
(Chapter 2).  
The kinetic assays confirmed the previous investigations which used SNAC 
substrates that the 2R,3R stereoisomer 187 is the substrate of the DH domain. This 
stereochemical arrangement at C-3 is the same as that known for mPKS domains.
[151]
 
Also the performed syn elimination similar to the catalytic reaction of SQTKS-DH is 
observed.
[151]
 In contrast to the SNAC results measured in Bristol the kinetic assays 
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were not analysed by LCMS because reliable calibration curves for the starting material 
187 or product compound 85 could not be made. The LCMS assay was only used in the 
acyl pantetheine assay as qualitative tool to validate the enzymatic reaction.
[146]
 
It was possible to measure the kinetic data and to calculate the Michaelis Menten 
curve. Similar to the previous ER domain assays, also for the DH domain faster rates in 
contrast to the SNAC assays were observed. For the SNAC compound a value of 
0.014 mM
-1
min
-1 
was reached for kcat/KM. In contrast to this the pantetheine result was 
0.087 mM
-1
min
-1
. The pantetheine substrate of the DH domain was dehydrated faster by 
the factor 6.2.
[146]
 
In these in vitro studies the additional part of the pantetheine residue has again a 
positive influence concerning the rate. Similar to the ER domain substrates, interacts the 
elongated residue with amino acid residues of the active site. A second advantage of the 
pantetheine residues is the lower flexibility in the active site. Several interactions 
between the substrate and the enzyme are expected. It is suggested that these 
interactions are important to locate the acyl group of the pantetheine faster in the correct 
distance of the catalytic residues.  
 
3.3.4 Inhibition Assays of the DH Domain with SQTK 
 
Interactions between the DH domain and tetraketide 102 were investigated. The 
tetraketide 102 was tested as an inhibitor of the DH domain. Assays were set up in 
which 102 was added to standard reaction assays containing the DH and its substrate 
187. These reactions clearly showed that addition of 102 causes measureable inhibition. 
Comparing the data of the pure- and inhibited assay shows a measureable 
inhibition by 102. This is very surprising for the enzyme. It would be expected that 102 
is not a substrate that can visit the active site: 102 is actually the product of the DH 
domain. A fast release with low interaction would be expected. On the other hand, it is 
known from different investigations that the dehydration process is an equilibrium in 
which the reverse (hydration) reaction can be catalysed by the DH domain. This would 
explain why SQTK 102 can interact with the active site strongly.
[151,152]
 Interestingly in 
this experiment, the inhibition occurs at a low concentration of 102 (0.13 M). The 
rates were slow down in comparison to the assays without SQTK by the factor 3. In 
contrast to this an amount of 0.13 M of SQTK lowers the rates of the ER domain by a 
 
82 
 
factor of only 0.5. Substrate and inhibitor concentrations were in both enzyme assays 
the same (Figure 56). 
 
Figure 56: Inhibition enzyme assay for the DH domain with 102. 
 
Further analysis about the inhibitory effect could be performed. It was shown that the 
natural tetraketide 102 inhibits the DH domain. Is the stereochemical arrangement of 
the methyl groups the reason? In additional tests the racemic compound 104 could be 
used. If the orientation of the methyl groups is important, the inhibition of this 
compound should be lower. 
 
3.4 Conclusion 
 
To confirm the stereoselectivity of the SQTKS-DH domain a pantetheine substrate with 
the expected stereochemical information was created. A successfull synthetic route was 
planned and implemented in the lab. Similar to the developed route in section 2.3.2, first 
a carboxylic acid was created and coupled with the pantetheine dimetyl ketal residue. 
The resulting product was transferred into the pantetheine substrate 187. A new and 
improved method was developed to analyse the different kinetic assays. First in vitro 
assays were analysed by LCMS but it was not possible to transfer this method to the 
pantetheine substrate. Only the general reaction of the enzyme with the starting material 
and product could be analysed on that way. 
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Analysis of the UV profiles of both compounds showed that 85 has an absorption 
maximum at 260 nm which is missing in the starting material. Final enzyme assays 
could be analysed by UV. For this the known method of the ER domain was used and 
modified. Again cuvettes were used instead of 96 well plates. 
The kcat/KM value could be calculated for the reaction. The results of the ER 
domain could be confirmed. The pantetheine residue interacts stronger to the active site 
of the enzymes than the SNAC residue. Also the dehydration process of the acyl 
pantetheine substrate works faster. 
It was shown that 102 acts as an inhibitor for the DH domain, and it can thus 
enter the active site. The stereochemistry of the methyl groups could be important for 
the DH domain. This was also shown for the ER domain. Further work will be required 
to test if this factor is important for the DH.  
 
In the biological part of the project a successfull expression of the DH domain was 
performed and the expression and purification was improved. A change in the 
fermentation medium was performed from LB to 2TY. High amounts (25 to 30 mg) of 
pure protein were expressed and purified. Size exclusion experiments showed that the 
DH domain does not form dimers in solution. 
 
3.5 Future Work  
 
It was possible to verify the correct stereochemistry of 187 of the DH substrates. 
Similar behaviour and results were obtained in kinetic studies in comparison to the ER 
domain.  
Interestingly also for this enzyme the inhibition assays with 102 were positive. 
This was very unexpected because 102 is a product of the reaction. Similar to the ER 
domain, investigations with different substrates could be possible. These substrates 
could have variations in chain length, methylation pattern and methylation position. 
Also in this case the investigations of the kinetics could show some stereochemical 
functions that are prefered by the DH domain (Figure 57). 
It is known for the ER domain that the stereochemistry is important for the 
catalytic reaction; also for the DH domain several different stereoisomers could be 
tested. In addition to the natural substrate a series of different isomers of tri- and 
tetraketides could be synthesized and tested (Figure 57). 
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Figure 57: Possible substrate library for DH domain investigations. 
 
A possible variant for the synthesis of substrates 188 and 192 are the Evans aldol 
reaction (Scheme 42). Starting with Evans auxiliary 197 and coupling with acetyl 
chloride results in compound 198. This is converted to amide 199 by an aldol reaction 
with butyraldehyde or hexanal. After that the amide can be cleaved and the final acids 
200 are formed. These acids could be used in EDCI coupling reactions to generate the 
corresponding pantetheine substrates 188 and 192.
[153]
 
 
Scheme 42: Synthesis of precursors for substrates 188 and 192. 
 
Another option to synthesize several substrates to investigate the active side of the DH 
domain is shown in scheme 43. This preparation starts with (1S,2R)-N-methyl-
ephedrine 201 that predicts in the later steps the stereochemistry of the carboxylic acid.  
In this proposed route 201 is used as starting material that is coupled with 
propionyl chloride in THF to give the ester 202. This gets converted with TMSCl and 
LDA to the stabilized silyl ketene acetal 203 which has a ratio of 95:5 E/Z 
selectivity.
[154,155]
 After that another aldol reaction, similar to the previous reported one,  
is required. In this step titanium tetrachloride and triphenylphoshine are used in the 
presence of an aldehyde to form compound 204. The tertiary amide blocks the attack to 
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the aldehyde from one side so that only the R-R-configuration can be prepared this time. 
This is the correct stereochemistry which was found out to be active for the DH domain 
(Scheme 43).
[154,155] 
  
Scheme 43: Synthesis of precursors for substrates 188 and 189. 
 
Finally the ester 204 is cleaved with sodium hydroxide in a methanol/ water mixture 
and the desired carboxylic acid 205 is obtained for the next coupling reactions with 
EDCI. During the PhD it was possible to create compound 203. Limited to the time and 
progress at this stage this method was not completed.
[154,155]
  
Several investigations showed the influence of different residues that were 
highlighted in the previous chapter. To confirm this structural motifs and orientations of 
the different amino acids in the active site a crystal structure of the DH domain has to 
be established. Analysing these crystals could represent the correct distances of the 
catalytic residues histidine and aspartic acid that are involved in the dehydration 
process. The predictions between the other motifs and their function could be analysed 
on that way.   
Another possibility could be the modification of the active site by mutagenesis 
experiments. Changing the proposed active residues should lead in an inactivation of 
the enzyme and show negative results in the dehydration process. For further 
investigations, which are shown in chapter 4 the mutagenesis of the active site is 
essential to create an experiment with reproducible results. 
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4.0 Project 3: Biophysical Investigations of DH and ER Domains 
 
Type I PKS, such as SQTKS, consist of several catalytic domains which are covalently 
linked together. In the previous chapters the individual selectivities of the isolated ER 
and DH domains of SQTKS have been examined. It is also possible that protein-protein 
interactions between the individual catalytic domains could modulate their activities and 
selectivities.  
 One example of PKS domain-domain interaction was found in the crystal 
structure of the ER-KR didomain of the second module of the spinosyn mPKS. In 
contrast to other ER domains, this domain exists as a monomer rather than a dimer. The 
interface between the ER and KR domains is around 600 Å
2
. This domain interface is 
more than 50% larger than the equivalent interface in mFAS. Most of the interaction 
results from contacts between nonconserved hydrophilic residues of the KR with the 
substrate binding subdomain of the ER.
[61,72]
 It is thus possible that contacts between the 
KR and ER could affect the ER active site, affecting its activity and selectivity. 
 Analysis of the complete protein structure of mFAS shows that its DH and ER 
domains are in contact (section 1.3.1).
[28,61]
 The overall sequence similarity between 
mFAS and SQTKS suggests that the SQTKS-ER and DH may also be in contact 
(Figure 58). The investigations of the stereoselectivity of the isolated SQTKS-ER 
domain performed by Doug Roberts showed that it cannot properly control the 
reprotonation step at the -carbon, resulting in racemic product. It is possible that this is 
caused by the lack of protein-protein interactions with the DH domain. 
 
 
 
Figure 58: Linker region between ER and DH. 
 
In order to investigate whether domain-domain interactions could be important in 
SQTKS, three different types of experiments were planned. First, kinetic experiments 
were planned in the presence or absence of different protein components. Second, 
interactions between the proteins themselves could be measured directly by isothermal 
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calorimetry (ITC). Finally, if protein protein interactions could be observed, then the 
rates of these interactions could be measured using surface plasmon resonance (SPR). 
 It is possible to measure kinetic constants for substrates of enzymes, and in this 
way map out the selectivities for isolated domains for compounds for which they 
catalyse reactions. However it is much harder to do this for non-substrates - i.e. 
compounds which for chemical reasons cannot be reacted. For example -ketones 
cannot be substrates for ER enzymes. In iterative PKS systems it is important to know if 
non-substrates can spend any time in non-reacting active sites - for example can 
-ketones spend time in ER active sites? If such interactions are significant they could 
contribute to the programming selectivity of the PKS. One way of investigating these 
non-reacting interactions is to study inhibition - for example we showed that 102 is an 
inhibitor of the ER and DH domains indicating that it can enter and bind, but such 
assays are tedious and do not show how much time non-reacting molecules spend in 
active sites (section 2.3.5 and section 3.3.4). These types of interactions have not been 
investigated before in any PKS or FAS systems and we reasoned that SPR could be 
very useful for these types of studies. 
 
4.1. Aims of the project 
 
To get more information about the protein structure of SQTKS and the recognition of 
substrates further investigations were planned. The focus of the project is on the 
interaction of the isolated domains with each other. Since it is assumed that both 
enzymes are connected
[61]
 an interaction may be observed. Also interactions between 
subtrates that are involved in SQTKS should be investigated. We also planned to 
investgate whether compounds which are not substrates may interact with the isolated 
catalytic domains of SQTKS. The first aim of this project is to find a method to measure 
interactions between the isolated DH and ER domains. Possible analytical systems are 
ITC and SPR. Kinetic assays will also be used to determine if the presence of both 
domains can change the observed rates of substrate processing.
[49]
 The second aim is the 
synthesis of acyl pantetheine substrates for the KR and C-MeT domains. These 
substrates should mimic possible intermediates of SQTKS. Further information about 
interactions between the isolated domains and different unusual substrates are expected. 
Key questions include whether it is possible for all substrates to visit every active site? 
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How long do they fill the active site? Do some structural motifs work as inhibitors? The 
third aim is to find an analytical system that can measure interactions between small 
molecules and isolated proteins. Possible candidates are ITC and SPR. It may also be 
possible to measure with both systems kinetic data that can give the expected 
information about interactions between substrates and protein. 
 
4.2. Biophysical Investigation of DH and ER Domains in Solution 
 
Assays of the ER domain in the presence of the DH domain. 
First, a concept for an enzyme assay was developed where both enzymes were 
investigated together. The assays were performed in the same way that was used in the 
previous tests (section 2.3.4) in cuvettes in a volume of 400 L using 0.25 M 
tigloylpantetheine 85 as the substrate, with NADPH 13 as the cofactor. The 
concentration of the ER domain was held constant at 0.1 mg / mL. A range of different 
DH domain concentrations were used in the assays (0.0-0.1 mg/ mL). The rate of 
consumption of 13 was observed at 340 nm in triplicate. Initial rates were measured and 
compared to the isolated stand-alone ER domain.  
 
 
Scheme 44: Enzyme assay of 85 in the presence of ER and DH domain. 
 
Low amounts of the DH domain (0.0125-0.025 mg/ mL) showed no significant changes 
in the initial rates catalysed by the ER. For higher amounts, the rates decreased 
(Figure 59). An effect to the ER domain is measurable. If a direct protein-protein 
interaction or if the reversed reaction of the DH domain is responsible for the decrease 
is unclear. 
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Figure 59: Triplices of initial rates of enzyme assays including DH and non DH domain for 85. 
 
 
Size exclusion Chromatography 
If the ER and DH domains can interact it is possible that they could form stable 
heterodimeric, or higher order, species. These would be larger than the isolated proteins 
and may be detectable by gel-filtration chromatography where the elution volume is 
sensitive to molecular size.  
 
Figure 60: Calibration of HiLoad 26/600 Superdex 200 column using 50 mmol TRIS, 150 mmol NaCl and 
20% glycerol buffer. 
 
A gel filtration column (Size exclusion column- HiLoad 26/600 Superdex 200pg, GE 
Healthcare, 320 ml) was calibrated using commercial standards (carbonic anhydrase, 
28 kDa; bovine serum albumin [BSA], 66 kDa; and apoferritin, 443 kDa; (Figure 60 
and Figure 61). All enzymes were diluted as a mixture in 50 mmol TRIS, 150 mmol 
NaCl and 20% glycerol buffer to make a standard curve. 
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Figure 61: Size-exclusion chromatogram of calibration enzymes. 
 
The size-exclusion of the DH domain analysis showed two peaks in the chromatogram. 
Only a small amount of the enzyme forms a dimer (Figure 62) in solution, peak at 
190 mL. Most of the DH domain was eluted as monomer (210 mL). 
 
Figure 62: Size-exclusion chromatogram of isolated DH domain in solution. 
 
The same test was performed with the stand alone ER domain. Also for this domain 
dimerization is known from mFAS and other PKS.
[61,156]
 In the FPLC chromatogram 
only one major peak was observed. Comparison of the elution volume with the standard 
curve shows a dimeric ER domain (Figure 63). This fragment is around ~76 kDa  
 
Figure 63: Size-exclusion chromatogram of isolated ER domain in solution. 
 
Finally a mixture of both enzymes was loaded on the FPLC. An interaction of the 
domains in solution should result in larger protein complexes (calculated as 160 kDa for 
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ER2DH2). Two peaks were detected, one for the ER- at 190 mL and one for the DH 
domain at 220 mL (Figure 64). No other peaks were observed in the chromatogram, 
which could show any other complexes of the DH and ER domain together. Interactions 
of both enzymes would be expected in signals around 150 to 160 mL. At this time 
fragments complexes with the expected mass of ~160 kDa of both enzymes would be 
eluted. 
 
Figure 64: Chromatogram of DH and ER in solution. 
 
For further analysis of the different FPLC runs fractions were collected over the whole 
elution time. After that the fractions were analysed by SDS page. On the SDS page the 
experiment showed the same results that were expected by the chromatograms of the 
single domains (Figure 65). The fractions F2 and F3 shows the ER in dimeric form and 
also the amount of DH dimer which was found in the analysis of the DH domain. These 
protein complexes have a size of ~76 kDa and are in agreement with the previous 
investigation. If a protein complex would be formed it should elute earlier than these 
peaks. Fraction F4 shows only the DH monomer. 
 
Figure 65: SDS page of the size exclusion experiment of ER and DH analysis by FPLC. 
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4.3 ITC investigation of isolated ER domain 
 
Isothermal titration calorimetry (ITC) can measure the direct interaction between two 
proteins, or between a protein and a small molecule. ITC relies on the use of two 
identical cells which are heated in an insulated jacket.
[157]
 Sensitive thermo elements 
detect differences in temperature between the cells. One of the cells (200 to 300 l) is 
used as a reference cell, the other one is the sample cell. Both cells have the same 
contents (protein, ligand and buffer) before the experiment starts. A typical 
concentration for the protein is 0.1 mM. A ligand is then titrated into the sample cell 
during the experiment. If the ligand and protein interact, there will be a change in 
temperature in the sample cell (Figure 66).
[157] 
 
 
Figure 66: Setup of isothermal titration calorimetry experiment.
[157] 
 
A test run of ITC experiments was performed (Figure 67). In this experiment, the ER 
domain was used as protein in the sample cell (protein concentration 0.1 mM). 
Tigloylpantetheine 85 was chosen as the test ligand (1.4 mM). This was injected in 
several aliquots over 7000 seconds to the sample. The temperature was held constant at 
20 °C. 
 The experimental results plot the observed energy change vs time (Figure 67). 
Every peak of graph a) corresponds to the introduction of 2.69 L of 85 to the sample 
cell. The reference cell is demonstrated by b). Compared with the results known from 
the kinetic studies, similar results in the M area were obtained. For Kd a value of 
1.33x 10-6 M was reached. The value for the enthalpy was 4.865 kJ / mol and for the 
entropy 0.130 kJ / mol. In the experiment n = 1.029 for the stoichiometry was 
calculated. 
 
93 
 
 
 
Figure 67: ITC run of 85 with the ER domain. 
 
Interestingly no NADPH 13 was needed in the measuring. This shows that for a 
complete folding and for the stabilization no cofactor is necessary. Also interactions and 
binding events between substrate and enzyme can be observed without 13. 
A problem that was observed during the experiment was the partial precipitation 
of the ER domain in the sample cell. Effects on the following experiments are possible. 
The precipitation could be the result of the used buffer, or of the stirrer in the chamber, 
or a problem of the heating. The biggest problem of this ITC experiment is the large 
amount of protein (0.1 mM) that is needed. Also is it limited to the lack of sensitivity. 
Only a small value for the enthalpy was detectable which shows also significant errors 
in the resulting curve. For further investigations higher amounts of enzyme seems to be 
necessary. Because of the requirement for a high amount of protein and the observed 
precipitation, the interaction between DH and ER domain was not performed. It was 
expected that the same problems would be observed like the ones of the substrate-
protein performance. 
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4.4 Surface Plasmon Resonance Studies 
 
Surface plasmon resonance (SPR) analysis is one of the newest analysis methods for 
protein-protein and protein-ligand interactions. The system allows measurements of 
both kinetic and thermodynamic properties of two possible binding partners. A major 
advantage is the small amount of protein required: typical protein concentration is in the 
M range.[158] 
In SPR a protein or ligand is immobilized on the surface of a metal - usually 
gold or silver - in a flow cell. A second ligand (small molecule or protein) is then passed 
through the flow cell. If an interaction between the two components takes place, a 
change in refractive index on the surface of the metal is measurable. The result is shown 
as a graph of resonance units vs time. From the generated interaction curve the 
association (kon) and dissociation (koff) rates can be measured. The ratio of kon/koff gives 
the binding constant. 
To create a higher density of immobilized ligand, special modified surfaces with 
carboxy dextran matrix have been developed. On these surfaces it is also possible to 
link smaller substrates. For example drugs can be immobilized and tested by the 
overflow of proteins on their efficiency.
[159] 
The general procedure is shown in Figure 68. The injection of the ligand results 
in an association curve that describes the interaction between both partners. In the 
following stage an equilibrium is reached. Finally, the injection of the ligand is stopped 
and a dissociation curve is observed.
[160,161]
  
 
Figure 68: Binding and unbinding states during SPR experiments. 
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4.4.1 SPR of Small Molecules 
 
The modification of the gold surface is one of the most important tasks which must be 
completed before SPR analysis. For the analysis of protein-small molecule interaction 
two approaches are possible. First, the protein itself can be attached to the surface, and 
the ligand flowed over it. Second the reverse protocol could be devised in which the 
small molecule is linked to the surface. In the first method it is usually simple to attach 
the protein to the surface, but the sensitivity of the subsequent measurement is low 
because addition of the small molecule causes only a small change in the refractive 
index. For this reason it is preferable to attach the small molecule to the surface, but this 
too can have problems, particularly if the binding moiety of the small molecule to the 
protein is masked by the surface. For this reason small molecules are often attached to 
the surfaces using linker molecules of varying lengths.
[162-163]
 
Kanoh et al. showed one possible strategy for a surface modification. A 
chemical modification strategy which could be used in a photo-cross linked reaction 
was developed. A tri(ethylene glycol) derivative 206 was first oxidized to an aldehyde 
207 which was then reductively aminated with a primary amine. The resulting diazarine 
208 has an active nitrogen bond that can be used in photo-cross-linking reactions 
(Scheme 45).
[164]
 
 
 
Scheme 45: Possible synthesis of photo-cross-linker. 
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This photoactive compound was cross-linked to the gold surface via the thiol. Small 
molecules with different functional groups could then be immobilised by a 
photochemical reaction with the diazarine group (Scheme 46).
[164] 
 
 
Scheme 46: Photo-cross-linked small molecule on gold surface. 
 
Further experiments with the modified gold surface were performed. To prove the 
linking system a library of commercial available small molecules and corresponding 
antibodies and proteins was established. This library included cyclosporine A, digoxin, 
digitoxin, digoxigenin, estradiol and corticosterone. In that way, specific bindings could 
be observed between the immobilized steroidal molecules and the corresponding 
antibodies. A regeneration cycle was also developed. A wash of the gold surface with 
10 mM aequeous HCL solution resulted in protein free surface and had no effect to the 
modified linker. The linker could then be used for another SPR test that showed the 
same results.
[164] 
 
4.4.2 SPR Investigation of Coupled ER domain on the Surface 
 
In our first performed experiments, the isolated ER domain was cross-linked on a 
carboxy-methyl dextran (CMD) chip by EDCI coupling. Free carboxyl groups are 
located on the surface which can be used for cross linking surface amines on the protein 
to form amides. The DH was then flowed over the ER-modified surface and the 
interaction monitored in the form of the change of the refractive index (Figure 69).
[165]
 
 However no response could be observed (Figure 70). It was not possible to 
measure the kon or koff rates. This seems to agree with the previous results, where no 
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interaction was observed between the ER and DH. The same negative results were 
observed in a complementary experiment where the DH was attached to the surface and 
the ER flowed over it. 
 
 
Figure 69: SPR overflow of ER- with DH domain. 
 
 The sample channel and the reference channel are shown to run similar. The injection 
of the protein started at 60 seconds and stopped at 230 seconds (Figure 70 a). A protein 
concentration of 2 mg/ mL of the DH domain was injected. The flow rate of the 
experiment was 10 L/ min. 
 
 
Figure 70: ER overflow with DH domain (a) and resulting interaction curve by the subtraction of reference 
and sample channel (b)
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The subtraction of both channels showed the previous base line (Figure 70b). At 
60 seconds and 230 seconds artefacts are visible that could result from small differences 
in buffer composition. Probably the reason for the artefacts are valve changings. 
 A second experiment was performed. In this experiment the DH domain was 
cross linked on the surface and used as possible binding ligand. The used protein 
concentration was similar to the previous performed experiment 2 mg/mL and also the 
same flow rate was used. Also the resulting subtracting curve of the experiment showed 
no interaction (Figure 71). 
 
Figure 71: Interaction curve of the DH domain with overflowed with DH. 
 
Both experiments are in agreement with the results that were obtained by the size 
exclusion experiments. For the DH-ER interaction no complexes around 160 kDa were 
found. Also for the DH domain was shown in the size exclusion experiments to be 
monomeric. Results from all analyses suggest that both separately expressed enzymes 
work individually and do not interact with each other. An interaction would be expected 
from the assumed model of FAS. In contrast to crystal structures of fatty acids the 
expected interaction between ER and DH domain is missing. 
 
4.4.3 Protein-Substrate Interaction Analysed by SPR 
 
The previous experiments showed no indication of an interaction between the DH and 
ER domains. In the following experiments SPR was used to investigate the selectivities 
of the individual DH and ER domains - and in particular whether small molecules 
which are not substrates can still be bound by, and spend time in, the active sites of the 
enzymes.  
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In the first experiments the ER domain was cross linked on the carboxy methyl dextran 
surface. The His6-tag of the purified protein was used as a linker for the binding process 
to the surface similar to the previous coupling process (section 4.3.2). A change in the 
refraction index was measured that showed the clear binding between the protein and 
surface. Then different concentrations of tigloylpantetheine 85 (0.1 mM to 10 mM) 
were flowed over the cross linked protein surface. Changes in the refraction index were 
measured between the reference channel and test-channel. The flow rate of the 
experiment was settled to 25 L/min and the dissociation time held constantly at 3 min. 
Subtracting the reference channel from the cross linked channel showed that no 
interaction was obtained. The calculation of an association and dissociation was not 
possible (Figure 72).  
 
 
Figure 72: SPR experiment of cross-linked ER domain with 85. 
 
The described SPR investigation was used without the known cofactor for the ER 
domain (section 2.3.4). It could be possible that NADPH is necessary for the binding 
between the substrate and the enzyme. A use of NADPH would result in the reduction 
of the substrate during the binding process. Another possibility would be the use of 
NADP
+
 to imitate the cofactor.  
The negative result of the experiment could have several reasons. For example, a 
small molecule is used as the ligand, which means that only a small interaction and a 
small change in the refraction index could be detected. Previous investigations showed 
that the use of small molecules as immobilized ligands were more successful.
[164] 
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4.4.4. Synthesis of Substrates for attachment to SPR Surfaces 
 
The previous results lead us to modify the experiment. Instead of binding the protein to 
the surface, we decided to bind the substrate component. We have already shown that 
acyl pantetheines are very good substrates of the ER and DH enzymes (section 2.3.4 
and section 3.4), and modelling has shown that specific interactions with the 
pantetheine itself are important. In order to move the pantetheine and acyl group 
slightly away from the surface, and to provide an attachment mechanism we decided to 
modify/extend the pantetheine with a short glycine linker which would allow the 
pantetheine to be tethered as an amide to the surface. (Figure 73). 
 
 
Figure 73: Library of substrates for SPR investigations. 
 
The library of compounds was designed to include diketides (209 - 213) and triketides 
(214 - 217). The library also contains all possible -processing intermediates such as 
ketones (209, 210, 214 and 215), alcohols (211), alkenes (212 and 217) and alkanes 
(213 and 217). The library also includes -methylated (210 - 213 and 215 - 217) and 
non-methylated (209 and 214) compounds. 
Precursors of compounds 209, 210, 214, and 215 were synthesized separately. 
The synthesis of all four compounds started with Meldrum's acid 218 reacted with 
appropriate acid chlorides in the presence of pyridine as described in the 
literature.
[166,167]
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Scheme 47: Synthesis of -carbonyl pantetheine substrates. 
 
The acylated product 220 was heated in toluene with pantetheine dimethyl ketal to give 
the desired product 221. This reaction is known to create SNAC substrates,
[100]
 but has 
not been previously described for pantetheines. Protected pantetheine 221 could either 
be deprotected directly to give 222 by standard methods or -methylated (e.g. 223) with 
potassium tert-butoxide and methyl iodide and then deprotected (Scheme 47).
[168] 
The known method for pantetheine substrate synthesis was used to create the 
pantetheine substrates 85, 91, and 187 (Chapter 2 and 3). These compounds were then 
reacted with BOC-glycine under standard EDCI coupling conditions to give the BOC-
gly-pant-acyl species, and these were simply deprotected to give the desired 211, 212, 
and 216 (Scheme 48). 
The pantetheine substrates were purified by HPLC and then extended with 
BOC-glycine to create the pantetheine modified compounds (Figure 75). In general the 
BOC-protected intermediate 224 was not isolated, but deprotection with TFA in 
dichloromethane took place. The final products were purified by HPLC (Scheme 48). 
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Scheme 48: Synthesis of tigloyl pantetheine glycine 212. 
 
Three intermediates were obtained during the final extension procedure (Figure 74). 
The main product of the reaction was the desired terminal coupled product 224. The 
esterification of the secondary alcohol to form 225 was also observed: this compound 
was characterized by NMR. Doubly reacted material 226 was found in traces by LCMS.  
 
 
Figure 74: Intermediates of coupling reaction between 85 and boc-glycine. 
 
 
 
4.4.5 SPR analysis of surface-linked ligands. 
 
Assays were set up to test whether the attachment of the terminal glycine might inhibit 
the enzymatic reaction. 0.13 M of compound 212 was incubated with the ER protein 
and NADPH 13. The consumption of 13 was observed, indicating that this change in the 
substrate was tolerated (Figure 75).  
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Figure 75:  Absorption curves of the three replicates of tigloyl pantetheine glycine 212 at 0.13 M. 
 
The following SPR measurements were performed with sensor chip HC1000m. This 
chip is optimized for small molecules/ and peptide/ protein interaction. The surface of 
the chip is modified by a polycarboxylate hydrogel with a medium charge density 
which has a thickness of 500 nm.
[169]
  
Under a continuous flow of 10 L/min the sensorchip was installed in the SPR. 
Several buffers were tested for the coupling process of 212 with the chip surface. As 
coupling buffer a 10 mM maleate solution with a pH 7 was selected. A premixed 
activation mix was loaded to the gold chip. This buffer contains 100 mM EDCI. The 
buffer was incubated with the chip surface for 15 minutes. After that the substrate was 
loaded on the surface and incubated with the activated surface. Concentrations of the 
substrate were tested for 5-10 mM solutions. For the highest concentration, the best 
binding in the following experiments was observed (Figure 76). 
 
 
Figure 76: Modification of the gold surface by injection of pantetheine-glycine substrates. 
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Then the whole surface was washed with ethanolamine to block possible active residues 
of the surface that did not interact with the substrate. Finally, several wash runs were 
performed before the cross linked substrate was overflowed with the ER domain at a 
flow rate of 10 L/ min. Concentrations of 0.25 mg/ mL to 10 mg/ mL of the ER 
domain were used (Figure 77).  
 
Figure 77: Coupled 212 on gold surface with ER- or DH domain overflow. 
 
In contrast to the previous experiments, a positive resonance for the interaction was 
observed. This time the change of the refractive index was more significant than the 
change of the previous tests: a kD 4.03 x 10
-6
 M was measured. Similar to the test of the 
ITC (section 4.2) no NADPH cofactor was used showing that the cofactor is not 
required to bind before the substrate.  
 
Figure 78: Reference and sample channel cross-linked 212 with ER domain (4 mg/mL). 
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The sample and reference channel shows the injection of the protein at 500 seconds 
(Figure 78). For both channels a change in the refractive index is visible. Change of the 
injection buffer is observed at 2500 seconds. At this point the protein overflow is 
stopped. The same baseline is reached which was observed before the injection started. 
The interaction of protein and substrate was calculated by the subtraction of sample and 
reference channel (Figure 79). The results show a clear association period 
(0-200 seconds) followed by equilibrium between bound and unbound protein 
(200-2000 seconds). After that the dissociation follows.   
 
 
Figure 79: Interaction of 212 with ER domain (4 mg/ mL).  
 
Another SPR experiment was set up with the same modified gold surface. This time 212 
was overflowed by a solution that contains the same concentrations of the DH domain. 
This experiment also indicates an interaction (Figure 80). For the DH domain it runs 
faster and reaches the equilibrium between 400 and 1500 seconds. At 2000 seconds the 
dissociation starts. However, first the signal rises at this position but shows the expected 
curve. 
 
Figure 80: SPR interaction between 212 and DH domain overflow. 
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This behaviour was unexpected because the tigloyl pantetheine glycine 212 unit is the 
product rather than the substrate of the DH domain and not expected to bind 
significantly. The result is, however, supported by the previous observation that SQTK 
can inhibit the DH domain (section 3.3.4). 
 Based on these experiments the other substrates of the library were also cross-
linked to the surface and overflowed with solutions of the ER and DH proteins. 
Generally the protein concentrations were varied between 0.25 mg/mL to 10 mg/mL. 
The flow rate of the instrument was set up to 10 L/min. 
 
SPR interactions of the DH domain 
In the following experiments, three different results were observed when a solution 
containing the isolated DH domain was flowed over the surface-linked substrates. The 
first SPR investigation was performed with the triketide 3-oxohexanoyl substrate 214 
(Figure 81). The experiment begins by flowing buffer over the surface and no signal is 
observed. After 50 seconds the flow is changed to buffer plus DH. A clear association is 
visible between 50 and 210 seconds. 214 interacts with the DH domain at this point 
until the maximum at 210 seconds is reached. For lower protein concentrations a linear 
graph is rising. For higher concentrations the expected curve was obtained. For all 
concentrations tested no equilibrium is reached during the experiment. 
 
 
Figure 81: DH overflow of 3-oxohexanoyl pantetheine glycine 214. Protein concentrations are shown by 
the different colours: 0.25 mg / mL, black; 0.5 mg / mL, red; 1 mg / mL, blue, 2 mg / mL, green, 4 mg / mL, 
yellow; 6 mg / mL, light blue; 10 mg / mL, purple. 
 
After 220 seconds the flow is changed back to buffer and a dissociation curve is 
observed. This experiment shows a clear interaction between enzyme and bound 
intermediate. Interestingly an unnatural substrate is recognized by the DH domain. 
Overall for the highest protein concentration an interaction of 120 resonance units was 
observed. Similar results were obtained for the diketide version 209 (see Appendix A1) 
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of this structural motif. Optimization of the SPR data could be performed by increasing 
the flow rate from 10 L/min to 25 L/min.  
 The 3-oxo-2-methylhexanoyl triketide 215 was analysed next (Figure 82). This 
compound is the true substrate of the KR domain. In comparison to 214 a hydrogen at 
C-2 is substituted with a methyl group. In the first 50 seconds, only buffer flows over 
the surface. Artefacts are visible at 50 seconds. At this point the buffer is changed to the 
protein solution for the next 160 seconds.  
 
Figure 82: DH overflow of 3-oxo-2-methylhexanoyl pantetheine glycine 215. 
 
In contrast to the first experiment, no association and dissociation could be measured. 
At 220 seconds a second artefact is visible which corresponds to the time at which the 
protein solution is changed to buffer. The same result was observed for the diketide 
version 210 (see Appendix A2). It seems that the methyl group in the -position has a 
significant influence to the experiment.  
It was not tried to measure interactions with compound 211 because this is a substrate 
of the DH and reactions would be expected to dehydrate the substrate on the surface. 
Also from the previous investigation it was already verified that 211 is a compound of 
the DH domain and can visit the active site. The next assay simulates used the 
2-methyl-hexenoyl triketide 216. Weak interactions of 20 resonance units were 
detectable between the substrate and DH which appeared to vary with protein 
concentration. However, the weakness of the data, and large artefacts caused by the 
switching valve made it impossible to calculate association and dissociation constants. 
Very similar results were obtained for 212 with only weak interactions observed (see 
Appendix A3). This is in contrast the previous performed studies where high 
interactions were measured (section 4.3.5). 
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Figure 83: DH overflow of 2-methylhexenoyl pantetheine glycine 216. Protein concentrations are shown 
by the different colours: 0.25 mg/ mL, underlined red; 0.5 mg/ mL, underlined red; 1 mg/ mL, red, 2 mg/ 
mL, light blue, 4 mg/ mL, green; 6 mg/ mL, purple; 10 mg/ mL, black. 
 
Finally the triketide alkane 217 was tested. For the first 50 seconds only buffer 
overflows the surface. After that the protein is injected from 50 to 220 seconds. Similar 
to the previous investigation of 216, the measurement of association and dissociation 
constants was not possible because of weak data and artefacts. The equilibrium between 
association and dissociation is not reached which is shown by the rising graph 
(Figure 84). Also 213 (see Appendix A4) agrees with this investigation and runs 
similar. 
 
Figure 84: Reduction of 2-methylhexanoyl pantetheine glycine 217. Protein concentrations are shown by 
the different colours: 0.25 mg/ mL, underlined blue; 0.5 mg/ mL, underlined blue; 1 mg/ mL, blue, 2 mg/ 
mL, purple, 4 mg/ mL, brown; 6 mg/ mL, green; 10 mg/ mL, red. 
 
A problem observed for all measurements are artefacts at 50 seconds and 240 seconds. 
For washing processes (dissociation and regeneration) the system is switched to the by-
pass mode. Before the association starts the valve is switched to the sample loop 
(Figure 85). The artefacts at 50 second and 240 seconds result from the switch of the 
 
109 
 
valve from position 1 to position 2 and back. In cases of weak association this makes it 
nearly impossible to measure the dissociation and association constants. 
 
 
Figure 85: Flow path during SPR investigation. 
 
Table 1 gives an overview of the nine different linked substrates that were overflowed 
and analysed by the DH domain.  
 
Structural 
motif 
Interaction Appendix Structural motif Interaction Appendix 
 
x A1 
 
x  
 
- A2 
 
-  
 
not 
measured 
- 
 
x  
 
x A3 
 
x  
 
x A4    
Table 1: Interaction partners of the DH domain. 
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SPR Analysis of the ER Domain 
The substrates for the different modification steps were also tested with the ER domain. 
Similar to the measurements of the DH domain it was possible to observe interactions 
between the ER domain and the -oxo triketide 214 (Figure 86).  
In contrast to the analysis of the DH experiment, the association does not follow 
the expexted curve, and this may be an indication of a flow rate which is too low. The 
equilibrium between bound ER domain and the substrate was not reached during the 
analysis time and association and dissociation constants are impossible to determine. 
However the data does show that the ER domain exhibits strong binding to the modified 
surface. This is visible in low dissociation curve. An interaction of 125 resonance units 
was observed for this experiment (Figure 86). Also for the diketide substrate 209 of 
these modification step shows the same result that was obtained for 214 (see 
Appendix, A8).  
 
Figure 86: ER overflow of 3-oxohexanoyl pantetheine glycine 214. Protein concentrations are shown by 
the different colours: 0.25 mg/ mL, not mentioned; 0.5 mg/ mL, black; 1 mg/ mL, red, 2 mg/ mL, blue, 4 mg/ 
mL, green; 6 mg/ mL, light blue; 10 mg/ mL, yellow. 
 
The -methylated ketones 210 and 215 interact very weakly with the ER (Figure 87). 
The data is similarly poor in each case since the expected curve is not observed. A 
negative interaction is observed also for 215 (see Appendix A5). Why the interactions 
show up negative is unclear, since for all investigations and the protein stock solution 
the same buffer was used. 
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Figure 87: ER overflow of 3-oxo-2-methyl-butyryl pantetheine glycine 210. Protein concentrations are 
shown by the different colours: 0.25 mg/ mL, not mentioned; 0.5 mg/ mL, yellow; 1 mg/ mL, black, 2 mg/ 
mL, light blue, 4 mg/ mL, blue; 6 mg/ mL, purple; 10 mg/ mL, green. 
 
The experiment of 212 shows an interaction with the ER domain (Figure 88). It is a 
natural substrate of the ER domain and is reduced in the first elongation step. In contrast 
to the triketide 216 (see Appendix A6) the mimicked diketide showed a clear 
interaction. This agrees with the expected behaviour of this substrate. For the different 
concentrations of the enzyme the increase was observed.  
For higher concentrations the equilibrium of bound enzyme was reached. The 
association shows for low concentrations a linear course. This indicates that the flow 
rate was too low. For higher concentrations the expected curve is visible. Also the 
dissociation curve is for all concentrations very slow. This is a second indication that 
the flow rate is too low.  
 
Figure 88: ER overflow of tigloyl pantetheine glycine 212. Protein concentrations are shown by the 
different colours: 1 mg/ mL, black, 2 mg/ mL, red, 4 mg/ mL, yellow; 6 mg/ mL, green; 10 mg/ mL, blue. 
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The bound material can not be washed away quickly by this flow rate. For the triketide 
version of this structural motif a similar graph to the analysis of 212 (Figure 88) was 
obtained. During the experiment no NADPH or NADP
+
 was used, ensuring that no 
reaction took place. 
In the next experiments, the alkanes 2-methylbutyryl diketide 213 and 
2-methylhexanoyl triketide 217 were investigated. For both substrates a negative 
interaction curve was again observed. This was an unexpected result for these 
compounds. Both compounds are the release products of the ER domain. They should 
leave the active site fast; otherwise the PKS would be blocked. The shown interaction is 
unexpected (see Appendix A7 and A10). 
 The final experiment shows the result of cross-linked tigloyl pantetheine glycine 
212 that is overflowed with the ER domain at a faster flow rate (25 L/ min). It shows 
clearer dissociation and association curves (Figure 89). The equilibrium is more 
pronounced in comparison to the previous investigations. That the equilibrium is 
reached between 150- and 220 seconds shows the sensitivity of the analysing system. A 
better dissociation curve could be generated in contrast to the previous runs. Increasing 
the flow rate has also reduced the influence of the artefacts at 50 and 250 seconds.   
 
 
Figure 89: ER overflow of 212 with a higher flow rate. Protein concentrations are shown by the different 
colours: 2 mg/ mL, red, 4 mg/ mL, yellow; 6 mg/ mL, green. 
. 
 
The results for interaction between ER domain and the synthesized substrates are 
summarized in table 2. The overview of the overflowed substrates were analysed by the 
ER domain. It seems that all substrates have interactions with the enzyme. 
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Structural motif Interaction Appendix Structural motif Interaction Appendix 
 
x A8 
 
x  
 
x  
 
x A5 
 
x A9 
 
x A6 
 
x  
 
 
x A7 
 
x A10    
               
Table 2: Interaction partners of the ER domain. 
 
 
4.5 Discussion 
 
To investigate potential interactions between the isolated DH and ER domains of 
SQTKS both individual domains were investigated in the presence of the other. Enzyme 
assays were performed that included both enzymes. In a kinetic analysis of the ER 
enzyme, it was found that the rate of reduction of substrate 85 was reduced by the 
presence of the DH enzyme in increasing concentrations. Two explanations are 
possible. The first one suggests interactions between the ER and DH. The presence of 
the second enzyme may have effects on the active site of the ER. The second one 
highlights the reversed reaction of the DH domain which has been observed in previous 
investigations (Figure 90).
[151,152]
  
 
Figure 90: Possible equilibrium between substrates 85, 187, 148. 
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Formation of -alcohol 187 would reduce the concentration of enoyl substrate 85 and 
thus slow the reaction. Since no other experiment suggested that the ER and DH 
associate this is the most likely reason for the observation. 
In further experiments no interactions between both isolated domains were 
observed. In our experiments size exclusion chromatography was used to detect 
possible protein-protein association. These experiments did not show any evidence for 
formation of ER-DH multimers. Further investigations by SPR also suggested minimal 
interactions between these domains. This was an unexpected result because, based on 
the crystal structure of mFAS, an enzyme to which SQTKS shows end-to-end sequence 
homology and the same domain organisation, we expected some measureable 
interactions.
[28,61]
  
There are several reasons for the inability to observe protein-protein interactions 
between these domains. First, it is possible that their interactions are actually minimal. 
The crysal structure of mFAS shows that only a small part of the DH and ER domains 
interact.
[28]
 Second, it may be possible that an additional linker sequence, not included 
as part of the current ER and DH sequences, is necessary to bring both domains 
together.
[28]
 An expression of the complete DH-ER fragment with additional 
crystallization could solve this question. A similar experiment was performed by Zheng 
and coworkers and discussed earlier (section 4.0).
[72]
 Currently for all isolated DH 
domains of PKS a dimeric structure for the DH has been observed.
[17,71]
 But the 
SQTKS-DH exists primarily as a monomer. This also suggests that an important part 
that is necessary for protein-protein interaction was not expressed. For the ER domain 
the expected dimeric organisation was observed, in agreement with the ER domain of 
mFAS.
[28]
 
 A third possibility for the lack of observed DH-ER interactions could be the 
requirement to include glycerol in all the purification and assay buffers. Glycerol is 
required to stabilise the isolated ER in particular, and without it rapid protein 
precipitation is observed. The glycerol could prevent protein-protein interactions by 
forming an amphiphilic surface around the isolated domains - indeed this was the 
rationalisation for using it in the first place. This could be the starting point for new 
investigations. For example it would be interesting to mix ER and DH in glycerol 
containing buffers, and then slowly dialyse away the glycerol to see if stable and 
soluble DH-ER multimers could be formed (Figure 91). 
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Figure 91: Glycerol surface of the DH domain. 
 
Investigation of protein-intermediate interactions formed the second part of this project. 
These experiments were performed by two different ways, ITC and SPR. The ITC 
experiment of tigloylpantetheine 85 and the ER showed the similar results to the 
performed enzyme assays (Chapter 2.3.4). During the experiment precipitation of the 
ER domain was observed. This could be reasoned to the heating process of ITC or the 
stirrer in the solution. The precipitation and the high amount of enzyme required meant 
that ITC was not a generally useful method for analysis of the isolated protein domains. 
In further experiments an SPR system was used. The modification of the surface is 
known by several experiments of this technique.
[170-172]
  
Information gained from enzyme assays and protein modelling (chapter 2) showed that 
the pantetheine arm interacts with both the ER and DH proteins because acyl 
pantetheines are significantly better substrates than the much shorter acyl SNACs. The 
pantetheine is already used by nature as a linker to connect the substrate to the ACP and 
allow it to penetrate deep into the active sites of the -processing enzymes. We 
reasoned that we could use the pantetheine as a similar linker to link the acyl groups to 
a metal surface. In order to move the pantetheine slightly further away from the surface, 
and also to provide an amine for chemical connection, we added BOC-glycine to the 
primary alcohol of the pantetheines which had already been synthesised (section 2.3.3). 
BOC-deprotection and then EDCI catalysed amide formation with free carboxylates on 
the metal surface effectively linked the acyl pantetheines to the surface. Also the 
synthesis of the different structural motifs of other PKS domains was possible. 
Modelling of substrate 216 into the ER domain in the presence of the cofactor 
NADPH 13 was performed by other members of the Cox group (Figure 92 b). The 
model shows that the terminal amine group of the acyl pantetheine glycine is positioned 
outside the ER domain (Figure 92 a). Similar to the previous modelled pantetheine 
substrates the interaction between the pantetheine arm and the protein is visible. The 
orientation of the hydride transfer of 13 to the substrate is also possible (Figure 92 c). 
The reduction process is not affected. 
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Figure 92: Modelling of substrate 216 into the ER domain (a). 
 
Interaction between surface and substrates 
Currently there are no studies known in literature that work with isolated PKS domains 
and SPR systems. Some other experiments of enzymes and cross-linkers are described 
in previous sections.  
 The DH enzyme has a high acceptance for the different functional groups that 
are involved in the -modification cycle of SQTKS. In general, the interactions were 
detected, but technical problems were encountered in the execution of the experiments 
by the system. The dissociation and association curves were influenced by valve 
changing. Also the buffers with 10% and 20% glycerol seems to be a problem. 
Repeating these experiments, maybe with a faster flow rate, would bring the enzyme-
substrate interaction faster in equilibrium. This would also effect the association and 
dissociation, which would lead in stronger curves. A faster flow rate would also result 
in less diffusion between the four channels. Possibly the artefacts that are produced by 
the valve changing would be limited or reduced.  
For the DH domain nearly all intermediates showed interaction. Compounds 211 
and 215 are the only intermediates that show no interaction. Possibly the three 
dimensional orientation of 215 does not fit in the active site. The DH domain normally 
accepts methyl groups, which is known from the programming of SQTKS. Compound 
214 also showed interaction with the DH domain. The KR domain reduces the structural 
motif of 215 that is used in the next modification by the DH domain. During this 
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reduction the three-dimensional structure changes from planar into tetrahedral. Possible 
that the planar structure with additional methyl group cannot enter the tunnel of the 
active site.  
 For some substrates in combination with the ER domain unclear results were 
detected. The -keto motif which is the substrate for the C-MeT small interactions 
could be measured. Also the experiment with 212 showed the expected results. For the 
other substrates the ER domain showed poor results. It seems that the measurings are 
influenced by something. However before the protein flows over the surface the signal 
decreases. The base line is similar before and after the injection of the protein solution. 
The same statement can be made for the used buffer. The running buffer of the SPR 
experiment was the same that was used for the stock solution of the ER enzyme. 
However, the ER domain seems to have a broad substrate specifity and accepts also 
other structural motifs of PKS intermediates. This was also shown in the previous 
enzymes assays were nearly all substrates up to the tetraketides could be reduced 
(section 2.3.4). Also reductions of pentaketides were possible.  
For both domains, ER and DH, it was shown that the SPR method is usable to 
prove interactions between the different substrates of a PKS and isolated enzymes. For 
better understanding of possible programming, it would be interesting to repeat the 
experiment series with different conditions. To increase the flow rate for example 
would load the protein faster on the cross linked surface. One test run was performed 
for the ER domain with a flow rate of 25 L/ min and this did give better quality data. 
However the flow rate is limited by the amount of glycerol required in the buffers, and 
in the longer term it would be a good idea to find other buffers in which the proteins are 
stable which do not requirev the addition of glycerol. The ER experiment could also be 
influenced by the use of a cofactor. A change could maybe observe with the use of 
NADP
+
 in the buffer. Maybe the interaction is stronger or lower for the different 
intermediates.  
 
4.6  Conclusion  
 
Different experiments of the isolated domains in solution were performed. Modified 
enzyme assays with isolated DH and ER domains showed a significant influence to the 
initial rates. The initial rates of 85 slow down in the presence of the DH domain. Size 
exclusion investigations of the isolated domains were performed. There was no 
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evidence that a protein complexe between the isolated domains was formed in solution. 
In further experiments by SPR investigations this result was confirmed: there was no 
interaction of the two isolated domains. Further protein-intermediate investigations 
were performed by SPR. For this an improved synthesis method for different 
pantetheine glycine substrates was developed and the synthesis of different structural 
motifs was possible. For the cross-linking process to the SPR surface different 
conditions were tried. It was possible to establish a method for the pantetheine glycine 
substrates for the cross-linking. The modification of the surface was possible and the 
modified surfaces could be used as analytical tools to investigate the interaction 
between the protein and intermediates. 
 The initial experiments reported here show that in general it is possible to 
observe interactions. The DH and ER show a broad of selectivity and seem to be able to 
interact with many of the intermediates. This means that the isolated domains of 
SQTKS are not programmed by strict structural motifs. Otherwise only two substrates 
should be recognised; the starting and end product of the catalysed reaction. 
A problem with the SPR analysis seems to be the low flow rate of 10 l/ min 
and the used buffer that contains 10 or 20 % glycerol. The equilibrium of bound and 
unbound protein was only reached for a few substrates. Another problem was the poor 
data that was calculated for partners of the ER domain. The final performed 
measurements using a flow rate of 25 l/ min resulted in optimized SPR curves in 
which equilibrium is reached, and the artefacts of the buffer are decreased. However the 
faster flow rate means that more enzyme will be required for the future assays. 
 
4.7  Future Work 
 
To get more significant data it is possible to combine SPR and MS.
[173]
 Two analytical 
independent analysis methods are described in literature. One is the direct coupling of 
MALDI-TOF to the sensor chip.
[174]
 The second method is analysis of captured ligands. 
The ligand gets bound in previous steps to an immobilized ligand on the surface. 
Unbound and weak bound material gets washed out from the ligand. Finally the buffer 
change can be performed that disrupts the interaction between analyte and surface. 
Collected ligands can be load directly into MALDI or post-processed.
[175,176] 
Combination of MS and SPR could be a useful tool for the investigation of the isolated 
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domains of SQTKS. Currently the modified surface is proven by the change of the 
refractive index. Removal of the sensor chip out of the SPR and chemical treatment of 
the surface could separate the cross linked material from the surface. 
 
It could also be used to create an inhibitor for the DH domain. It is known by E. 
coli FAS that the structural motif of 227 binds covalently to the active site (Figure 93). 
The investigation in the FAS project was based on ACP derived substrates. Compound 
227 shows the pantetheine motif with additional glycine residue that could act as an 
inhibitor. If the inhibitor works the DH domain should be covalently bound to the 
surface.
[177] 
 
Figure 93: Possible inhibitor of DH domain. 
 
It seems, that in the previous investigations the high amount of glycerol was the crucial 
effect that the interactions were not visible. Similar performance could be tried again 
with the isolated DH and ER domains with other buffers. For this several tests could be 
performed to test the stability of the isolated proteins. The lower amount of glycerol 
could result in a more sensitive system. A reduce of spikes in the measuring could be a 
possible consequence. Also the mechanical part could be influenced. In most of the 
measuring’s the switching of the valves is seen. The viscosity of the used buffer could 
increase this effect.  
 
Figure 94: Further pantetheineglycine compounds could give conclusions for the programming of SQTKS. 
 
Since the previous investigations showed that it is possible to perform this type of 
experiment, also the extension of a substrate library could be possible. From the kinetic 
analysis, it is clear that 102 is an inhibitor of the isolated enzymes. The comparison of 
the racemic- with the enantiopure substrate could highlight selectivity of the active site 
(Figure 94).   
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5.0 Project 4: Tailoring Enzymes Involved in the Biosynthesis of 
Squalestatin S1 
 
Tailoring enzymes catalyse many different reactions during the later stages of natural 
product biosynthesis, and are thus responsible for the diversification of natural product 
structures. A good example of this is the conversion of proansamycin X 231 to the 
bioactive compound rifamycin B 234.
[178-183]
 
 
 
Scheme 49: Formation of proansamycin X 231. 
 
Proansamycin X 231 is the product of a modular PKS (RifA – RifE) which uses 
3-amino-5-hydroxybenzoic acid 230 as a starter unit. Extensions are performed with 
malonyl-CoA 6 and methylmalonyl-CoA 232 (Scheme 49).
[179-183]
 RifF then releases the 
cyclic amide 231 as the first enzyme-free intermediate. The rifamycin tailoring enzymes 
perform a hydroxylation at C-34 and an oxidation at C-8 to create rifamycin W 233 
(Scheme 50) which is a central intermediate of several rifamycin derivatives and a 
known precursor of rifamycin B 234.
[179-183]
 
 During the formation of 234 a backbone rearrangement is observed. The C-12 to 
C-29 olefin is cleaved, and an oxidative removal of formic acid at C-34 and reduction of 
the quinone is also observed. Final modifications include O-acetylation at C-25 and 
O-methylation at HO-27. The introduction of these side chains during rifamycin B 
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biosynthesis is the final modification. Similar late-stage acylations are also observed for 
compounds like lovastatin 26.
[184,185]
 
 
 
Scheme 50: Post-PKS modification of rifamycin W 233 to rifamycin B 234. 
 
5.1 Acyltransferases 
 
Lovastatin 26 is formed from a nonaketide 29 linked as an ester to a diketide 235 
(Scheme 51). The transfer of the diketide acyl residue is the final step of the 
biosynthesis, however, no free diketide intermediate was found by LCMS analysis. This 
is because the -methylbutyryl acyl group 235 is captured directly by the 46 kDa acyl 
transferase (AT) protein LovD from the diketide synthase LovF. 
 
 
 
Scheme 51: Diketide transfer during lovastatin biosynthesis. 
 
In the second step the hydroxyl group of 29 reacts in a transacylation with the LovD-
bound diketide. Ser-76 was proposed as the active site nucleophile of LovD. Other 
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possible catalytic amino acids of LovD are Lys-79, Tyr-188, and Lys-315 
(Scheme 52).
[186,187]
 
 
 
Scheme 52: Proposed mechanism of the transacylase LovD.  
 
Tang and coworkers showed that LovD could be used in vitro for chemoenzymatic 
modifications. LovD was expressed in E. coli BL21 and purified by Nickel-NTA 
chromatography and then used in enzyme assays. Butyryl-CoA 236 was incubated with 
the precursor 29 and LovD and the expected product 237 was obtained 
(Scheme 53).
[186, 187] 
 
 
Scheme 53: Enzyme assay of 29 and butyryl CoA 236.  
 
It was also possible to create the more biologically active compound simvastatin 239 
using this methodology. For the chemoenzymatic reaction -dimethylbutyryl-SNAC 
238 was used (Scheme 54).  
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Scheme 54: Enzyme assay of 29 and α-dimethylbutyryl-SNAC 238 to form simvastatin 239.  
 
Other lovastatin analogues were also produced by chemoenzymatic reactions. Analysis 
of the different enzyme assays showed a preference of LovD for C3-C6 chain-length 
acyl groups. Different decalin cores were tested. One variation investigated the 
replacement of the methyl group at C-6 by a hydroxy group. Two possible positions for 
an acyl transfer were now available. The resulting product of the enzyme assays showed 
high selectivity for HO-4 acylation. Diacetylation was not observed. This showed the 
broad substrate specifity of LovD to the side chain that is transferred to the final core 
compound. In contrast to that, the position of the acyl transfer is very specific 
(Scheme 55).
[186, 187]
 
 
Scheme 55: Chemoenzymatic synthesis of huvastatin 241. 
 
The AT enzyme tricothocene-3-O-acetyltransferase (Tri101) is known from the 
biosynthetic pathway for T-2 toxin 243 which is produced by various species of the 
fungus Fusarium and is responsible for grain contamination (Scheme 56). Similar to the 
biosynthesis of lovastatin 26 the AT works almost at the end of the biosynthetic 
pathway. The AT is responsible for the acetylation of the HO-3 hydroxyl group of the 
precursor of T-2 toxin (Scheme 56).
[188] 
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Scheme 56: Acetylation of T-2 toxin by Tri101. 
 
Acetylation at HO-3 lowers the toxicity of the tricothecene core drasticly. Without an 
acyl group at this position a much higher biological effect was observed. It is proposed 
that acetylation is used as a self protection mechanism by the Fusarium fungus. HO-3 
could also be a possible position for a resistance mechanism for plants. Lowering or 
removal of the toxicity could protect plants from fungal disease. Modifications with 
glycosyl residues at C-3 showed successful reduction of the toxic effect. Also oxidation 
of the C-3 hydroxy motif into a keto group showed significant effects.
[188]
 
Isolation and purification of Tri101 was performed in a similar way to LovD. 
Crystallisation experiments in the presence of CoA substrates showed important motifs 
that were found in other AT domains including HXXXD and DFGWG. The HXXXD 
motif is located near to the acetyl-CoA and substrate binding sites and is an essential 
catalytic motif. The DFGWG motif is a component of a structurally important loop.
[188] 
 
5.2 Aims of the project 
 
Squalestatin S1 56 is synthesized by two independent iPKS. Further investigations 
showed that two possible ATs are present in the squalestatin gene cluster. Both were 
expressed by group members of the Cox group. It is assumed that both ATs work late 
during the biosynthesis of squalestatin S1. One aim of this project is the synthesis of 
possible precursors that are involved in the acyl transfer. These precursors are the 
squalestatin tetraketide 61 and different squalestatin cores. The development of a 
suitable enzyme assay is the second aim of this project. Several assay conditions and 
substrate structures will be tested. Also the synthesis of new squalestatins will be 
attempted using the AT as a catalyst in vitro.  
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5.3 Investigation of AT1 and AT2 from the Squalestatin Gene Cluster 
 
Squalestatin S1 56 consists of a highly modified hexaketide esterified to a tetraketide. 
The hexaketide makes up the core structure of the compound, and, as in lovaststin 26, 
the tetraketide forms an ester side-chain, in this case to O-6. The tetraketide and the 
hexaketide are produced by two separate highly reducing PKS. In addition an acetyl 
unit is esterified at O-12. Two squalestatin biosynthetic gene clusters were found by 
genome analysis of the two different fungi (Phoma sp. C2932 and MF5453) which 
produce 56. Both clusters contain PKS genes which encode SQTKS (squalestatin 
tetraketide synthase) and SQHKS (squalestatin hexaketide synthase), and this has been 
verified by gene knockout experiments. The clusters also include two acyl transferase 
encoding genes (mfM4 encoding AT1 and mfR4 encoding AT2) which could be 
responsible for the two esterifications required during biosynthesis (Scheme 57).
[97] 
 
 
 
Scheme 57: Crucial steps during biosynthesis of 56. 
 
At the start of this project it was not clear which of the two ATs was responsible for 
each step. Also the substrates that are used by the AT domains are unclear: it was not 
known in which order the acetyl and tetraketide groups were added, and it was not 
known whether the tetraketide should be linked to CoA as in T-toxin biosynthesis, or to 
acyl carrier protein (ACP) as in lovastatin biosynthesis.
[97]
 It was therefore planned to  
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investigate the activity of the two ATs in vitro. This would require cloning and 
expression of each AT-gene, production of suitable substrates, and development of 
sensitive analytical methods for the detection of substrates and products. 
 
5.4 Heterologous Expression of the Acyltransferases AT1 and AT2 
 
AT1 belongs to family of acyltransferases with an HXXDG motif. This motif is 
important for the function of the active site. AT1 is similar to Tri101 (20% identity, 
37% similarity). In particular, important residues for CoA binding in Tri101 such as 
L282, T298, D300, and L425 are conserved in AT1 suggesting that AT1 itself might 
accept CoA substrates.
[97]
 For AT2, homology to the acyltransferase 3 superfamily was 
observed. Good alignments were found with an uninvestigated acyltransferase from 
Dothistroma septosporum (39% identity, 54% similarity), but no further useful 
information could be found. Which motif or which residues are important for the 
transfer reaction are currently unknown.
[97]
 
For in vitro analysis the enzymes had to be isolated. The heterologous 
expression of AT1 started with ligation of DNA from MF5453 into pET28a(+). After 
that the resulting plasmid was transformed into E.coli BL21 DE3. Cells were grown in 
liquid culture and the protein production was induced with 0.1 mM IPTG. Finally the 
cells were lysed by sonification and the lysate purified by FPLC. The target protein was 
tagged with His6-tag and purified using a Nickel-NTA column.
[97]
 This work was 
performed by Dr Nina Duensing and Verena Belt in the Cox group. Despite significant 
effort the AT2 protein could not be expressed in soluble form. 
 
5.5 Chemical Cleavage of SQS1 and Substrate Synthesis 
 
In order to set up in vitro assays for AT1 suitable substrates were required. Most AT 
enzymes seem to act near the end of their biosynthetic pathways and we guessed that 
this might also be true for AT1. However it was not known if AT1 acted before or after 
AT2, and we did not know if AT1 acylated at O-6 or O-12. We therefore needed to 
produce substrates containing the squalestatin core attached to either no acyl group 246, 
just the O-6 tetraketide 245 or just the O-12 acetyl group 244.  
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Squalestatin S1 56 was hydrolysed under basic conditions using less than 2.0 
equivalents of hydroxide. Analytical LCMS showed that this produced a mixture of 
unreacted 56, the two mono-acylated compounds 244 and 246 and the doubly 
hydrolysed core compound 245. All squalestatin derivatives were purified by HPLC. 
Compounds 244-246 were obtained as pure single compounds in this way and 
enzymatic assays could not be influenced by chemical inpurities.
[97]
 The tetraketide 61 
itself was also observed. Organic extraction of the reaction mixture at pH 11 removed 
compounds 244-246 which were then purified by high pressure liquid reversed phase 
chromatography. The aqueous phase was then acidified to pH 1 and extracted a second 
time with ethyl acetate to give the tetraketide 61 in pure form. NMR analysis of all 
compounds showed them to be pure and of the expected structures (Scheme 58).
[97]
 
 
Scheme 58: Synthesis of potential precursors in the biosynthesis of 56. 
 
To investigate the AT domains an LCMS method was developed. First a standard 
solution of SQS1 was measured (Figure 95a). In a second experiment the metabolites of 
the fungus MF 5453 were extracted (Figure 95c). Comparison of retention times and 
masses of the extract from the wild-type fungus showed that 56 was produced. 
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Figur 95: ES
-
 TIC LCMS traces of of 56: a) Standard of 56; b) standards of squalestatin derivatives; c) wild 
type extract of 56 with 244 as by product; d) gene knock out of AT1 results in 244 as main product.
[97] 
 
As by-product the squalestatin derivative 244 was extracted. Additional knock out 
experiments showed that compound 244 as main product was produced (Figure 95d). 
This is more evidence that the transfer of the tetraketide to the core product is the last 
step in the biosynthesis.
[97] 
 
 
Scheme 59: Synthesis of 4S-6S-dimethyloct-2-enoylpantetheine 102. 
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The coupling substrates were synthesized in the following way. Tetraketide 61 was 
converted to the corresponding pantetheine thiolester 102 by the usual coupling method, 
followed by TFA deprotection. The synthesis of the CoA substrate was performed in the 
presence of CDI followed by the addition of coenzyme A (Scheme 60). Purification of 
248 was difficult, but reaction mixtures containing a significant proportion of 248 
(LCMS analysis) could be used successfully in assays (section 5.6). 
 
 
Scheme 60: Synthesis of 4-6-dimethyloct-2-enoyl CoA 248. 
 
5.6 In vitro Investigation of the Acyl Transferase AT1 
 
In vitro assays in a volume of 100 L were set up to test the activity of AT1. Each of the 
three core substrates 244-246 were incubated in potassium phosphate buffer at pH 8, 
30 °C for 24 h with purified AT1 and tetraketide pantetheine 102.  
At the end of the reaction time the protein was precipitated by addition of 
acetonitrile and the supernatant was analysed by HPLC-MS. No assay solution showed 
any conversion to the predicted target. Different assay conditions, for example changes 
in the pH or temperature were tried, but no product could be observed. Additionally the 
same investigations were made for incubation of core 245 and AT1 enzyme in the 
presents of acetyl pantetheine but no transfer was observed. 
These results showed that pantetheines cannot act as substrates for AT1. We then 
repeated the assays using CoA substrates under identical conditions. Initial reactions 
used commercially available acetyl-CoA 249 (Scheme 61). 
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Scheme 61: Acyl transfer to the different cores of 56. 
 
Analysis of reaction with the fully hydrolysed core 245 did not show new compounds. 
In contrast to that, the new squalestatin analogue 250 was found in the LCMS-traces 
using the acetylated core 244 in combination with acetyl CoA 249 (Figure 96). In 
contrast, no reaction was observed for the reaction of the O-6 tetraketide substrate 246 
with acetyl CoA 249 in the presence of AT1. 
 
 
Figure 96: LCMS-trace of successful transfer of 249 to core 244. 
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It was not clear at which position the acetylation occurred, as hydroxyls are also 
available at C-4 and C-7. However, the successful transfer indicated three important 
points: first, AT1 requires a CoA-residue; secondly this step in the biosynthesis requires 
the prior acetylation at O-12; and third that only a single acyl transfer occurs. 
Acetylation at O-12 is most-likely catalysed by AT2 in an earlier step. 
 To extend the previous experiments, other CoA substrates were fed to AT1 in 
the presence of the 12-O-acetylated core 244. Investigations with commercial available 
hexanoyl-CoA and octanoyl-CoA showed transfer of the acyl-group to the core 244. 
Similar to the tests before, only enzyme assays with AT1 and the acetylated core 244 
showed the new compounds 252 and 253 (Figure 97). 
 
Figure 97: New squalestatin compounds 252 and 253 generated by enzymatic reaction with AT1. 
 
Finally the position of where the acyl group is transferred needed to be confirmed. To 
test that the transfer goes to the expected position of the core, the tetraketide CoA 248 
was incubated with core 244 and AT1 and transfer was successfully observed. The 
retention time of the product of this reaction was compared with the retention time of 
squalestatin S1 56 itself. The comparison to 56 showed that the product of the enzyme 
assay has the same retention time and MS fragmentation pattern. This shows that the 
reaction produced squalestatin S1 56 and thus transfer must be to the O-6 position.  
 
Figure 98: ES
-
 LCMS traces of acyl transfer from CoA to 244. In vitro assay of AT1 and 244 with hexanoyl 
CoA (1), in vitro assay of AT1 and 244 with octanoyl CoA (2) and incubation of 244 and AT1 with SQTK-
CoA 
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5.7 Discussion 
 
Comparing the structures of the known squalestatins (section 1.5) it seems that different 
polyketides and fatty acids form the O-6 sidechains with the 
4,8-dioxabicyclo[3.2.1]octane core which is identical in all known compounds. In most 
cases at position C-12 an acyl ester is found. This position was very important in the 
previous enzyme assays. Interesting could be the investigation of this acetyl ester 
moiety in other statins, if the same importance can be observed. The final step of the 
biosynthesis must be the acyl transfer at O-6.  
The O-6 side chain of the squalestatin compounds has a much higher diversity in 
chain length, methylation pattern and methylation position. Comparing 56 with 
zaragozic acid C 57 the hexaketide is still the same, also with similar post PKS 
modifications without the ethylene group at C-12, where a methyl group of SAM was 
not transferred. The diversity between the two compounds is found for the side chains. 
A tetraketide is transferred for 56 in contrast to a pentaketide chain, for 57 (section 1.5). 
Only squalestatin core 244 could show activity for enzyme reactions with AT1. 
The other two different cores 245 and 246 were not recognized by the enzyme. Also a 
broad substrate specifity of AT1 was shown by the different CoA substrates that were 
used in the different assays. The current investigations showed that substrates from two 
to eight carbon atoms could be transferred. In that way it was possible to develop new 
squalestatin derivatives. Also other substrates were tested in combination with AT1. But 
new compounds could not be observed by the use of acyl pantetheine substrates. This 
highlights the importance of the adenine residue of the CoA substrates. It is assumed by 
the structure of 244 that the acyl transfer of the tetraketide is the last step in the 
biosynthesis of SQS1 56. 
 Another investigation for AT domains in fungal PKS was performed by Tang et 
al. The lovastatin precursor monacolin J 29 was incubated with the AT enzyme LovD. 
Also this transferase acts in the last step of the biosynthesis of 26. In this work CoA and 
SNAC substrates were used to show the successful acyl transfer to the core compound. 
In contrast to the performed enzyme assays with AT1 required in this project the CoA 
structure of the acyl substrates was not important.  
In contrast to 26 a different mechanism is proposed for the formation of 56. It is 
proposed, that the tetraketide gets released by phpks1. After that the tetraketide is 
transferred to CoA to generate the corresponding coenzyme A intermediate. How this 
CoA transfer works and which other enzymes are involved is currently unknown. 
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Finally the squalestatin core 244 attacks the CoA substrate with the hydroxyl group at 
C-6 (Scheme 62).  
 
Scheme 62: Proposed mechanism of acyl transfer to form 56. 
 
The adenine residue of CoA is important for recognition. Without it the transfer cannot 
take place, which was shown in different pantetheine assays. This proposal is similar to 
the mechanism of Tri101, which has similar active residues in the active site. Other 
amino acid residues that are important for the binding of the tetraketide are currently 
unknown. Possible candidates involved in CoA binding conserved between AT1 and 
Tri101 are L282, T298, D300, and L425. These residues were found in crystal analysis 
of Tri101 (Scheme 62).
[188]
 
 
5.8 Conclusion 
 
To investigate the functions of two AT enzymes that are involved in the biosynthesis of 
squalestatin S1 56 different substrates were prepared. Three different cores were created 
by hydrolysis of squalestatin S1 56 itself. For the enzymatic investigation an assay was 
developed that showed the successful transfer of the different CoA esters to the core 
244. The core 244 was identified as the natural substrate for AT1. It is also the natural 
substrate of the last step in the biosynthesis of 56. Both other isolated cores, 245 and 
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246 showed no activity to AT1, which shows for the core substrate the high selectivity 
of the enzyme. Acytylation at position C-12 is important for the observed selectivity.  
In contrast to this was it possible to create several new substrates by reaction 
with a variety of acyl CoAs. Two new squalestatins (252 and 253) could by synthesized 
in vitro. To validate the specific transfer to position O-6 the natural tetraketide was 
synthesized as its CoA thiolester. This produced a compound identical to 
squalestatin S1 56 by LCMS analysis.  
 
5.9 Future Work 
 
The contrast of substrate selectivity of AT1 is interesting. AT1 can clearly catalyse the 
transfer of various acyl groups to O-6, but it seems quite selective for the structure of 
the core and very regioselective for the nucleophilic oxygen. How the interaction of the 
core works with the AT domain enzyme and which residues are important is currently 
unknown and could be useful to investigate in future. Protein alignment could highlight 
several motifs of amino acid residues that could be important. Predictions of the active 
site could also be made, also about possible catalytic residues of the active site that 
could be involved in the side chain transfer. Confirmation of these active residues by 
mutation experiments and / or production of protein crystals could be another target. 
Results of these investigations could give another perspective to other formed 
squalestatin compounds. 
Another open question is the function of AT2. Is AT2 the missing acyl 
transferase which is responsible for the second transfer of the acyl group at position 
C-12? The structure that is the possible acceptor molecule in this transfer is currently 
unknown. A possible structure for the acceptor molecule could be an open chain in the 
previous biosynthesis of the hexaketide. This acceptor molecule could be generated in a 
chemical way or by gene knock outs. However the insolubility of the AT2 protein 
remains a problem which must also be solved for future in vitro experiments. It may be 
possible to isolate several compounds by knock out experiments that are involved in the 
biosynthesis of SQS1. These compounds could be tested with the isolated AT2 protein. 
Interesting in this case could be the substrate selectivity of AT2. Is the domain similarly 
programmed to AT1? If so, it should have a high selectivity for the acceptor molecule. 
In contrast a variation in the side chain should be possible. 
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Scheme 63: Possible in vitro assays for new squalestatins. 
 
Another possible target for the future work could be an investigation of AT1 in more 
detail. For the moment only the broad substrate selectivity is known. The position on 
which the side chain is transferred seems to be selective. Further investigations 
concerning the length of the side chain could be interesting (Scheme 63). How tolerant 
is the enzyme against different other structures of side chains. Replacement of a carbon 
atom in the side chain by an oxygen to form an ether could be tested. Is it possible to 
create a statin that is similar to zaragosic C 57 for example with this AT domain? If this 
behavior could be observed it could be a possible explanation of shunt products that was 
reported by Glaxo and Merck. In that way, new motifs and structures could be observed 
with different functional groups. This could have a positive change to the general use of 
squalestatin analogues as a drug. Side effects could be potentially limited by changes of 
the structure.  
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6.0 Experimental details 
 
All Solvents were used without any purification or drying process unless otherwise described. Anhydrous 
tetrahydrofuran, diethyl ether and dichloromethane and NADPH were bought from Carl Roth. Other 
chemicals were obtained from Sigma Aldrich and Acros Organics. 
6.1 Equipment 
 
NMR analysis: 
1
H-NMR analysis was performed using BRUKER DPX 200, Avance 400, DPX 400 and 
DRX 500 instruments. Signals are determined in some cases with two dimensional NMR 
1
H, 
1
H-COSY, 
1H, 
13
C-HSQC and 
1
H, 
13
C-J3-HMBC. 
13
C-NMR analysis was performed using BRUKER Avance 400, 
DPX 400 and DRX 500 instruments. Deuterated chloroform (ref. 7.26 ppm / 77.2 ppm)
[189]
 and deuterated 
acetonitrile (ref. 1.94 ppm / 118.4 ppm) were used as solvents and served as internal reference. All  
values are in ppm. All J values are in Hz. 
 
Column Chromatography: For column chromatography silica 60 Å (particle size 35-70 micron, Sigma-
Aldrich or 40-63 micron, Macherey-Nagel) was used. Columns were packed under N2 pressure. Products 
were eluted with the indicated solvent mixtures. Purified fractions were analysed by TLC and combined if 
same Rf was observed. Final products were evaporated in vacuo.  
 
TLC: TLC analysis was preformed on TLC plates with a poly Ester backed 0.2 mm silica gel phase from 
Macherey and Nagel using the indicated solvent systems. Analysis of the plates were performed by 
ultraviolet light (254 nm) or with potassium permanganate (5 mmol) or o-anisaldehyde anisaldehyde 
(15 g), EtOH (250 ml) and concentrated H2SO4 (2.5 ml) solution.  
 
Analytical LCMS: Analytical LC-MS data were obtained with using a Waters LCMS system comprising 
of a Waters 2767 autosampler, Waters 2545 pump system, a Phenomenex Kinetex column (2.6 μ, C18, 
100 Å, 4.6 × 100 mm) equipped with a Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted at 
1 mL/min. Detection was by Waters 2998 Diode Array detector between 200 and 600 nm; Waters 2424 
ELSD and Waters SQD-2 mass detector operating simultaneously ines + and ES- modes between 100 m/z 
and 650 m/z. Solvents were: A, HPLC grade H2O containing 0.05% formic acid; B, HPLC grade MeOH 
containing 0.045% formic acid; and C, HPLC grade CH3CN containing 0.045% formic acid. Gradients 
were as follows. Method 1. Kinetex/CH3CN: 0 min, 10% C; 10 min, 90% C; 12 min, 90% C; 13 min, 
10% C; 15 min, 10% C. 
 
Preparative LCMS: Purification of compounds was generally achieved using a Waters mass-directed 
autopurification system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a 
Phenomenex Kinetex Axia column (5μ, C18, 100 Å, 21.2 × 250 mm) equipped with a Phenomenex 
Security Guard precolumn (Luna C5 300 Å) eluted at 20 mL/min at ambient temperature. Solvent A, 
HPLC grade H2O + 0.05% formic acid; Solvent B, HPLC grade CH3CN + 0.045% formic acid. The post-
 
137 
 
column flow was split (100:1) and the minority flow was made up with HPLC grade CH3CN + 0.045% 
formic acid to 1 mL·min
-1
 for simultaneous analysis by diode array (Waters 2998), evaporative light 
scattering (Waters 2424) and ESI mass spectrometry in positive and negative modes (Waters SQD-2). 
Detected peaks were collected into glass test tubes. Combined tubes were evaporated (vacuum 
centrifuge), weighed, and residues dissolved directly in solvent for use or analysis. 
 
IR analysis: IR analysis was performed with the Fourier transform spectrophotometer IRAffinity-1S 
from the company Shimadzu. 
 
Protein purification: The protein purification was performed with an FPLC ÄKTA pure system from the 
company GE Healthcare. For FPLC analysis a combination with the software UNICORN 6.3 and 
different columns (Nickel column Protino Ni-NTA Columns 5 mL, Size exclusion column- HiLoad 
26/600 Superdex 200pg (GE Healthcare), 320 mL) was used.  
 
UV-Analysis: UV assays were measured with a JASCO-V630-spectrophotometer in quartz glass cuvettes 
with a diameter of 10 mm. The temperature was controlled by the JASCO-V630-Spectrophotometer at 
25 °C. The processed data (by JASCO/Spectramanager) was after that recalculated with Microsoft 
EXCEL. 
 
Curve Fitting: The recalculated initial rates from EXCEL were plotted in the free available software 
Curve Expert. From this plotted curvesthe KM and vMax values were determined with this plotting 
program. Corresponding vMax over KM values were then drawn by Microsoft EXCEL. 
 
Surface Plasmon Resonance: The SPR analysis was performed with a four channel instrument from the 
company Reichert (Reichert 4SPR). The instrument includes an internal autosampler up to 768 samples. 
Other internal features are a degasser, sample loop and optical analysis system. As basic solvents maleate 
buffer (pH 7) and double destilled water were used. As software an internal programmed system of the 
company Reichert was used. This system allowed the measurings of interactions between two partners. 
TRACE DRAWER, a second developed software of Reichert, performed addtitional the analysis of the 
measurements. 
 
Isothermal Titration Calorimetry (ITC): For ITC measurements an instrument of the company 
Taininstruments was used. Cells are made of gold. The volume of the reaction and reference chamber is 
limited to 190 L. Optimal temperature for investigations in the cells is between 2 °C and 80 °C. As basic 
solvents double destilled water and TRIS buffer were used. 
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6.2 Synthesis of Intermediates and Substrates  
6.2.1 Preparation of SNAC Compounds 
 
N-S-diacetyl cysteamine (259).
[190] 
 
To a solution of cysteamine (2.4 g, 30.8 mmol) in water (20 mL) potassium hydroxide (6 M) was added at 
0 °C until pH 8 was reached. Acetic anhydride (9.5 mL, 92.40 mmol) was added dropwise to the mixture 
keeping the pH at 8. After that the pH was adjust to 7 with 2 M HCl and stirred for 1.5 hours. Then NaCl 
was added until saturation and the solution was extracted with dichloromethane (3 × 15 ml), dried over 
MgSO4 and concentrated in vacuo. No further purification was necessary. The obtained product was a 
colourless oil (4.7 g, 30.00 mmol, 98%) Rf: 0.18 (ethyl acetate / hexane 1:1). 
1
H-NMR (CDCl3, 400 
MHz): δ 1.90 (s, 3H, 5-CH3); 2.28 (s, 3H, 7-CH3); 2.95 (t, J = 6.4, 2H, 1-CH2); 3.42 (dt, J = 6.3, J = 6.3, 
2H, 2-CH2); 5.95 (brs, 3-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 23.2 (5-CH3); 28.8 (7-CH3); 30.6 (1-CH2); 
39.6 (2-CH2), 170.5 (4-CO); 196.4 (6-CO). ES-MS: m/z (%): 323.5 [M2]H
+
 (22%), 203.5 [M+CH3CN]H
+
 
(12%), 162.2 [M]H
+
 (100%), 161.0 [M-CH3CO + CH3CN]H
+
 (15%), 120.2 [M-CH3CO]H
+
 (82%).
[125]
 
 
N-acetyl cysteamine (260).
[191] 
 
To a solution of N-S-diacetyl cysteamine (2.48 g, 15.4 mmol) in water (10 mL) potassium hydroxide 
(2.79 g, 49.4 mmol) was added at 0 °C. After that the solution was warmed to room temperature and 
stirred for one hour. Then the reaction was cooled down to 0 °C and acidified to pH 5 with 2 M HCl. 
Then NaCl was added until saturation and the solution was extracted with dichloromethane (3 × 15 mL), 
dried over MgSO4 and concentrated in vacuo. No further purification was necessary. The obtained 
product was a colourless oil (1.77 g, 14.80 mmol, 98%). Rf: 0.07 (ethyl acetate/ hexane 1:1). 
1
H-NMR 
(CDCl3, 400 MHz): δ 1.35 (t, J = 7.9, 1H, 6-SH); 1.95 (s, 3H, 5-CH3); 2.65 (dt, J = 6.5, J = 6.2, 2H, 
1-CH2); 3.41 (dt, J = 6.2, J = 6.2, 2H, 2-CH2); 6.06 (brs, 3-NH). 
13
C-NMR (CDCl3, 75 MHz): 
δ 23.2 (5-CH3); 24.2 (2-CH2); 42.5 (1-CH2), 170.5 (4-CO). ES-MS: m/z (%): 239.3 [M2]H
+
 (14 %), 
161.3 [M+CH3CN]H
+
 (32 %), 120.2 [M]H
+
 (100 %). IR (cm-1): 3294 (N-H), 3080 (C-H), 2936 
(C-H), 1649 (C=O), 1545 (N-H).
[125]
 
 
General Procedure SNAC-Compounds.
 
Acid (4.00 mmol) and N-acetylcysteamine (0.48 g, 4.00 mmol) were dissolved in dichloromethane 
(9 mL) and the mixture was cooled to 0 °C. Then N, N-dimethylaminopyridine (0.1 g, 0.8 mmol) and 
N-(3-Diethylamino-propyl)-N-ethyl-carbodiimide (0.83 g, 4.00 mmol) were added to the reaction. The 
mixture was warmed to 25 °C and then stirred for three hours. The mixture was quenched with 2 M HCl 
(10 mL) and extracted with dichloromethane (3 × 15 mL). The organic layer was washed with saturated 
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NaHCO3 and brine. The product was dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (ethyl acetate).
[125]
 
 
Tigloyl-N-acetylcysteamine (107).
[129] 
 
The obtained product was an oil (0.78 g, 3.90 mmol, 98%). Rf: 0.56 (ethyl acetate). 
1
H-NMR (CDCl3, 
200 MHz): δ 1.86 (s, 3H, 4-CH3); 1.90 (s, 3H, 5-CH3); 2.00 (s, 3H, 10-CH3); 3.10 (t, J = 6.5, 2H, 6-CH2); 
3.48 (dt, J = 6.2, J = 6.2, 2H, 7-CH2); 5.97 (brs, 1H, 8-NH); 6.89 (qq, J = 1.3, J = 7.0, 1H, 3-CH). 
ES-MS: m/z (%): 403.4 [M2]H
+
 (100%), 202.4 [M]H
+
 (61%). IR (cm-1): 3280 (N-H), 3080 (CH=C), 
2931 (C-H), 1649 (C=O), 1545 (N-H).
[192]
 
 
Angelic-N-acetylcysteamine (261).
[129]
 
 
The obtained product was an oil (0.76 g, 3.70 mmol, 94%). Rf: 0.58 (ethyl acetate). 
1
H-NMR (CDCl3, 
200 MHz): δ 1.86 (s, 3H, 4-CH3); 1.90 (s, 3H, 5-CH3); 2.00 (s, 3H, 10-CH3); 3.10 (q, J = 6.5, 2H, 6-CH2); 
3.48 (dt, J = 6.2, J = 6.2, 2H, 7-CH2); 5.97 (brs, 1H, 8-NH); 6.1 (qq, J = 1.3, J = 7.0, 1H, 3-CH). ES-MS: 
m/z (%): 403.4 [M2]H
+
 (100%), 243.4 [M+CH3CN]H
+
 (8%), 202.2 [M]H
+
 (56%). IR (cm-1): 3274 
(N-H), 3079 (CH=C), 2933 (C-H), 1684 (C=O), 1650 (C=O), 1546 (N-H).
[192]
 
 
Crotonyl-N-acetyl-cysteamine (262).
[129]
 
 
The obtained product was a yellow oil (0.10 g, 0.50 mmol, 14%).
 
Rf: 0.49 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 1.90 (dd, J = 1.7, J = 7.1, 3H, 4-CH3); 1.96 (s, 3H, 9-CH3); 3.08 (t, J = 
6.6, 2H, 5-CH2); 3.45 (q, J = 6.1, 2H, 6-CH2); 5.89 (brs, 1H, 7-NH); 6.15 (dq, J = 1.7, J = 15.4, 1H, 
2-CH); 6.94 (dq, J = 6.8, J = 15.4, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 18.0 (4-CH3); 23.2 
(9-CH3 ); 28.2 (5-CH2); 39.9 (6-CH2); 129.9 (2-CH); 141.9 (3-CH); 170.3 (8-CO); 190.2 (1-CO). ES-MS: 
m/z (%): 376.4 [M2]H
+
 (25%), 188.2 [M]H
+
 (100%). IR (cm-1): 3258 (N-H), 3068 (CH=CH), 2942 
(C-H), 1684 (C=O), 1659 (C=O), 1634 (C=O).
[192]
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(±)-2-Methyl-butyryl-N-acetylcysteamine (263).
[129]
 
 
The obtained product was an oil (0.45 g, 2.20 mmol, 55%). Rf: 0.53 (ethyl acetate). 
1
H-NMR (CDCl3, 
400 MHz): δ 0.90 (t, J = 7.6, 3H, 4-CH3); 1.15 (d, J = 7.2, 3H, 5-CH3); 1.50 (m, 2H, 3-CH2); 1.95 (s, 3H, 
10-CH3); 2.57 (m, 1H, 2-CH); 3.01 (t, J = 6.6, 2H, 6-CH2); 3.42 (dt, J = 6.1, J = 6.1, 2H, 7-CH2); 5.88 
(brs, 1H, 8-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.5 (4-CH3), 17.2 (5-CH3); 23.2 (10-CH3); 27.1 
(3-CH2); 28.1 (6-CH2); 39.8 (7-CH2); 50.2 (2-CH); 170.3 (9-CO); 204.6 (1-CO). ES-MS: m/z (%): 204.2 
[M]H
+
 (58%), 162.2 [M-CH3CO + H]H
+
 (100%). IR (cm-1): 3276 (N-H), 3079 (C-H), 2968 (C-H), 
2933 (C-H), 2876 (C-H), 1684 (C=O), 1651 (C=O), 1546 (N-H).
[192]
 
 
Benzoic-N-acetylcysteamine (264).
[193] 
 
The obtained product was an oil (0.76 g, 3.40 mmol, 85 %). Rf: 0.58 (ethyl acetate). 
1
H-NMR (CDCl3, 
200 MHz): δ 2.00 (s, 3H, 10-CH3); 3.26 (t, J = 6.7, 2H, 6-CH2); 3.56 (q, J = 6.5, 2H, 7-CH2); 5.93 (brs, 
1H, 8-NH); 7.49 (m, 2H, 4-CH), 7.6 (m, 5H, 5-CH); 7.99 (m, 2H, 3-CH). ES-MS: m/z (%): 447.4 [M2]H
+
 
(1%), 224.2 [M]H
+
 (13%), 118 [M-C7H5O]H
+
 (8%), 105.2 [M-C4H8NOS]H
+ 
(100%). IR (cm-1): 3300 
(N-H), 3084 (C-H), 2930 (C-H), 1649 (C=O), 1596 (C=O), 1550 (N-H).
[192]
 
 
6.2.2 Preparation of Carboxylic Acids. 
 
General method 1: Malonic acid (2.5 g, 24.00 mmol) and aldehyde (38.00 mmol) were dissolved in 
pyridine (8 mL) and morpholine (35 L). The solution was stirred for 17 hours at 25 °C and was heated to 
115 °C and stirred for further 6 hours. The mixture was quenched with 1 M NaOH (20 mL) and extracted 
with diethyl ether (3 × 15 mL). Then the aqueous phase was acidified with 2 M HCl and extracted with 
diethyl ether (3 × 15 mL). The organic layer was dried over MgSO4 and concentrated in vacuo.
[115]  
 
Hex-2-enoic acid (116).
[129] 
 
The obtained product was a colourless oil (1.43 g, 9.00 mmol, 50%) 
1
H-NMR (CDCl3, 400 MHz): δ 0.94 
(t, J = 7.4, 3H, 6-CH3); 1.50 (m, 2H, 5-CH2); 2.25 (dq, J = 1.4, J = 7.2, 2H, 4-CH2); 5.84 (dt, J = 1.5, 
J = 15.4, 1H, 2-CH); 7.10 (dt, J = 7.1, J = 15.4, 1H, 3-CH); 9.78 (brs, 1H, OH). 
13
C-NMR (CDCl3, 
100 MHz): δ 13.6 (6-CH3), 21.1 (5-CH2); 34.3 (4-CH2); 120.7 (2-CH); 152.3 (3-CH); 172.0 (1-COOH). 
ES-MS: m/z (%): 227 [M2]H
 -
 (100%), 158 [M+CH3CN]H
+
 (12%) IR (cm-1): 2962 (C-H), 2933 
(O-H), 2875 (C-H), 2671 (C-H), 1694 (C=O), 1650 (C=C).
[115, 116]
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(±)-4-Methylhex-2-enoic acid (115a).
[129]
 
 
The obtained product was a yellow oil (1.43 g, 11.00 mmol, 47%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.89 
(t, J = 7.1, 3H, 6-CH3); 1.06 (d, J = 6.6, 1H, 7-CH3); 1.39-1.46 (m, 2H, 5-CH2); 2.21-2.31 (m, 1H, 4-CH); 
5.79 (dd, J = 1.3, J = 15.7, 1H, 2-CH); 6.99 (dd, J = 7.7, J = 15.7, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 
MHz): δ 11.6 (6-CH3), 18.8 (7-CH3); 28.7 (5-CH2); 38.3 (4-CH); 119.0 (2-CH); 157.5 (3-CH); 172.1 
(1-CO). ES-MS: m/z (%): 170 [M+CH3CN]H
+
 (100%), 129 [M]H
+
 (28%);. IR (cm
-1
): 2964 (C-H), 
2929 (O-H), 2877 (C-H), 1692 (C=O), 1650 (C=C).
[115, 116] 
 
Hept-2-enoic acid (117).
[129]
 
 
The obtained product was a yellow oil (1.71 g, 13.00 mmol, 57 %). 
1
H-NMR (CDCl3, 400 MHz): δ 0.94 
(t, J = 6.9, 3H, 7-CH3); 1.40 (m, 4H, 6-5-CH2); 2.23 (qd, J = 1.6, J = 7.0, 2H, 4-CH2); 5.82 (dt, J = 1.6, 
J = 15.7, 1H, 2-CH); 7.10 (dt, J = 6.5, J = 15.2, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.8 
(7-CH3), 22.2 (6-CH2); 29.9 (5-CH2); 32.0 (4-CH2); 120.4 (2-CH); 152.5 (6-CH); 171.9 (1-CO). ES-MS: 
m/z (%): 257 [M2]H
 +
 (3%), 170 [M+CH3CN]H
+
 (100%), 129 [M]H
+
 (8%), 111 [M-H2O]H
+
 (9%), 
IR (cm-1): 2959 (C-H), 2930 (O-H), 2873 (C-H), 1693 (C=O), 1649 (C=C).[115, 116] 
 
Oct-2-enoic acid (118).
[129]
 
 
The obtained product was a yellow oil (1.81 g, 13.00 mmol, 53%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91 
(t, J = 6.9, 3H, 8-CH3); 1.25-1.50 (m, 6H, 7-6-5-CH2); 2.23 (qd, J = 1.6, J = 7.0, 2H, 4-CH2); 5.82 (dt, J = 
1.6, J = 15.7, 1H, 2-CH); 7.06 (dt, J = 6.5, J = 15.2, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 14.0 
(8-CH3), 22.4 (7-CH2); 27.5 (6-CH2); 31.7 (5-CH2); 32.3 (4-CH2); 120.5 (2-CH); 152.6 (3-CH); 171.8 
(1-COOH). ES-MS: m/z (%): 283 [M2]H
-
 (21%), 141 [M]H
-
 (100%). IR (cm-1): 2958 (C-H), 2929 
(O-H), 2859 (C-H), 1693 (C=O), 1650 (C=C).
[115, 116]
 
 
Dec-2-enoic acid (119).
[129] 
 
The obtained product was a yellow oil (1.8 g, 11.00 mmol, 28%) 
1
H-NMR (CDCl3, 400 MHz): δ 0.90 (t, 
J = 5.2, 3H, 10-CH3); 1.29-1.50 (m, 10H, 9-8-7-6-5-CH2); 2.25 (dq, J = 1.3, J = 7.0, 2H, 4-CH2); 5.84 (dt, 
J = 1.6, J = 15.4, 1H, 2-CH); 7.10 (dt, J = 7.0, J = 15.4, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 14.1 
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(10-CH3), 22.6 (9-CH2); 27.8 (8-CH2); 29.0 (7-CH2); 29.1 (6-CH2); 31.7 (5-CH2); 32.3 (4-CH2); 120.5 
(2-CH); 152.5 (3-CH); 171.9 (1-CO). ES-MS: m/z (%): 511.5 [M3]H
+
 (25%), 341.7 [M2]H
+
 (100%), 
212.4 [M]H
+
 (97%), 171.2 [M]H
+
 (10%), 153.5 [M-H2O]H
+
 (70%). IR (cm-1): 2956 (C-H), 2925 
(O-H), 2858 (C-H), 2671 (C-H), 1694 (C=O), 1650 (C=C).
[115, 116]
 
 
General Method 2:
 
Step 1. A solution of dichloromethane (5 mL) and butanale (0.07 mL, 1.00 mmol) was stirred at 0 °C. 
(Carbethoxyethylidene)triphenylphosphorane (0.72 g, 2.00 mmol) was added to this solution warmed to 
25 °C and stirred for 18 hours. Then the solvent was evaporated under a nitrogen flow. The crude product 
was purified by column chromatography (ethyl acetate/ hexane 1:10).  
Step 2. To a solution of the corresponding Ester in ethanol/water 5:1 (5 mL/ 1 mL) potassium hydroxide 
was added to the solution. After stirring under reflux for 3 hours diethyl ether was added. The mixture 
was washed with NaHCO3 (3 × 10 mL). Then the aqueous layer was acidified with 2 M HCl until pH 1 
and extracted with ethyl acetate (3x 10 ml). The organic layer was dried over MgSO4 and concentrated in 
vacuo.
[116, 117]
  
 
Ethyl-2-methylhex-2-enoate (120a).
[129] 
  
The obtained product was a colourless oil (0.06 g, 0.40 mmol, 37%). Rf: 0.95 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.93 (t, J = 7.3, 3H, 6-CH3); 1.29 (t, J = 7.1, 3H, 9-CH3); 1.39-1.55 (m, 
2H, 5-CH2); 1.82 (m, 3H, 7-CH3); 2.18 (qd, J = 1.2, J = 7.4, 2H, 4-CH2); 4.18 (q, J = 6.9, 2H, 8-CH2); 
6.74 (tq, J = 1.4, J = 7.5, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.4 (6-CH3), 13.9 (9-CH3), 14.3 
(7-CH3), 21.9 (5-CH2); 30.7 (4-CH2); 60.4 (8-CH2); 127.9 (2-C); 142.2 (3-CH); 168.4 (1-CO). ES-MS: 
m/z (%): 313 [M2]H
 +
 (12%), 198 [M+CH3CN]H
+
 (100%), 157 [M]H
+
 (95%). IR (cm
-1
): 2961 (C-H), 
2934 (O-H), 2873 (C-H), 1710 (C=O), 1650 (C=C).
[116]
 
 
2-Methylhex-2-enoic acid (121a).
[129]
 
 
The obtained product was a red oil (0.16 g, 1.30 mmol, 50%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 
6.84, 3H, 6-CH3); 1.32-1.50 (m, 2 H, 5-CH2); 1.85 (s, 3H, 7-CH3); 2.22 (q, J = 7.2, 2H, 4-CH2); 6.93 (tq, 
J = 1.4, J = 7.6, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.0 (6-CH3), 13.8 (7-CH3), 21.7 (5-CH2), 
30.6 (4-CH2), 127.0 (2-C), 145.2 (3-CH), 173.1 (1-CO). ES-MS: m/z (%): 257 [M2]H
 +
 (12%), 170 
[M+CH3CN]H
+
 (100%), 129 [M]H
+
 (60%); 111 [M-H2O]H
+
 (12%). IR (cm
-1
): 2956 (C-H), 2931 
(C-H), 2857 (C-H), 1685 (C=O), 1644 (C=C).
[117]
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(±)-Ethyl-2, 4-dimethylhex-2-enoate (120b).
[129] 
 
The obtained product was a colourless oil (0.28 g, 1.60 mmol, 80%). Rf: 0.78 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.85 (t, J = 7.1, 3H, 6-CH3); 1.00 (d, J = 7.1, 3H, 7-CH3); 1.28-1.55 (m, 
2H, 5-CH2); 1.30 (t, J = 6.4, 3H, 10-CH3); 1.82 (s, 3H, 8-CH3); 2.41 (m, 1H, 4-CH); 4.19 (q, J = 7.1, 2H, 
9-CH2); 6.52 (dq, J = 1.3, J = 10.3, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.9 (6-CH3), 12.6 
(7-CH3), 14.3 (10-CH3), 19.7 (8-CH3), 29.7 (5-CH2), 34.9 (4-CH), 60.4 (9-CH2), 126.6 (2-C), 147.9 
(3-CH), 168.4 (1-CO) ES-MS: m/z (%): 184 [M-CH2CH3+CH3CN]H
+
 (100%), 171 [M]H
+
 (52%), 142 
[M-CH2CH3]H
+
 (12%). IR (cm-1): 2961 (C-H), 2930 (C-H), 1709 (C=O), 1650 (C=C).[116] 
 
(±)-2-4-Dimethylhex-2-enoic acid (121b).
[129]
 
 
The obtained product was a red oil (0.19 g, 1.30 mmol, 50%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 
6.0, 3H, 6-CH3); 1.01 (d, J = 6.0, 3H, 7-CH3); 1.24-1.49 (m, 2H, 5-CH2); 1.85 (s, 3H, 8-CH3); 2.38-2.49 
(m, 1H, 4-CH); 6.68 (qq, J = 1.4, J = 11.6, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.8 (6-CH3), 
12.2 (7-CH3), 19.5 (8-CH3), 29.5 (5-CH2), 35.1 (4-CH), 125.7 (2-C), 150.8 (3-CH), 173.3 (1-CO). 
ES-MS: m/z (%): 184 [M+CH3CN]H
+
 (100%), 143 [M]H
+
 (22%). IR (cm
-1
): 2961 (C-H), 2929 
(C-H), 2875 (C-H), 1682 (C=O), 1643 (C=C).
[117]
 
 
(±)-Methyl-4-methylhex-2-enoate (120c).
[129]
 
 
The obtained product was a colourless oil (0.51 g, 3.60 mmol, 90%). Rf: 0.78 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 6.4, 3H, 6-CH3); 1.04 (d, J = 6.9, 3H, 7-CH3); 1.36-1.44 (m, 
2H, 5-CH2); 2.17-2.27 (m, 1H, 4-CH); 3.73 (s, 3H, 8-CH3); 5.78 (dd, J = 1.1, J = 15.6, 1H, 2-CH); 6.87 
(dd, J = 6.9, J = 16.3, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.7 (6-CH3), 18.9 (7-CH3), 28.7 
(5-CH2), 38.1 (4-CH), 51.4 (8-CH3), 119.3 (2-CH), 154.8 (3-CH), 167.3 (1-CO) ES-MS: m/z (%): 143 
[M]H
+
 (100%), 111 [M-OCH3]H
+
 (72%). IR (cm-1): 2963 (C-H), 2876 (C-H), 1722 (C=O), 1656 
(C=C).
[116] 
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Ethyl-2-methylhept-2-enoate (120d).
[129] 
 
The obtained product was a colourless oil (0.18 g, 0.90 mmol, 94%). Rf: 0.82 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 7.2, 3H, 7-CH3); 1.29 (t, J = 7.2, 3H, 10-CH3); 1.35-1.44 (m, 
4H, 5-6-CH2); 1.82 (s, 3H, 8-CH3); 2.16 (q, J = 7.1, 2H, 4-CH2); 4.18 (q, J = 7.2, 2H, 9-CH2); 6.74 (tq, 
J = 1.4, J = 7.5, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.3 (7-CH3), 13.9 (8-CH3), 14.3 (10-CH3), 
22.5 (6-CH2), 28.4 (4-CH2), 30.7 (5-CH2); 60.4 (9-CH2); 127.7 (2-C); 142.4 (3-CH); 168.4 (1-CO). 
ES-MS: m/z (%): 341 [M2]H
 +
 (18%), 212 [M+CH3CN]H
+
 (100%), 171 [M]H
+
 (78%). IR (cm
-1
): 
2926 (O-H), 2857 (C-H), 1685 (C=O), 1644 (C=C).
[117]
 
 
2-Methylhept-2-enoic acid (121d).
[129]
 
 
The obtained product was a red oil (0.11 g, 0.80 mmol, 93%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 
6.84, 3H, 7-CH3); 1.32-1.50 (m, 4H, 5-6-CH2); 1.83 (s, 3H, 8-CH3); 2.18 (q, J = 7.2, 2H, 4-CH2); 6.90 (tq, 
J = 1.4, J = 7.6, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.9 (7-CH3), 13.9 (8-CH3), 22.4 (6-CH2), 
28.6 (4-CH2), 30.5 (5-CH2), 126.8 (2-C), 145.5 (3-CH), 172.8 (1-CO). ES-MS: m/z (%): 285 [M2]H
+
 
(10%), 184 [M+CH3CN]H
+
 (100%), 143 [M]H
+
 (10%); 125 [M-H2O]H
+
 (10%). IR (cm
-1
): 2956 
(C-H), 2931 (C-H), 2857 (C-H), 1685 (C=O), 1644 (-C=C).
[116]
 
 
Ethyl-2-methyloct-2-enoate (120e).
[129]
 
 
The obtained product was a colourless oil (0.18 g, 0.90 mmol, 94%). Rf: 0.65 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 6.5, 3H, 8-CH3); 1.25-1.55 (m, 9H, 7-6-5-CH2-11-CH3); 1.82 
(d, J = 0.93, 3H, 9-CH3); 2.15 (q, J = 7.2, 2H, 4-CH2); 4.18 (q, J = 7.2, 2H, 10-CH2); 6.77 (tq, J = 1.6, J = 
7.6, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.3 (8-CH3), 14.0 (9-CH3), 14.3 (11-CH3), 22.5 
(7-CH2), 28.3 (5-CH2), 28.7 (4-CH2), 31.6 (6-CH2), 60.4 (10-CH2), 127.7 (2-C), 142.5 (3-CH), 168.4 
(1-C) ES-MS: m/z (%): 369 [M2]H
+
 (33%), 226 [M+CH3CN]H
+
 (100%), 185 [M]H
+
 (65%). 
IR (cm-1): 2926 (C-H), 2859 (C-H), 1709 (C=O), 1650 (C=C).[116] 
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2-Methyloct-2-enoic acid (121e).
[129]
 
 
The obtained product was a red oil (0.16 g, 1.30 mmol, 50 %). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 (t, 
J = 6.9, 3H, 8-CH3); 1.26-1.52 (m, 6H, 5-6-7-CH2); 1.86 (d, J = 1.33, 3H, 9-CH3); 2.22 (q, J = 7.3, 2H, 
4-CH2); 6.94 (tq, J = 1.4, J = 7.5, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.0 (8-CH3), 14.0 
(9-CH3), 22.5 (7-CH2), 28.1 (5-CH2), 28.8 (4-CH2), 31.5 (6-CH2), 126.8 (2-C), 145.5 (3-CH), 173.1 
(1-CO). ES-MS: m/z (%): 313 [M2] H
 +
 (10%), 198 [M+CH3CN]H
+
 (100%), 157 [M]H
+
 (22%). 
IR (cm-1): 2926 (OH), 2859 (C-H), 1682 (C=O), 1642 (C=C).[117] 
 
Ethyl-2-methyldec-2-enoate (120f).
[129] 
 
The obtained product was a colourless oil (0.15 g, 0.70 mmol, 66%). Rf: 0.85 (ethyl acetate/ hexane 1:7). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 6.8, 3H, 10-CH3); 1.25-1.58 (m, 13H, 9-8-7-6-5-CH2-
13-CH3); 1.82 (d, J = 0.93, 3H, 11-CH3); 2.15 (q, J = 7.4, 2H, 4-CH2); 4.18 (q, J = 7.2, 2H, 12-CH2); 6.75 
(tq, J = 1.3, J = 7.4, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.3 (10-CH3), 14.1 (11-CH3), 14.3 
(13-CH3), 22.6 (9-CH2), 28.6 (7-CH2), 28.7 (6-CH2), 29.1 (5-CH2), 29.4 (4-CH2), 31.8 (8-CH2), 60.4 
(12-CH2), 127.6 (2-C), 142.5 (3-CH), 168.4 (1-CO) ES-MS: m/z (%): 425 [M2]H
+
 (50%), 254 
[M+CH3CN]H
+
 (100%), 213 [M]H
+
 (52%). IR (cm
-1
): 2925 (-C-H), 2856 (-C-H), 1710 (C=O), 1650 
(-C=C), 1463 (CO), 1366 (C-O), 1266 (C-O).
[116]
 
 
2-Methyldec-2-enoic acid (121f).
[129]
 
 
The obtained product was a red oil (0.11 g, 0.60 mmol, 86%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.87-0.90 
(m, 3H, 10-CH3); 1.26-1.30 (m, 10H, 9-8-7-6-5-CH2); 1.83 (d, J = 0.93, 3H, 11-CH3); 2.19 (q, J = 7.3, 
2H, 4-CH2); 6.90 (td, J = 1.5, J = 7.6, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.3 (10-CH3), 14.1 
(11-CH3), 22.6 (9-CH2), 28.4 (7-CH2), 28.9 (6-CH2), 29.1 (5-CH2), 29.3 (4-CH2), 31.8 (8-CH2), 126.8 
(2-C), 145.6 (3-CH), 172.8 (1-CO). ES-MS: m/z (%): 369 [M2]H
+
 (10%), 226 [M+CH3CN]H
+
 (100%), 
167 [M-H2O]H
+
 (52%). IR (cm
-1
): 2925 (C-H), 2363 (O-H), 1712 (C=O), 1650 (C=C).
[117]
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General Method 3:  
Step 1. Potassium tert-butanoxide (1.63 g, 14.5 mmol) was added to dry THF (20 mL) and cooled down 
to 0 °C. After that triethylphosphonobutyrate (3.5 mL, 14.5 mmol) was added and the solution stirred for 
10 min. Aldehyde (14 mmol) was added and the mixture warmed up to roomtemperature. The solution 
was stirred for 3 hours and then water (20 mL) was added and extracted 3 × with ethyl acetate (20 mL). 
The combined organic layers were washed with brine and dried over MgSO4. The crude product was 
purified by column chromatography (ethyl acetate/ hexane 1:10).  
Step 2. To a solution of the corresponding Ester in ethanol/water 5:1 (5 mL/ 1 mL) potassium hydroxide 
was added to the solution. After stirring under reflux for 3 hours diethyl ether was added. The mixture 
was washed with NaHCO3 (3 × 10 mL). Then the aqueous layer was acidified with 2 M HCl until pH 1 
and extracted with ethyl acetate (3x 10 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo.
[118]
 
 
Ethyl-2-ethylhex-2-enoate (123a).
[129]
 
 
The mixture of the E- and Z-isomers was a colourless oil (1.50 g, 8.80 mmol, 63%). Rf: 0.69 (ethyl 
acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.90-1.05 (m, 6H, 6-8-CH3); 1.28-1.32 (m, 3H, 
10-CH3); 1.38-1.52 (m, 2H, 5-CH2); 2.16 (q, J = 6.9, 2H, 4-CH2); 2.24-2.40 (m, 2H, 7-CH2); 4.16-4.23 
(m, 2H, 9-CH2); 5.83 (t, J = 7.9, 0.3 H, 3-CH); 6.71 (t, J = 7.4, 0.7 H, 3-CH). 
13
C-NMR (CDCl3, 
100 MHz): δ 13.6 (6-CH3), 13.9 (8-CH3), 14.3 (10-CH3), 20.0 (7-CH2E), 22.1 (4-CH2E), 22.7 (9-CH2Z), 
27.3 (5-CH2Z), 30.4 (4-CH2E), 31.5 (4-CH2Z), 59.8 (9-CH2Z), 60.3 (9-CH2E), 133.9 (2-CZ), 134.1 (2-Ce), 
140.0 (3-CHZ), 141.4 (3-CHE), 168.0 (1-CZ), 168.4 (1-CE) ES-MS: m/z (%): 184 
[M-CH2CH3+CH3CN]H
+
 (18%), 171 [M]H
+
 (8%), 143 [M-CH2CH3]H
+
 (100%). IR (cm-1): 2963 
(C-H), 2935 (C-H), 2874 (C-H), 1709 (C=O), 1646 (C=C).
[118]
 
 
2-Ethylhex-2-enoic acid (125a).
[129]
 
 
The obtained product was a red oil (1.2 g, 8.40 mmol, 96%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91-1.08 
(m, 6H, 6-8-CH3); 1.40-1.54 (m, 2H, 5-CH2); 2.20 (q, J = 7.7, 2H, 4-CH2); 2.26-2.34 (m, 2H, 7-CH2); 
6.03 (t, J = 7.6, 1H, 3-CHZ); 6.88 (t, J = 7.6, 1H, 3-CHE). 
13
C-NMR (CDCl3, 100 MHz): δ 13.8 (6-CH3), 
13.8 (8-CH3), 19.7 (7-CH2Z), 22.0 (7-CH2E), 27.4 (5-CH2), 30.5 (4-CH2Z), 31.7 (4-CH2E), 132.6 (2-CZ), 
133.3 (2-CE), 144.8 (3-CHZ), 144.9 (3-CHE), 173.3 (1-CO). ES-MS: m/z (%): 184 [M+CH3CN]H
+
 (18%), 
143 [M]H
+
 (100%). IR (cm
-1
): 2963 (C-H), 2934 (C-H), 2874 (C-H), 1681 (C=O), 1637 (C=C).
[118]
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Ethyl-2-ethyloct-2-enoate (123b).
[129]
 
 
The mixture of the E- and Z-isomers was a colourless oil (2.10 g, 10.60 mmol, 74%). Rf: 0.63 (ethyl 
acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.86-1.05 (m, 6H, 8-10-CH3); 1.27-1.33 (m, 7H, 
5-7-CH2-12-CH3); 1.36-1.48 (m, 2H, 6-CH2); 2.16 (q, J = 7.2, 2H, 4-CH2); 2.23-2.43 (m, 2H, 9-CH2); 
4.16-4.23 (m, 2H, 11-CH2); 5.83 (t, J = 7.9, 0.3 H, 3-CH); 6.71 (t, J = 7.2, 0.7 H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.6 (8-CH3), 13.9 (10-CH3), 14.3 (12-CH3), 20.0 (9-CH2E), 22.1 
(9-CH2Z), 22.7 (7-CH2), 28.3 (5-CH2Z), 28.5 (5-CH2E), 29.3 (6-CH2Z), 29.4 (6-CH2E), 31.5 (4-CH2E), 31.6 
(4-CH2Z), 59.9 (11-CH2Z), 60.3 (11-CH2E), 133.7 (2-CZ), 133.9 (2-CE), 140.0 (3-CHZ), 142.4 (3-CHE), 
168.0 (1-CZ), 168.4 (1-CE ES-MS: m/z (%): 199 [M]H
+
 (18%), 171 [M-H2O]H
 +
 (72%). IR (cm-1): 
2960 (C-H), 2929 (C-H), 2873 (C-H), 1709 (C=O), 1645 (C=C).
[118]
 
 
2-Ethyl-oct-2-enoic acid (125b).
[129]
 
 
The obtained product was a red oil (1.0 g, 6.00 mmol, 60 %). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91-1.08 
(m, 6H, 8-10-CH3); 1.28-1.38 (m, 4H, 6-7-CH2); 1.40-1.49 (m, 2H, 5-CH2); 2.20 (q, J = 7.4, 2H, 4-CH2); 
2.26-2.34 (m, 2H, 9-CH2); 2.49 (q, J = 7.4, 2H, 5-CH2); 6.02 (t, J = 7.1, 1H, 3-CHZ); 6.88 (t, J = 7.4, 1H, 
3-CHE). 
13
C-NMR (CDCl3, 100 MHz): δ 13.8 (8-CH3), 13.9 (10-CH3), 19.8 (9-CH2Z), 22.5 (9-CH2E), 
27.4 (7-CH2), 28.4 (6-CH2), 29.2 (5-CH2), 30.5 (4-CH2Z), 31.7 (4-CH2E), 132.4 (2-CZ), 133.3 (2-CE), 
144.7 (3-CHZ), 146.1 (3-CHE), 172.8 (1-CO). ES-MS: m/z (%): 212 [M+CH3CN]H
+
 (11%), 171 [M]H
+
 
(82%). IR (cm-1): 2959 (C-H), 2927 (C-H), 2859 (C-H), 1681 (C=O), 1637 (C=C).[118] 
 
6.2.3 Further Preparations of Carboxylic Acids 
 
(2E, 4S)-Dimethylhex-2-enoic acid (121g).
[129]
 
 
2S-methylbutanol (1.00 mL, 10 mmol) and pyridinium chlorochromate (2.2 g, 10 mmol) and celite 
(1.31 g) were dissolved in THF (30 mL). The reaction was followed by TLC and after full consumption 
of the alcohol (Carbethoxyethylidene)triphenylphosphorane (4.20 g, 12.00 mmol) was added and the 
reaction refluxed for 7 hours. Then diethyl ether was added and the mixture was filtered by Florosil. The 
filtered solution was concentrated under vacuo and purified by column chromatographie (hexane/ ethyl 
acetate, 4:1). To a solution of (2E, 4S)-dimethylhex-2-enoate (0.40 g, 3.40 mmol) in ethanol/water 5:1 
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(5 mL/ 1 mL) potassium hydroxide (1.22 g, 22.00 mmol) was added to the solution. After stirring under 
reflux for 3 hours diethyl ether was added. The mixture was washed with NaHCO3 (3 × 10 mL). Then the 
aqueous layer was acidified with 2 M HCl until pH 1 and extracted with ethyl acetate (3 × 10 mL). The 
organic layer was dried over MgSO4 and concentrated in vacuo. The obtained product was a red oil 
(0.57 g, 3.30 mmol, 98%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.4, 3H, 6-CH3); 1.17 (d, J = 6.9, 
3H, 7-CH3); 1.40-1.60 (m, 2H, 5-CH2); 1.85 (d, J = 1.5, 3H, 8-CH3); 2.32-2.49 (m, 1H, 4-CH), 6.69 (dd, 
J = 1.5, J = 10.0, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.9 (6-CH3), 12.6 (7-CH3), 19.7 (8-CH3), 
29.7 (5-CH2), 34.9 (4-CH), 126.6 (2-C), 147.9 (3-CH), 168.4 (1-CO). ES-MS: m/z (%): 143 
[M+CH3CN]H
+
 (100%). D = +11.0 (CH2Cl2) IR (cm
-1
): 2966 (C-H), 2935 (C-H), 2877 (C-H), 
1697 (C=O).
[119, 120]
 
 
Methyl-6-methylhept-2-enoate (131).
[129]
  
 
4-Methyl-pentanol (0.5 ml, 3.6 mmol), pyridinium chlorochromate (1.09, 5.0 mmol) and celite (1.31 g) 
were dissolved in THF (30 ml). The reaction was followed by TLC and after full consumption of the 
alcohol methyl(triphenylphosphor-anylidene)acetate (2.03 g, 6.1 mmol) was added and the reaction 
refluxed for 7 hours. Then diethyl ether was added and the mixture was filtered by Florosil. The filtered 
solution was concentrated in vacuo and purified by column chromatography (hexane/ ethyl acetate, 4:1). 
The obtained product was a colourless oil (0.42 g, 2.6 mmol, 72%) Rf: 0.72 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.89 (d, J = 6.5, 6H, 7-CH3); 1.31-1.36 (m, 2H, 5-CH2); 1.53-1.61 (m, 
1H, 6-CH2); 2.17-2.23 (m, 2H, 4-CH2); 3.72 (s, 3H, 9-CH3); 5.82 (dt, J = 1.7, J = 15.6, 1H, 2-CH), 6.97 
(dt, J = 7.0, J = 15.7, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 22.4 (7-2xCH3), 27.5 (6-CH), 30.1 
(4-CH2), 37.0 (5-CH2), 51.4 (8-CH3), 120.6 (2-CH), 150.0 (3-CH), 167.2 (1-CO) ES-MS: m/z (%): 157 
[M+CH3CN]H
+
 (100%).
[120]
 
 
6-Methylhept-2-enoic acid (132).
[129]
 
 
To a solution of methyl-6-methylhept-2-enote (0.42 g, 2.60 mmol) in ethanol/water 5:1 (5 mL/ 1 mL) 
potassium hydroxide (1.22 g, 22.00 mmol) was added to the solution. After stirring under reflux for 3 
hours diethyl ether was added. The mixture was washed with NaHCO3 (3 × 10 ml). Then the aqueous 
layer was acidified with 2 M HCl until pH 1 and extracted with ethyl acetate (3 × 10 mL). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The obtained product was a yellow oil (0.26 g, 
1.80 mmol, 70%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.89 (d, J = 5.5, 6H, 7-CH3); 1.33-1.38 (m, 2H, 
5-CH2); 1.53-1.62 (m, 1H, 6-CH2); 2.21-2.27 (m, 2H, 4-CH2); 5.82 (dt, J = 1.5, J = 15.5, 1H, 2-CH), 6.97 
(dt, J = 6.9, J = 15.5, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 22.4 (7-2xCH3), 27.5 (6-CH), 30.1 
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(4-CH2), 37.0 (5-CH2), 120.6 (2-CH), 152.7 (3-CH), 171.3 (1-CO). ES-MS: m/z (%): 157 [M+CH3CN]H
+
 
(100%). IR (cm-1): 2957 (C-H), 2872 (C-H), 1694 (C=O), 1650 (-C=C).[117] 
 
Methyl-7-methyloct-2-enoate (134).
[129]
  
 
5-Methyl-hexanol (0.5 ml, 3.6 mmol), pyridinium chlorochromate (1.09, 5.0 mmol) and celite (1.30 g) 
were dissolved in THF (30 mL). The reaction was followed by TLC and after full consumption of the 
alcohol methyl(triphenylphosphor-anylidene)acetate (2.03 g, 6.1 mmol) was added and the reaction 
7 hours refluxed. Then diethyl ether was added and the mixture was filtered through Florosil. The filtered 
solution was concentrated in vacuo and purified by column chromatography (hexane/ ethyl acetate, 4:1). 
The obtained product was a colourless oil (0.52 g, 3.1 mmol, 86%) Rf: 0.75 (ethyl acetate/ hexane 1:10). 
1
H-NMR (CDCl3, 400 MHz): δ 0.87 (d, J = 6.6, 6H, 8-CH3); 1.15-1.22 (m, 2H, 5-6-CH2); 1.43-1.58 (m, 
1H, 7-CH); 2.18 (dq, J = 1.5, J = 7.2, 2H, 4-CH2); 3.73 (s, 3H, 9-CH3); 5.82 (dt, J = 1.5, J = 15.6, 1H, 
2-CH), 6.97 (dt, J = 7.0, J = 15.7, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 22.5 (8-2xCH3), 25.9 
(5-CH3), 27.8 (7-CH), 32.5 (4-CH2), 38.4 (6-CH2), 51.4 (9-CH3), 120.8 (2-CH), 149.9 (3-CH), 167.2 
(1-CO). ES-MS: m/z (%): 171 [M+CH3CN]H
+
 (100%). IR (cm-1): 2954 (C-H), 2870 (C-H), 1725 
(C=O), 1658 (-C=C).
[120]
 
 
7-Methyloct-2-enoic acid (135).
[129]
 
 
To a solution of methyl-7-methyloct-2-enoate (0.42 g, 2.60 mmol) in ethanol/water 5:1 (5 mL/ 1 ml) 
potassium hydroxide (1.22 g, 22.00 mmol) was added to the solution. After stirring under reflux for 
3 hours diethyl ether was added. The mixture was washed with NaHCO3 (3 × 10 mL). Then the aqueous 
layer was acidified with 2 M HCl until pH 1 and extracted with ethyl acetate (3 × 10 ml). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The obtained product was a yellow oil (0.24 g, 
1.50 mmol, 58%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (d, J = 5.5, 6H, 8-CH3); 1.17-1.23 (m, 4H, 5-6-
CH2); 1.43-1.58 (m, 1H, 7-CH); 2.22 (dq, J = 1.5, J = 7.3, 2H, 4-CH2); 5.82 (dt, J = 1.5, J = 15.5, 1H, 
2-CH), 7.09 (dt, J = 6.8, J = 15.5, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): δ 22.4 (8-2xCH3), 25.7 
(5 CH2), 27.8 (7-CH), 32.5 (4-CH2), 38.4 (6-CH2), 120.5 (2-CH), 152.3 (3-CH), 171.5 (1-CO) ES-MS: 
m/z (%): 157 [M]H
+
 (17%), 139 [M-H2O]H
+
 (70%), 121 [M-2x H2O]H
+
 (17%). IR (cm-1): 
2955(C-H), 2930(C-H), 2870 (C-H), 1694 (C=O), 1650 (-C=C).
[117]
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(4S, 6S)-Dimethyloct-2-enoic acid (61).
[97]
 
 
To a solution of squalestatin S1 (1.00 g, 1.40 mmol) in ethanol/water 5:1 (5 mL/ 1 mL) potassium 
hydroxide (1.22 g, 22.00 mmol) was added to the solution. After stirring under reflux for 3 hours, diethyl 
ether was added through the solution and washed 3 × with NaHCO3 (3 × 10 mL). The aqueous layer with 
the (4S, 6S)-2-4-dimethyloct-2-enoic acid was acidified with 2 M HCl until pH 1 and extracted with ethyl 
acetate (3 × 10 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The obtained 
product was a red oil (0.21 g, 0.12 mmol, 86%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.4, 6H, 8-9-
CH3); 1.07 (d, J = 6.2, 3H, 10-CH3); 1.27-1.46 (m, %H, 7-5-CH2-6-CH); 2.41-2.52 (m, 1H, 4-CH), 5.81 
(dd, J = 1.7, J = 16.0, 1H, 2-CH), 6.96 (dd, J = 8.8, J = 16.0, 1H, 3-CH). 
13
C-NMR (CDCl3, 100 MHz): 
δ 11.1 (8-CH3); 20.2 (9-CH3); 20.7 (10-CH3); 29.8 (7-CH2); 31.9 (6-CH); 34.4 (4-CH); 43.1 (5-CH2), 
118.3 (2-CH); 164.6 (3-CH); 176.7 (1-CO). ES-MS: m/z (%): 171 [M+CH3CN]H
+
 (100%). 
IR (cm-1): 2960 (C-H), 2914 (C-H), 2873 (C-H), 1693 (C=O), 1649 (-C=C). 
 
6.2.4 Preparation of Acyl Meldrums Acids. 
 
General Procedure: Meldrums acid (2.9 g, 20 mmol) in 50 mL dichloromethane, pyridine (3.3 mL, 
40 mmol) stirred under nitrogen for 10 min. After that the temperature of the mixture was settled down to 
0 °C and acid chloride (28 mmol) was added slowly to the reaction. The reaction was warmed up to 
roomtemperature and stirred overnight. The mixture was washed with 2 M HCl and water. After that it 
was concentrated and purified by column chromatography (hexane/ ethyl acetate 10:1).
[166, 167]
  
 
Acyl meldrums acid (222a).
[166]
 
 
The product was a white solid (2.9 g, 16 mmol, 80%) 
1
H-NMR (CDCl3, 400 MHz): δ 1.74 (s, 6H, 6-7-
CH3); 2.86 (s, 3H, 1-CH3). 
13
C-NMR (CDCl3, 100 MHz): δ 23.5 (1-CH3), 26.8 (6-7-CH3); 91.9 (3-CH); 
104.9 (5-C); 170.2 (4-CO); 194.6 (2-CO). ES-MS: m/z (%): 184 [M]H
-
 (97%). IR (cm-1): 2985 
(C-H), 1732 (C=O), 1658 (C=O), 1546 (C-O). HR-MS: m/z (%): calculated 185.0450, found 
185.0453.
[166] 
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Butyryl meldrums acid (222b).
[166]
 
 
The product was a yellow oil (1.6 g, 7.4 mmol, 78%) 
1
H-NMR (CDCl3, 400 MHz): δ 1.03 (t, J = 8.4, 3H, 
4-CH3); 1.74 (s, 6H, 8-9-CH3); 1.72-1.79 (m, 2H, 3-CH2); 3.06 (t, J = 7.3, 2H, 2-CH2). 
13
C-NMR (CDCl3, 
100 MHz): δ 13.9 (4-CH3), 19.6 (3-CH2), 26.6 (8-9-CH3); 37.5 (2-CH2); 91.3 (5-C); 104.8 (7-C); 170.6 
(6-CO); 198.2 (1-CO). ES-MS: m/z (%): 213 [M]H
-
 (97%). IR (cm-1): 2956 (C-H), 2877 (C-H), 1735 
(C=O), 1660 (C=O), 1568 (C-O). HR-MS: m/z (%): calculated 237.0745, found 237.0739.
[166, 167] 
 
6.2.5 Preparation of Pantetheine Dimethyl Ketal Substrates  
 
Pantetheine dimethyl ketal (144).
[49]
 
 
D-pantothenic acid hemicalcium salt (2.50 g, 10.50 mmol), p-toluensulfonic acid (2.30 g, 13.00 mmol) 
and 5 g molecular sieves were suspended in 125 mL dry acetone and stirred at 25 °C for 12 hours under a 
nitrogen atmosphere. The suspension was filtered with celite and washed with 200 ml acetone. The 
filtrate was concentrated to a colourless oil, redissolved in 200 ml ethyl acetate and washed two times 
with brine (25 mL) and dried over MgSO4. After that the ethyl acetate was removed in vacuo and hexane 
was added to the flask to get a white solid that was dried under high vacuum. The corresponding D-
pantothenic dimethyl ketal (1.90 g, 7.00 mmol was dissolved in 40 mL dry THF with CDI (1.70 g, 
11.00 mmol) and stirred for one hour at 25 °C. Then cysteamine (1.30 g, 11.00 mmol) was added to the 
solution and stirred for 12 hours. The solution was concentrated under vacuum and dichloromethane was 
added. The organic layer were washed with NH4Cl (25 mL) and brine (25 mL), dried over MgSO4 and 
concentrated in vacuo. After that the colourless oil was purified by column chromatography (ethyl 
acetate) to get a white solid (1.90 g, 6.00 mmol, 86%) Rf: 0.1 (ethyl acetate). 
1
H-NMR (CDCl3, 
400 MHz): δ 0.98 (s, 3H, 13-CH3); 1.05 (s, 3H, 12-CH3); 1.39 (t, J = 8.6, 1H, SH); 1.43 (s, 3H, 15-CH3); 
1.47 (s, 3H, 16-CH3); 2.40 (t, J = 5.8, 2H, 5-CH2); 2.64-2.70 (m, 2H, 1-CH2); 3, 29 (d, J = 12.0, 1H, 
11a-CHH); 3.37-3.63 (m, 4H, 2-6-CH2); 3, 69 (d, J = 12.0, 1H, 11b-CHH); 4.09 (s, 1H, 9-CH); 6.37 (bt, 
J = 5.2, 1H, 3-NH); 7.03 (bt, J = 5.9, 1H, 7-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 18.7 (12-CH3); 18.9 
(13-CH2); 22.1 (15-CH3); 24.6 (1-CH2); 29.5 (16-CH3); 33.0 (10-C); 34.9 (6-CH2); 36.2 (5-CH2); 42.4 
(2-CH2); 71.4 (11-CH2); 77.2 (9-CH); 99.1 (14-C); 170.3 (4-CO); 171.1 (8-CO). ES-MS: m/z (%): 319 
[M]H
+
 (65%), 261 [M-(CH3)2CO]H
+
 (100%). IR (cm-1): 3419 (N-H), 3324 (N-H), 2980 (C-H), 2944 
(C-H), 2872 (C-H), 1659 (C=O).
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General Procedure Pantetheine Dimethyl Ketal-Compounds. 
Acid (1.00 mmol) and pantetheine dimethyl ketal (0.32 g, 1.00 mmol) were dissolved in dichloromethane 
(9 mL) and the mixture was cooled to 0 °C. Then N, N-dimethylaminopyridine (0.1 g, 0.8 mmol) and 
N-(3-diethylamino-propyl)-N-ethyl-carbodiimide (N-(3-diethyl-aminopropyl)-N-ethyl-carbodiimide 
(0.38 g, 2.00 mmol) were added to the reaction. The mixture was warmed to 25 °C and then stirred for 
three hours. The mixture was quenched with 2 M HCl (10 mL) and extracted with dichloromethane (3 × 
15 mL). The organic layer was washed with saturated NaHCO3 and brine. The product was dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column chromatography (ethyl 
acetate).
[192]
 
 
Acyl pantetheine dimethyl ketal (145a).
[129]
 
 
The obtained product was a colourless oil (0.13 g, 0.40 mmol, 40%).
 
Rf: 0.46 (ethyl acetate). 
1
H-NMR 
(CDCl3, 400 MHz): δ 0.99 (s, 3H, 14-CH3); 1.04 (s, 3H, 15-CH3); 1.44 (s, 3H, 117-CH3); 1.48 (s, 3H, 
18-CH3); 1.85 (s, 3H, 2-CH3); 2.44 (t, J = 6.5, 2H, 7-CH2); 3.08 (t, J = 6.3, 2H, 3-CH2); 3.28 (d, J = 11.7, 
1H, 13a-CHH); 3.41-3.62 (m, 4H, 4-8-CH2); 3.68 (d, J = 11.6, 1H, 13b-CHH); 4.08 (s, 1H, 11-CH); 6.13 
(bt, J = 5.8, 1H, 5-NH); 7.03 (bt, J = 5.9, 1H, 9-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 14.4 (14-CH3); 
18.7 (15-CH3); 22.1 (17-CH3 ); 28.3 (3-CH2); 29.5 (18-CH3); 30.6 (2-CH3); 32.9 (12-C); 34.8 (7-CH2); 
35.9 (8-CH2); 39.7 (4-CH2); 71.5 (13-CH2); 77.2 (11-CH); 99.1 (16-C); 170.1 (6-CO); 171.1 (10-CO); 
196.1 (1-CO). ES-MS: m/z (%): 383.3 [M]Na
+
 (5%), 361.4 [M]H
+
 (18%), 303.4 [M-C3H6O]H
+
 (100%). 
HR-MS: m/z (%): calculated 383.1617, found 383.1619.
[192]
 
 
2-Bromopropionyl pantetheine dimethyl ketal (145b).
 [129]
 
 
The obtained product was a colourless oil (0.28 g, 0.62 mmol, 62%).
 
Rf: 0.45 (ethyl acetate). 
1
H-NMR 
(CDCl3, 400 MHz): δ 0.97 (s, 3H, 15-CH3); 1.04 (s, 3H, 16-CH3); 1.41 (s, 3H, 18-CH3); 1.46 (s, 3H, 
19-CH3); 1.85 (d, J = 6.7, 3H, 3-CH3); 2.44 (t, J = 6.1, 2H, 8-CH2); 3.01-3.14 (m, 2H, 4-CH2); 3.28 (d, 
J = 11.7, 1H, 14a-CHH); 3.40-3.62 (m, 4H, 5-9-CH2); 3.68 (d, J = 11.8, 1H, 14b-CHH); 4.07 (s, 1H, 
12-CH); 4.52 (dq, J = 1.1, 7.2, 1H, 2-CH); 6.13 (bt, J = 6.8, 1H, 6-NH); 7.02 (bt, J = 7.4, 1H, 10-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 18.7 (15-CH3); 18.9 (16-CH3); 21.9 (3-CH3 ); 22.1 (18-CH3 ); 29.5 
(19-CH3); 29.7 (4-CH2); 32.9 (13-C); 34.7 (8-CH2); 36.0 (9-CH2); 39.1 (5-CH2); 47.7 (2-CH); 71.5 
(14-CH2); 77.1 (12-CH); 99.1 (17-C); 170.0 (7-CO); 171.2 (11-CO); 196.1 (1-CO). ES-MS: m/z (%): 
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455.7 [M
81
Br]H
+
 (60%), 453.3 [M
79
Br]H
+
 (46%), 397.5 [M
81
Br-(CH3)2CO]H
+
 (100%), 395.8 
[M
79
Br-(CH3)2CO]H
+
 (88%). IR (cm-1): 3294 (N-H), 2940 (C-H), 1651 (C=O), 1524 (C-O). HR-MS: 
m/z (%): calculated 475.0878, found 475.0872.
[192]
 
 
2-Methylbutyryl pantetheine dimethyl ketal (145c).
[129]
 
 
The obtained product was a yellow oil (1.00 g, 2.4 mmol, 88%).
 
Rf: 0.40 (ethyl acetate).
 
1
H-NMR (CDCl3, 400 MHz): δ 0.90 (t, J = 7.6, 3H, 4-CH3); 0.96 (s, 3H, 17-CH3); 1.03 (s, 3H, 18-CH3); 
1.15 (d, J = 6.8, 3H, 5-CH3); 1.41 (s, 3H, 20-CH3); 1.45 (s, 3H, 21-CH3); 1.45-1.77 (m, 2H, 3-CH2); 2.42 
(t, J = 6.4, 2H, 10-CH2); 2.52-2.61 (m, 1H, 2-CH); 2.99 (t, J = 6.5, 2H, 6-CH2); 3.27 (d, J = 11.2, 1H, 
16a-CHH); 3.36-3.59 (m, 4H, 7-11-CH2); 3.68 (d, J = 11.7, 1H, 16b-CHH); 4.07 (s, 1H, 14-CH); 6.23 (bt, 
J = 5.7, 1H, 8-NH); 7.03 (bt, J = 5.7, 1H, 12-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.9 (4-CH3); 17.1 
(5-CH3); 18.7 (17-CH3); 18.9 (18-CH3); 22.1 (20-CH3); 27.1 (3-CH2 ); 28.1 (6-CH2); 29.5 (21-CH3); 32.9 
(15-C); 34.8 (10-CH2); 35.9 (11-CH2); 39.7 (7-CH2); 50.2 (2-CH); 71.5 (16-CH2); 77.2 (14-CH); 99.1 
(19-C); 170.0 (9-CO); 171.2 (13-CO); 204.8 (1-CO). ES-MS: m/z (%): 403.7 [M]H
-
 (100%). 
IR (cm-1): 3305 (C-H), 2956 (C-H), 2873 (C-H), 1653 (C=O), 1521 (C-O). HR-MS: m/z (%): 
calculated 425.2088, found 425.2086.
[192]
 
 
Angeloyl pantetheine dimethyl ketal (145d).
[129]
 
 
The obtained product was a yellow oil (0.29 g, 0.70 mmol, 70 %).
 
Rf: 0.49 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.97 (s, 3H, 17-CH3); 1.04 (s, 3H, 18-CH3); 1.41 (s, 3H, 20-CH3); 1.46 (s, 
3H, 21-CH3); 1.92-1.97 (m, 3H, 4-CH3); 1.99 (t, J = 1.5, 3H, 5-CH3); 2.42 (t, J = 6.0, 2H, 10-CH2); 3.07 
(t, J = 6.7, 2H, 6-CH2); 3.27 (d, J = 11.6, 1H, 16a-CHH); 3.40-3.62 (m, 4H, 7-11-CH2); 3.68 (d, J = 11.6, 
1H, 16b-CHH); 4.07 (s, 1H, 14-CH); 5.89 (dt, J = 1.3, 7.3, 1H, 3-CH); 6.11 (bt, J = 5.1, 1H, 8-NH); 7.03 
(bt, J = 5.9, 1H, 12-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 15.9 (5-CH3); 18.7 (17-CH3); 18.9 (18-CH3); 
20.5 (4-CH3); 22.1 (20-CH3); 28.4 (6-CH2); 29.5 (21-CH3); 32.9 (15-C); 34.8 (10-CH2); 35.9 (11-CH2); 
39.8 (7-CH2); 71.5 (16-CH2); 77.3 (14-CH); 99.1 (19-C); 134.1 (2-C); 134.9 (3-CH); 170.0 (9-CO); 171.2 
(13-CO); 193.9 (1-CO). ES-MS: m/z (%): 423.4 [M]Na
+
 (25%), 401.4 [M]H
+
 (28%), 343.4 
[M-C3H6O2]H
+
 (100%). IR ( cm-1): 3260 (N-H), 3078 (C-H), 2924 (C-H), 1651 (C=O). HR-MS: 
m/z (%): calculated 423.1930, found 423.1932.
[192]
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Tigloyl pantetheine dimethyl ketal (145e).
[129]
 
 
The obtained product was a colourless oil (0.32 g, 0.80 mmol, 80%).
 
Rf: 0.46 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.99 (s, 3H, 17-CH3); 1.04 (s, 3H, 18-CH3); 1.44 (s, 3H, 21-CH3); 1.48 (s, 
3H, 22-CH3); 1.85-1.87 (m, 6H, 4-5-CH3); 2.44 (t, J = 6.5, 2H, 10-CH2); 3.08 (t, J = 6.3, 2H, 6-CH2); 
3.28 (d, J = 11.7, 1H, 16a-CHH); 3.41-3.62 (m, 4H, 7-11-CH2); 3.68 (d, J = 11.6, 1H, 16b-CHH); 4.08 (s, 
1H, 14-CH); 6.13 (bt, J = 5.8, 1H, 8-NH); 6.93 (qq, J = 1.4, 6.8, 1H, 3-CH); 7.03 (bt, J = 5.9, 1H, 
12-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.2 (4-CH3); 14.4 (5-CH3); 18.7 (17-CH3); 18.9 (18-CH3); 
22.1 (21-CH3); 28.3 (6-CH2); 29.5 (22-CH3); 32.9 (15-C); 34.8 (10-CH2); 35.9 (11-CH2); 39.7 (7-CH2); 
71.5 (16-CH2); 77.2 (14-CH); 99.1 (19-C); 136.8 (2-C); 136.9 (3-CH); 170.1 (9-CO); 171.1 (13-CO); 
190.2 (1-CO). ES-MS: m/z (%): 479.3 [M]Na
+
 (5%), 457.4 [M]H
+
 (18%), 399.4 [M-C3H6O]H
+
(100%). 
IR (cm-1): 3306 (N-H), 2940 (C-H), 1648 (C=O), 1523 (C-O). HR-MS: m/z (%): calculated 
423.1930, found 423.1929.
[192]
  
 
2RS-2-Methylhexanoyl pantetheine dimethyl ketal (145f).
[129]
 
 
The obtained product was a yellow oil (0.36 g, 0.8 mmol, 88%).
 
Rf: 0.45 (ethyl acetate).
 1
H-NMR 
(CDCl3, 400 MHz): δ 0.88 (t, J = 7.6, 3H, 6-CH3); 0.96 (s, 3H, 19-CH3); 1.03 (s, 3H, 20-CH3); 1.23-1.33 
(m, 4H, 4-5-CH2); 1.41 (s, 3H, 22-CH3); 1.46 (s, 3H, 23-CH3); 1.85 (s, 3H, 7-CH3); 1.64-1.74 (m, 2H, 
3-CH2); 2.42 (t, J = 6.4, 2H, 12-CH2); 2.60-2.65 (m, 1H, 2-CH); 2.99 (t, J = 6.5, 2H, 8-CH2); 3.27 (d, J = 
11.2, 1H, 18a-CHH); 3.37-3.60 (m, 4H, 9-13-CH2); 3.68 (d, J = 11.7, 1H, 18b-CHH); 4.08 (s, 1H, 
16-CH); 6.17 (bt, J = 5.7, 1H, 10-NH); 7.05 (bt, J = 5.7, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): 
δ 13.9 (6-CH3); 17.6 (7-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (22-CH3); 22.6 (5-CH2 ); 28.1 (8-CH2); 
29.3 (4-CH2); 29.5 (23-CH3); 33.3 (3-CH2); 32.9 (17-C); 34.8 (12-CH2); 35.9 (13-CH2); 39.7 (9-CH2); 
48.7 (2-CH); 71.5 (18-CH2); 77.2 (16-CH); 99.1 (21-C); 170.0 (11-CO); 171.2 (15-CO); 204.5 (1-CO). 
ES-MS: m/z (%): 429.7 [M]H
-
 (100%). IR (cm-1): 2956 (C-H), 2872 (C-H), 1653 (C=O), 1527 
(C-O), 1460 (C=C). HR-MS: m/z (%): calculated 453.2406, found 453.2406.
[192]
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2E-Hex-2-enoyl pantetheine dimethyl ketal (145g).
[129]
 
 
The obtained product was a yellow oil (0.32 g, 0.70 mmol, 70%). Rf: 0.49 (ethyl acetate). 
1
H-NMR 
(CDCl3, 400 MHz): δ 0.92-0.96 (m, 3H, 6-CH3); 0.97 (s, 3H, 18-CH3); 1.03 (s, 3H, 19-CH3); 1.41 (s, 3H, 
22-CH3); 1.46 (s, 3H, 21-CH3); 1.50 (m, 2H, 5-CH2); 2.19 (dq, J = 1.5, 7.3, 2H, 4-CH2); 2.42 (t, J = 6.3, 
2H, 11-CH2); 3.08 (t, J = 6.3, 2H, 7-CH2); 3.27 (d, J = 11.6, 1H, 17a-CHH); 3.40-3.62 (m, 4H, 8-12-
CH2); 3.68 (d, J = 11.6, 1H, 17b-CHH); 4.07 (s, 1H, 15-CH); 6.10 (bt, J = 1.6, 1H, 2-CH); 6.14 (bt, J = 
1.5, 1H, 9-NH); 6.92 (dt, J = 6.9, 15.6, 1H, 3-CH); 7.03 (bt, J = 5.9, 1H, 13-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 13.7 (6-CH3); 18.7 (18-CH3); 18.9 (19-CH3); 21.2 (5-CH2); 22.1 (21-CH3); 28.2 (7-CH2); 29.5 
(22-CH3); 32.9 (16-C); 34.2 (4-CH2); 34.8 (11-CH2); 35.9 (12-CH2); 39.7 (8-CH2); 71.5 (17-CH2); 77.3 
(15-CH); 99.1 (20-C); 128.4 (2-CH); 146.6 (3-CH); 170.0 (10-CO); 171.2 (14-CO); 190.2 (1-CO). 
ES-MS: m/z (%): 415.4 [M]H
+
 (100%). IR (cm-1): 3306 (N-H), 2960 (C-H), 2872 (C-H), 1655 
(C=O). HR-MS: m/z (%): calculated 437.2086, found 437.2088.
[192]
  
 
2E-2-Methylhex-2-enoyl pantetheine dimethyl ketal (145h).
[129]
 
 
The obtained product was a yellow oil (0.38 g, 0.88 mmol, 88%).
 
Rf: 0.45 (ethyl acetate).
 
1
H-NMR (CDCl3, 400 MHz): δ 0.96 (t, J = 7.6, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.44-1.55 (m, 2H, 5-CH2); 1.41 (s, 3H, 22-CH3); 1.46 (s, 3H, 23-CH3); 1.87 (s, 3H, 7-CH3); 2.20 (q, J = 
7.4, 2H, 4-CH2); 2.42 (t, J = 6.1, 2H, 12-CH2); 3.05 (t, J = 6.5, 2H, 8-CH2); 3.27 (d, J = 11.2, 1H, 18a-
CHH); 3.39-3.62 (m, 4H, 9-13-CH2); 3.68 (d, J = 11.7, 1H, 18b-CHH); 4.07 (s, 1H, 16-CH); 6.10 (bt, J = 
5.7, 1H, 10-NH); 6.77 (dt, J = 1.3, 6.9, 1H, 3-CH); 7.03 (bt, J = 5.7, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 12.5 (6-CH3); 13.9 (7-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 21.8 (5-CH2); 22.1 (22-CH3); 28.4 
(8-CH2); 28.8 (4-CH2); 29.5 (23-CH3); 32.9 (17-C); 34.8 (12-CH2); 35.9 (13-CH2); 39.7 (9-CH2); 71.5 
(18-CH2); 77.2 (16-CH); 99.1 (21-C); 135.9 (2-C); 142.1 (3-CH); 170.0 (11-CO); 171.2 (15-CO); 193.7 
(1-CO). ES-MS: m/z (%): 429.7 [M]H
+
 (100%). IR (cm-1): 3293 (N-H), 2959 (C-H), 2870 (C-H), 
1648 (C=O). HR-MS: m/z (%): calculated 451.2243, found 451.2244.
[192]
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2EZ-2-Ethylhex-2-enoyl pantetheine dimethyl ketal (145i).
[129]
 
 
The obtained product was a yellow oil (0.38 g, 0.88 mmol, 88%).
 
Rf: 0.45 (ethyl acetate).
 
1
H-NMR (CDCl3, 400 MHz): δ 0.86-1.08 (m, 12H, 6-8-20-21-CH3); 1.40-1.53 (m, 2H, 5-CH2); 1.41 (s, 
3H, 23-CH3); 1.46 (s, 3H, 24-CH3); 2.20 (q, J = 7.5, 2H, 4-CH2); 2.31-2.38 (m, 2H, 7-CH2E); 2.40-2.44 
(m, 2H, 7-CH2Z); 3.03-3.09 (m, 2H, 9-CH2); 3.27 (d, J = 11.2, 1H, 19a-CHH); 3.39-3.64 (m, 4H, 10-14-
CH2); 3.68 (d, J = 11.7, 1H, 19b-CHH); 4.07 (s, 1H, 17-CH); 5.62 (t, J = 7.7, 1H, 3-CHZ); 6.12 (bt, J = 
5.7, 1H, 11-NH); 6.71 (t, J = 7.5, 1H, 3-CHE); 7.04 (bt, J = 5.7, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 13.9 (6-CH3); 14.1 (8-CH3); 18.7 (20-CH3); 18.9 (21-CH3); 22.2 (5-CH2); 22.1 (23-CH3); 28.4 
(9-CH2); 28.8 (7-CH2); 29.5 (24-CH3); 30.9 (4-CH2); 32.9 (18-C); 34.8 (13-CH2); 35.9 (14-CH2); 39.7 
(10-CH2); 71.5 (19-CH2); 77.2 (17-CH); 99.1 (22-C); 135.9 (2-C); 142.1 (3-CH); 170.0 (12-CO); 171.2 
(16-CO); 193.7 (1-CO). ES-MS: m/z (%): 465.4 [M]Na
+
 (51%), 443.7 [M]H
+
 (28%), 385.4 [M-C4H8]H
+
 
(100%). HR-MS: m/z (%): calculated 465.2399, found 465.2396.
[192]
 
 
4RS-4-Methylhex-2-enoyl pantetheine dimethyl ketal (145j).
[129]
 
 
The obtained product was a colourless oil (0.35 g, 0.82 mmol, 82%).
 
Rf: 0.45 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.2, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.06 (d, J = 6.7, 3H, 7-CH3), 1.40-1.45 (m, 2H, 5-CH2); 1.41 (s, 3H, 22-CH3); 1.46 (s, 3H, 23-CH3); 2.17-
2.26 (m, 1H, 4-CH); 2.42 (t, J = 6.3, 2H, 12-CH2); 3.05 (t, J = 6.3, 2H, 8-CH2); 3.27 (d, J = 11.9, 1H, 18a-
CHH); 3.40-3.62 (m, 4H, 9-13-CH2); 3.68 (d, J = 11.7, 1H, 18b-CHH); 4.07 (s, 1H, 16-CH); 6.08 (dd, J = 
1.2, 15.6, 1H, 2-CH); 6.12 (bt, J = 5.1, 1H, 10-NH); 6.77 (dd, J = 7.5, 15.5, 1H, 3-CH); 7.03 (bt, J = 6.0, 
1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.6 (6-CH3); 12.2 (7-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 
22.1 (22-CH3); 28.3 (5-CH2); 28.4 (8-CH2); 29.5 (23-CH3); 32.9 (17-C); 34.8 (12-CH2); 35.9 (13-CH2); 
38.1 (4-CH); 39.7 (9-CH2); 71.5 (18-CH2); 77.2 (16-CH); 99.1 (21-C); 126.7 (2-CH); 151.7 (3-CH); 
170.0 (11-CO); 171.2 (15-CO); 190.3 (1-CO). ES-MS: m/z (%): 429.7 [M]H
+
 (100%). IR (cm-1): 
3305 (N-H), 2961 (C-H), 2873 (C-H), 1655 (C=O). HR-MS: m/z (%): calculated 451.2243, found 
451.2243.
[192]
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4RS-2-4-Dimethylhex-2-enoyl pantetheine dimethyl ketal (145k).
[129]
 
 
The obtained product was a colourless oil (0.38 g, 0.89 mmol, 89%).
 
Rf: 0.45 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.87 (t, J = 7.9, 3H, 6-CH3); 0.97 (s, 3H, 20-CH3); 1.04 (s, 3H, 21-CH3); 
1.03 (d, J = 7.5, 3H, 7-CH3), 1.24-1.49 (m, 3H, 4-CH, 5-CH2); 1.41 (s, 3H, 23-CH3); 1.46 (s, 3H, 24-
CH3); 1.88 (s, 3H, 8-CH3); 2.42 (t, J = 5.9, 2H, 13-CH2); 3.05 (t, J = 6.4, 2H, 9-CH2); 3.27 (d, J = 11.4, 
1H, 19a-CHH); 3.39-3.64 (m, 4H, 10-14-CH2); 3.68 (d, J = 11.7, 1H, 19b-CHH); 4.07 (s, 1H, 17-CH); 
6.09 (bt, J = 5.4, 1H, 11-NH); 6.53 (dd, J = 1.4, 9.8, 1H, 3-CH); 7.03 (bt, J = 5.8, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.9 (6-CH3); 12.2 (7-CH3); 18.7 (20-CH3); 18.9 (21-CH3); 19.9 
(8-CH3); 22.1 (23-CH3); 28.5 (9-CH2); 29.5 (24-CH3); 29.6 (5-CH2); 32.9 (18-C); 34.4 (13-CH2); 35.0 
(4-CH); 35.9 (14-CH2); 39.7 (10-CH2); 71.5 (19-CH2); 77.2 (17-CH); 99.1 (22-C); 134.5 (2-C); 147.6 
(3-CH); 170.0 (12-CO); 171.2 (16-CO); 193.9 (1-CO). ES-MS: m/z (%): 442.7 [M]H
+
 (100%). 
IR (cm-1): 3291 (N-H), 2923 (C-H), 2872 (C-H), 1651 (C=O). HR-MS: m/z (%): calculated 
465.2399, found 465.2396.
[192]
 
 
(2E, 4S)-Dimethylhex-2-enoyl pantetheine dimethyl ketal (145l).
[129]
 
 
The obtained product was a colourless oil (0.30 g, 0.68 mmol, 68%).
 
Rf: 0.45 (ethyl acetate). 
1
H-NMR 
(CDCl3, 400 MHz): δ 0.91 (t, J = 7.9, 3H, 6-CH3); 0.97 (s, 3H, 20-CH3); 1.04 (s, 3H, 21-CH3); 1.17 (d, 
J = 7.5, 1H, 7-CH3), 1.24-1.49 (m, 2H, 5-CH2); 1.42 (s, 3H, 23-CH3); 1.46 (s, 3H, 24-CH3); 1.88 (s, 3H, 
8-CH3); 2.42 (t, J = 6.1, 2H, 13-CH2); 2.54-2.62 (m, 1H, 4-CH); 3.05 (t, J = 6.5, 2H, 9-CH2); 3.27 (d, J = 
11.7, 1H, 19a-CHH); 3.38-3.62 (m, 4H, 10-14-CH2); 3.68 (d, J = 12.1, 1H, 19b-CHH); 4.08 (s, 1H, 
17-CH); 6.09 (bt, J = 5.4, 1H, 11-NH); 6.53 (dd, J = 1.5, 10.2, 1H, 3-CH); 7.03 (bt, J = 5.8, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.6 (6-CH3); 17.2 (7-CH3); 18.7 (20-CH3); 18.9 (21-CH3); 19.9 
(8-CH3); 22.1 (23-CH3); 28.5 (9-CH2); 29.5 (24-CH3); 29.6 (5-CH2); 32.9 (18-C); 34.8 (13-CH2); 35.1 
(4-CH); 35.9 (14-CH2); 39.7 (10-CH2); 71.5 (19-CH2); 77.2 (17-CH); 99.1 (22-C); 135.6 (2-C); 147.6 
(3-CH); 170.1 (12-CO); 171.1 (16-CO); 204.1 (1-CO). ES-MS: m/z (%): 442.7 [M]H
+
 (100%). 
IR (cm-1): 3302 (N-H), 2960 (C-H), 2873 (C-H), 1649 (C=O). HR-MS: m/z (%): calculated 
443.2580, found 443.2583.
[192]
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2E-2-Methylhept-2-enoyl pantetheine dimethyl ketal (145m).
[129]
 
 
The obtained product was a colourless oil (0.24 g, 0.50 mmol, 54%).
 
Rf: 0.39 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 (t, J = 7.2, 3H, 7-CH3); 0.97 (s, 3H, 20-CH3); 1.04 (s, 3H, 21-CH3); 
1.31-1.49 (m, 4H, 5-6-CH2); 1.41 (s, 3H, 23-CH3); 1.46 (s, 3H, 24-CH3); 1.87 (s, 3H, 8-CH3); 2.22 (q, J = 
7.1, 2H, 4-CH2); 2.42 (t, J = 6.3, 2H, 13-CH2); 3.05 (t, J = 6.5, 2H, 9-CH2); 3.27 (d, J = 11.9, 1H, 
19a-CHH); 3.39-3.62 (m, 4H, 10-14-CH2); 3.68 (d, J = 11.9, 1H, 19b-CHH); 4.07 (s, 1H, 17-CH); 6.08 
(bt, J = 5.0, 1H, 11-NH); 6.77 (dq, J = 1.3, 7.1, 1H, 3-CH); 7.03 (bt, J = 6.1, 1H, 15-NH). 
13
C-NMR 
(CDCl3, 100 MHz): δ 12.5 (8-CH3); 13.9 (7-CH3); 18.7 (20-CH3); 18.9 (21-CH3); 22.1 (23-CH3); 22.5 
(6-CH2); 28.4 (9-CH2); 28.5 (4-CH2); 29.5 (24-CH3); 30.6 (5-CH2); 32.9 (18-C); 34.8 (13-CH2); 35.9 
(14-CH2); 39.7 (10-CH2); 71.5 (19-CH2); 77.2 (17-CH); 99.1 (22-C); 135.7 (2-C); 142.4 (3-CH); 170.0 
(12-CO); 171.1 (16-CO); 193.7 (1-CO). ES-MS: m/z (%): 465.5 [M]Na
+
 (3%), 443.3 [M]H
+
 (100%). 
IR (cm-1): 3296 (N-H), 2937 (C-H), 2872 (C-H), 1647 (C=O). HR-MS: m/z (%): calculated 
465.2399, found 465.2396.
[192]
 
 
2E-6RS-6-Methylhept-2-enoyl pantetheine dimethyl ketal (145n).
[129]
 
 
The obtained product was a colourless oil (0.22 g, 0.52 mmol, 52%).
 
Rf: 0.53 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 (d, J = 6.7, 6H, 7-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.32-1.38 (m, 3H, 5-6-CH2); 1.42 (s, 3H, 22-CH3); 1.46 (s, 3H, 23-CH3); 2.22 (dq, J = 1.9, 7.1, 2H, 
4-CH2); 2.42 (t, J = 6.1, 2H, 12-CH2); 3.08 (t, J = 6.4, 2H, 8-CH2); 3.28 (d, J = 11.7, 1H, 18a-CHH); 
3.40-3.62 (m, 4H, 9-13-CH2); 3.68 (d, J = 11.6, 1H, 18b-CHH); 4.07 (s, 1H, 16-CH); 6.10 (bt, J = 1.6, 
1H, 10-NH); 6.14 (t, J = 1.5, 1H, 2-CH); 6.93 (dt, J = 7.1, 15.6, 1H, 3-CH); 7.02 (bt, J = 6.0, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (22-CH3 ); 22.4 (7-2xCH3 ); 27.6 
(6-CH); 28.2 (8-CH2); 29.5 (23-CH3); 30.1 (4-CH2); 32.9 (17-C); 34.8 (12-CH2); 35.9 (13-CH2); 36.9 
(5-CH2); 39.7 (9-CH2); 71.5 (18-CH2); 77.2 (16-CH); 99.1 (21-C); 128.2 (2-CH); 147.1 (3-CH); 170.1 
(11-CO); 171.4 (15-CO); 190.2 (1-CO). ES-MS: m/z (%): 465.3 [M]Na
+
 (28%), 443.3 [M]H
+
 (12%), 385 
[M-C3H6O]H
+
(100%). IR (cm-1): 3303 (N-H), 2953 (C-H), 2870 (C-H), 1655 (C=O). HR-MS: 
m/z (%): calculated 465.2399, found 465.2396.
[192]
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2E-2-Methyloct-2-enoyl pantetheine dimethyl ketal (145o).
[129]
 
 
The obtained product was a colourless oil (0.27 g, 0.60 mmol, 60%).
 
Rf: 0.47 (ethyl acetate). 
1
H-NMR 
(CDCl3, 400 MHz): δ 0.90 (t, J = 7.4, 3H, 8-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 1.31-1.51 
(m, 6H, 5-6-7-CH2); 1.41 (s, 3H, 24-CH3); 1.46 (s, 3H, 25-CH3); 1.87 (s, 3H, 9-CH3); 2.21 (g, J = 7.3, 
2H, 4-CH2); 2.42 (t, J = 5.8, 2H, 14-CH2); 3.05 (t, J = 6.7, 2H, 10-CH2); 3.27 (d, J = 11.8, 1H, 22a-CHH); 
3.39-3.62 (m, 4H, 11-15-CH2); 3.68 (d, J = 12.2, 1H, 22b-CHH); 4.07 (s, 1H, 18-CH); 6.08 (bt, J = 5.8, 
1H, 12-NH); 6.92 (dt, J = 1.5, 7.4, 1H, 3-CH); 7.03 (bt, J = 5.8, 1H, 16-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 12.5 (8-CH3); 13.9 (9-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (24-CH3); 22.5 (7-CH2); 28.2 
(10-CH2); 28.4 (5-CH2); 28.8 (4-CH2); 29.5 (25-CH3); 31.6 (6-CH2); 32.9 (21-C); 34.8 (14-CH2); 35.9 
(15-CH2); 39.7 (11-CH2); 71.5 (22-CH2); 77.2 (18-CH); 99.1 (23-C); 135.7 (2-C); 142.4 (3-CH); 170.0 
(13-CO); 171.1 (17-CO); 193.7 (1-CO). ES-MS: m/z (%): 457.7 [M]H
+
 (100%). IR (cm-1): 3306 
(N-H), 2929 (C-H), 2860 (C-H), 1652 (C=O). HR-MS: m/z (%): calculated 479.2556, found 
479.2552.
[192]
 
 
2EZ-2-Ethyloct-2-enoyl pantetheine dimethyl ketal (145p).
[129]
 
 
The obtained product was a yellow oil (1.3 g, 2.7 mmol, 45%).
 
Rf: 0.55 (ethyl acetate).
 1
H-NMR (CDCl3, 
400 MHz): δ 0.86-1.10 (m, 12H, 8-10-22-23-CH3); 1.29-1.53 (m, 6H, 5-6-7-CH2); 1.44 (s, 3H, 25-CH3); 
1.48 (s, 3H, 26-CH3); 2.20 (m, 2H, 4-CH2); 2.31-2.38 (m, 2H, 9-CH2E); 2.40-2.44 (m, 2H, 9-CH2Z); 
3.03-3.11 (m, 2H, 11-CH2); 3.30 (d, J = 11.8, 1H, 21a-CHH); 3.41-3.64 (m, 4H, 12-16-CH2); 3.70 (d, J = 
11.7, 1H, 21b-CHH); 4.10 (s, 1H, 19-CH); 5.62 (t, J = 7.4, 1H, 3-CHZ); 6.12 (bt, J = 6.2, 1H, 13-NH); 
6.73 (t, J = 7.5, 1H, 3-CHE); 7.06 (bt, J = 6.8, 1H, 17-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.5 (8-CH3); 
13.9 (10-CH3); 18.7 (22-CH3); 18.9 (23-CH3); 21.8 (25-CH2); 22.1 (7-CH2); 28.2 (11-CH2); 28.4 (5-CH2); 
28.8 (4-CH2); 29.5 (26-CH3); 30.9 (6-CH2); 32.9 (20-C); 34.8 (15-CH2); 35.9 (16-CH2); 39.7 (12-CH2); 
71.5 (19-CH2); 77.2 (21-CH); 99.1 (24-C); 136.3 (2-C); 142.1 (3-CH); 170.1 (14-CO); 171.2 (18-CO); 
193.6 (1-CO). ES-MS: m/z (%): 493.4 [M]Na
+
 (12%), 471.7 [M]H
+
 (56%), 413.4 [M-C4H8]H
+
 (100%). 
IR (cm-1): 3307 (N-H), 2958 (C-H), 2872 (C-H), 1653 (C=O). HR-MS: m/z (%): calculated 
493.2712, found 493.2707.
[192]
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2E-7-Methyloct-2-enoyl pantetheine dimethyl ketal (145q).
[129]
 
 
The obtained product was a colourless oil (0.18 g, 0.40 mmol, 40%).
 
Rf: 0.43 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.89 (d, J = 6.7, 6H, 8-CH3); 0.97 (s, 3H, 20-CH3); 1.04 (s, 3H, 21-CH3); 
1.42 (s, 3H, 23-CH3); 1.46 (s, 3H, 24-CH3); 1.43-1.62 (m, 5H, 7-CH-5-6-CH2); 2.22 (dt, J = 1.7, 7.3, 2H, 
4-CH2); 2.42 (t, J = 6.3, 2H, 13-CH2); 3.08 (t, J = 6.3, 2H, 9-CH2); 3.28 (d, J = 11.7, 1H, 19a-CHH); 
3.42-3.64 (m, 4H, 10-14-CH2); 3.68 (d, J = 11.6, 1H, 19b-CHH); 4.08 (s, 1H, 17-CH); 6.10 (bt, J = 1.6, 
1H, 11-NH); 6.17 (t, J = 15, 1H, 2-CH); 6.93 (dt, J = 6.9, 15.4, 1H, 3-CH); 7.02 (bt, J = 6.2, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 18.7 (20-CH3); 18.9 (21-CH3); 22.1 (23-CH3 ); 22.4 (8-2xCH3); 25.8 
(6-CH2); 27.8 (7-CH); 28.2 (9-CH2); 28.4 (5-CH2); 29.5 (24-CH3); 32.5 (4-CH2); 32.9 (18-C); 34.8 
(13-CH2); 35.9 (14-CH2); 39.7 (10-CH2); 71.5 (19-CH2); 77.2 (17-CH); 99.1 (22-C); 128.4 (2-CH); 147.1 
(3-CH); 170.1 (12-CO); 171.4 (16-CO); 190.2 (1-CO). ES-MS: m/z (%): 479.3 [M]Na
+
 (5%), 457.4 
[M]H
+
 (18%), 399.4 [M-C3H6O]H
+
(100%). IR (cm-1): 3307 (N-H), 2952 (C-H), 2869 (C-H), 1655 
(C=O). HR-MS: m/z (%): calculated 479.2556, found 479.2557.
[192]
  
 
6RS,4RS-2E-4,6-Dimethyloct-2-enoyl-pantetheine dimethyl ketal (145r).
[129]
 
 
The obtained product was a colourless oil (0.32 g, 0.65 mmol, 65%).
 
Rf: 0.46 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.83 (m, 6H, 8-9-CH3); 0.97 (s, 3H, 22-CH3); 1.04 (s, 3H, 23-CH3); 1.14 
(m, 3H, 10-CH3), 1.24-1.49 (m, 5H, 5-6-7-CH2); 1.42 (s, 3H, 25-CH3); 1.46 (s, 3H, 26-CH3); 1.87 (s, 3H, 
10-CH3); 2.42 (t, J = 6.1, 2H, 15-CH2); 2.54-2.62 (m, 1H, 4-CH); 3.05 (t, J = 6.5, 2H, 11-CH2); 3.27 (d, 
J = 11.7, 1H, 21a-CHH); 3.38-3.62 (m, 4H, 12-16-CH2); 3.68 (d, J = 12.1, 1H, 21b-CHH); 4.07 (s, 1H, 
19-CH); 6.05 (m, 1H, 2-CH); 6.12 (bt, J = 5.4, 1H, 13-NH); 6.74-6.88 (m, 1H, 3-CH); 7.03 (bt, J = 5.8, 
1H, 17-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.1 (8-CH3); 17.6 (9-CH3); 18.7 (22-CH3); 18.9 (23-CH3); 
21.9 (10-CH3); 22.1 (25-CH3); 28.2 (11-CH2); 29.5 (26-CH3); 29.6 (7-CH2); 32.1 (6-CH); 32.9 (20-C); 
34.7 (15-CH2) 35.9 (16-CH2); 39.7 (12-CH2); 40.8 (4-CH), 46-5 (5-CH2) 71.5 (21-CH2); 77.2 (19-CH); 
99.1 (24-C); 126.9 (2-CH); 147.6 (3-CH); 170.1 (14-CO); 171.1 (18-CO); 204.1 (1-CO). ES-MS: 
m/z (%): 471 [M]H
+
 (100%) IR (cm-1): 2958 (C-H), 2927 (C-H), 2872 (C-H), 1654 (C=O), 1629 
(C=O). HR-MS: m/z (%): calculated 471.2893, found 471.2891.
[192]
 
 
  
 
161 
 
2E-4S,6S-Dimethyloct-2-enoyl-pantetheine dimethyl ketal (145s).
[129]
 
 
The obtained product was a colourless oil (0.34 g, 0.70 mmol, 70%).
 
Rf: 0.46 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.87 (m, 6H, 8-9-CH3); 0.97 (s, 3H, 22-CH3); 1.04 (s, 3H, 23-CH3); 
1.13-1.19 (m, 2H, 7-CH3), 1.26-1.49 (m, 3H, 5-6-CH2); 1.44 (s, 3H, 25-CH3); 1.48 (s, 3H, 26-CH3); 2.34 
(m, 1H, 4-CH); 2.45 (t, J = 5.9, 1H, 14-CH); 3.10 (t, J = 6.5, 2H, 11-CH2); 3.27 (d, J = 11.7, 1H, 
21a-CHH); 3.42-3.62 (m, 4H, 12-16-CH2); 3.70 (d, J = 11.6, 1H, 21b-CHH); 4.09 (s, 1H, 19-CH); 6.12 
(dd, J = 1.0, 16.0, 1H, 2-CH); 6.28 (bt, J = 6.3, 1H, 13-NH); 6.80 (dd, J = 8.2, 15.8, 1H, 3-CH); 7.06 (bt, 
J = 5.8, 1H, 17-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.1 (8-CH3); 14.2 (9-CH3); 18.7 (22-CH3); 18.9 
(23-CH3); 22.1 (25-CH3); 28.2 (11-CH2); 29.5 (26-CH3); 29.7 (7-CH2); 32.9 (6-CH); 32.9 (18-C); 34.4 
(4-CH); 34.7 (15-CH2) 35.9 (16-CH2); 39.7 (12-CH2); 43-5 (5-CH) 71.5 (21-CH2); 77.2 (19-CH); 99.1 
(24-C); 126.6 (2-CH); 152.1 (3-CH); 170.1 (14-CO); 171.1 (18-CO); 190.1 (1-CO). ES-MS: m/z (%): 
471 [M]H
+
 (100%), 413 [M-C3H6O2]H
+
 (12%). IR (cm-1): 2958 (C-H), 2927 (C-H), 2872 (C-H), 
1654 (C=O), 1629 (C=O). HR-MS: m/z (%): calculated 493.2712 found 493.2619.
[192]
 
 
2E-2-Methyldec-2-enoyl pantetheine dimethyl ketal (145t).
[129]
 
 
The obtained product was a colourless oil (0.28 g, 0.58 mmol, 58%).
 
Rf: 0.45 (ethyl acetate). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.6, 3H, 10-CH3); 0.97 (s, 3H, 21-CH3); 1.04 (s, 3H, 22-CH3); 
1.30-1.47 (m, 10H, 5-6-7-8-9-CH2); 1.41 (s, 3H, 25-CH3); 1.46 (s, 3H, 26-CH3); 1.87 (s, 3H, 11-CH3); 
2.21 (q, J = 7.1, 2H, 4-CH2); 2.42 (t, J = 6.2, 2H, 16-CH2); 3.05 (t, J = 6.2, 2H, 12-CH2); 3.27 (d, J = 
12.2, 1H, 24a-CHH); 3.39-3.62 (m, 4H, 13-17-CH2); 3.68 (d, J = 12.2, 1H, 24b-CHH); 4.07 (s, 1H, 
20-CH); 6.08 (bt, J = 5.0, 1H, 14-NH); 6.77 (dt, J = 1.9, 6.9, 1H, 8-CH); 7.03 (bt, J = 5.5, 1H, 18-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.5 (11-CH3); 14.0 (10-CH3); 18.7 (21-CH3); 18.9 (22-CH3); 22.1 
(25-CH3); 22.6 (9-CH2); 28.4 (5-CH2); 28.5 (12-CH2); 28.8 (6-CH2); 29.1 (7-CH2); 29.5 (26-CH3); 31.8 
(8-CH2); 32.9 (C); 33.2 (4-CH2); 34.8 (16-CH2); 35.9 (17-CH2); 39.7 (13-CH2); 71.5 (24-CH2); 77.2 
(20-CH); 99.1 (23-C); 135.7 (2-C); 142.4 (3-CH); 170.0 (15-CO); 171.2 (19-CO); 193.7 (11-CO). 
ES-MS: m/z (%): 485.7 [M]H
+
 (100%). IR (cm-1): 3307 (N-H), 2926 (C-H), 2856 (C-H), 1652 
(C=O). HR-MS: m/z (%): calculated 507.2869, found 507.2870.
[192]
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3-Oxobutanoyl pantetheine dimethyl ketal (145u).
[129]
 
 
Acetyl meldrums acid (1.60 g, 5.4 mmol) stirred in toluene with pantetheine dimethyl ketal (1.7 g, 
5.3 mmol) under nitrogen at 90 °C. After 6 hours the reaction was stopped and the mixture concentrated 
in vacuo. The mixture was purified by flash column chromatography (ethyl acetate) and then concentrated 
to a colourless oil (1.1 g, 2.7 mmol, 50%). Rf: 0.40 (ethyl acetate).
 1
H-NMR (CDCl3, 400 MHz): δ 0.96 
(s, 3H, 16-CH3); 1.03 (s, 3H, 17-CH3); 1.41 (s, 3H, 19-CH3); 1.45 (s, 1H, 20-CH2); 1.94 (s, 1H, 4-CH3); 
2.26 (s, 2H, 4-CH3); 2.43 (t, J = 5.7, 2H, 9-CH2); 2.99 (t, J = 6.5, 2H, 5-CH2); 3.27 (d, J = 11.2, 1H, 
15a-CHH); 3.40-3.50 (m, 6H, 6-10-CH2); 3.68 (d, J = 11.7, 1H, 15b-CHH); 3.70 (s, 2H, 3-CH2); 4.07 (s, 
1H, 13-CH); 6.32 (bt, J = 5.7, 1H, 7-NH); 7.03 (bt, J = 5.9, 1H, 11-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 
18.7 (16-CH3); 18.9 (17-CH3); 22.4 (19-CH3 ); 27.8 (5-CH2); 29.5 (20-CH3); 30.1 (4-CH3); 32.9 (14-C); 
34.8 (9-CH2); 35.9 (10-CH2); 39.7 (6-CH2); 58.1 (2-CH2); 71.5 (13-CH2); 77.7 (15-CH); 99.1 (18-C); 
170.1 (8-CO); 171.4 (12-CO); 192.1 (1-CO); 199.8 (3-CO). IR (cm-1): 2989 (C-H), 2872 (C-H), 1720 
(C=O), 1654 (C=O). ES-MS: m/z (%): 425 [M+Na]H
+
 (35%), 403 [M]H
+
 (100%). HR-MS: m/z (%): 
calculated 425.1722, found 425.1722.
[192]
 
 
3-Oxohexanoyl pantetheine dimethyl ketal (145v).
[129] 
 
Butyryl meldrums acid (1.6 g, 7.4 mmol) stirred in toluene with pantetheine dimethyl ketal (2.4 g, 
7.8 mmol) under nitrogen at 90 °C. After 6 hours the reaction was stopped and the mixture concentrated 
in vacuo. The mixture was purified by flash column chromatography (ethyl acetate) and then concentrated 
to a colourless oil (1.1 g, 2.4 mmol, 32%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.93 (t, J = 6.7, 3H, 6-CH3); 
1.02 (s, 3H, 18-CH3); 1.08 (s, 3H, 19-CH3); 1.25 (m, 2H, 5-CH2); 1.41 (s, 3H, 21-CH3); 1.45 (s, 3H, 
22-CH2); 2.43 (t, J = 5.7, 2H, 11-CH2); 3.05-3.16 (m, 2H, 7-CH2); 3.27 (d, J = 11.2, 1H, 17a-CHH); 
3.37-3.59 (m, 6H, 4-9-12-CH2); 3.68 (d, J = 11.7, 1H, 17b-CHH); 3.73 (s, 2H, 2-CH2); 4.11 (s, 1H, 
15-CH); 6.38 (bt, J = 5.7, 1H, 9-NH); 7.33 (bt, J = 5.9, 1H, 13-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.5 
(6-CH3), 18.8 (5-CH2), 20.4 (18-CH3); 21.7 (19-CH3); 22.1 (21-CH3); 29.0 (22-CH3); 30.6 (7-CH2); 32.6 
(16-C); 35.1 (12-CH2); 35.6 (11-CH2); 39.3 (8-CH2); 40.9 (4-CH2); 57.9 (2-CH2); 70.9 (17-CH2); 77.7 
(15-CH); 99.9 (20-C); 171.9 (10-CO); 174.3 (14-CO); 192.5 (1-CO); 200.4 (3-CO). ES-MS: m/z (%): 
453 [M+Na]H
+
 (35%), 431 [M]H
+
 (100%). IR (cm-1): 2958 (C-H), 2873 (C-H), 1720 (C=O), 1654 
(C=O). HR-MS: m/z (%): calculated 453.2035, found 453.2035.
[192]
 
 
 
163 
 
6.2.6 Synthesis of Pantetheine Substrates. 
 
Acyl pantetheine dimethyl ketal (0.1 g, 0.4 mmol) stirred in a mixture of acetonitrile and water (1:1) and 
10% TFA for 20 minutes. The reaction was followed by TLC and LCMS. After that the solvents were 
liphophilized. 0.03 g of the product were purified by HPLC (acetonitrile). 
 
Acetylpantetheine (249). 
 
0.03 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.93 (s, 3H, 
14-CH3); 1.04 (s, 3H, 15-CH3); 2.37 (s, 3H, 2-CH3); 2.40-2.44 (m, 2H, 7-CH2); 3.02-3.11 (m, 2H, 3-CH2); 
3.38-3.41 (m, 2H, 8-CH2); 3.48-3.60 (m, 4H, 4-13-CH2); 3.99 (s, 1H, 11-CH); 6.02 (bt, J = 5.5, 1H, 
5-NH); 7.40 (bt, J = 6.1, 1H, 9-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 20.4 (14-CH3); 21.5 (15-CH3); 28.2 
(3-CH2); 30.7 (2-CH3); 35.2 (7-CH2); 35.6 (8-CH2); 39.4 (12-C); 39.8 (4-CH2); 70.9 (13-CH2); 77.9 
(11-CH); 171.5 (6-CO); 173.2 (10-CO); 197.1 (1-COS). ES-MS: m/z (%): 343.3 [M]Na
+
 (4%), 321.4 
[M]H
+
 (22%), 269.4 [M-C3H6O]
+ 
(100%). HR-MS: m/z (%): calculated 321.1484, found 321.1485. 
 
Tigloylpantetheine (85).
[129] 
 
 
The obtained product was a colourless oil (0.14 g, 0.40 mmol, 50%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 
(s, 3H, 17-CH3); 0.92 (s, 3H, 18-CH3); 1.82-1.87 (m, 6H, 4-5-CH3); 2.41 (t, J = 5.9, 2H, 10-CH2); 
3.01-3.10 (m, 2H, 6-CH2); 3.32-3.60 (m, 6H, 7-11-16-CH2); 3.99 (s, 1H, 14-CH); 6.33 (bt, J = 5.8, 1H, 
8-NH); 6.86 (qq, J = 1.3, 6.8, 1H, 3-CH); 7.40 (bt, J = 5.6, 1H, 12-NH). 
13
C-NMR (CDCl3, 100 MHz): 
δ 12.2 (5-CH3); 14.5 (4-CH3), 20.4 (17-CH3); 21.5 (18-CH3); 28.2 (6-CH2); 35.2 (11-CH2); 35.6 
(10-CH2); 39.3 (15-C); 39.9 (7-CH2); 70.9 (16-CH2); 77.9 (14-CH); 136.8 (3-C); 137.3 (2-CH); 171.8 
(9-CO); 173.5 (13-CO); 194.1 (1-COS). ES-MS: m/z (%): 383 [M]Na
+
 (8%), 361 [M]H
+
 (100%), 343 
[M-H2O]H
+
 (2%), 231 [M -C6H11O3]H
+
 (5%). HR-MS: m/z (%): calculated 383.1617, found 383.1621. 
 
Crotonyl-pantetheine (87).
[129]
 
 
The obtained product was a colourless oil (0.18 g, 0.50 mmol, 34%) 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 
(s, 3H, 16-CH3); 1.03 (s, 3H, 17-CH3); 1.90 (dd, J = 1.3, 6.8, 3H, 4-CH3); 2.41 (t, J = 5.9, 2H, 9-CH2); 
3.02-3.16 (m, 2H, 5-CH2); 3.36-3.60 (m, 6H, 6-10-15-CH2); 3.99 (s, 1H, 13-CH); 6.13 (dd, J = 5.8, 1H, 
2-CH); 6.23 (bt, J = 5.8, 1H, 7-NH); 6.95 (dq, J = 1.3, 6.8, 1H, 3-CH); 7.36 (bt, J = 5.6, 1H, 11-NH). 
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13
C-NMR (CDCl3, 100 MHz): δ 18.1 (4-CH3), 20.4 (16-CH3); 21.7 (17-CH3); 28.1 (5-CH2); 35.2 
(8-CH2); 35.6 (9-CH2); 39.3 (14-C); 39.9 (6-CH2); 70.9 (15-CH2); 77.9 (13-CH); 129.7 (2-CH); 142.3 
(3-CH); 171.8 (8-CO); 173.5 (12-CO); 190.5 (1-COS). ES-MS: m/z (%): 716 [M2]Na
+
 (5%), 693 [M2]H
+
 
(48%), 369 [M]Na
+
 (2%), 347 [M]H
+
 (100%), 329 [M-H2O]H
+
 (2%). HR-MS: m/z (%): calculated 
369.1460, found 369.1461. IR ( = cm-1): 3308 (O-H), 2932 (C-H), 1645 (C=C), 1530 (-N-H). 
 
2-Methylbutyrylpantetheine (148).
[129]
 
 
The obtained product was a colourless oil (0.035 g, 0.10 mmol, 36%) 
1
H-NMR (CDCl3, 400 MHz): 
δ 0.90 (t, J = 7.6, 3H, 4-CH3); 0.92 (s, 3H, 17-CH3); 1.01 (s, 3H, 18-CH3); 1.15 (d, J = 7.5, 3H, 5-CH3); 
1.36-1.78 (m, 2H, 3-CH2); 2.40 (t, J = 6.1, 2H, 10-CH2); 2.53-2.63 (m, 1H, 2-CH); 2.96-3.05 (m, 2H, 
6-CH2); 3.37-3.60 (m, 6H, 7-11-16-CH2); 3.99 (s, 1H, 14-CH2); 6.32 (t, J = 5.4, 1H, 8-NH); 7.44 (bt, J = 
5.9, 1H, 12-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 11.5 (4-CH3), 17.1 (5-CH3), 20.4 (17-CH3); 21.5 
(18-CH3); 27.1 (3-CH2); 27.4 27.9 (6-CH2); 35.1 (10-CH2); 35.6 (11-CH2); 39.3 (15-C); 39.7 (7-CH2); 
50.2 (2-CH2); 70.8 (16-CH2); 172.5 (9-CO); 174.5 (13-CO); 205.1 (1-COS). ES-MS: m/z (%): 385 
[M]Na
+
 (3%), 363 [M]H
+
 (100%), 345 [M-H2O]H
+
 (3%), 233 [M-C6H11O3]H
+
 (8%), 100 [C5H11O2] 
(35%). HR-MS: m/z (%): calculated 361.1797, found 361.1796. 
 
Angeloylpantetheine (86).
[129]
  
 
0.03 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 (s, 3H, 
17-CH3); 1.01 (s, 3H, 18-CH3); 1.83-1.90 (m, 6H, 4-5-CH3); 2.40-2.44 (m, 2H, 10-CH2); 2.99-3.14 (m, 
2H, 6-CH2); 3.34-3.59 (m, 6H, 7-11-16-CH2); 3.99 (s, 1H, 14-CH); 5.90 (dq, J = 1.2, 7.3, 1H, 3-CH); 
6.35 (bt, J = 5.5, 1H, 8-NH); 7.40 (bt, J = 6.1, 1H, 12-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 15.9 
(5-CH3), 20.4 (17-CH3); 20.6 (4-CH3); 21.5 (18-CH3); 28.2 (6-CH2); 35.2 (10-CH2); 35.6 (11-CH2); 39.4 
(15-C); 39.8 (7-CH2); 70.9 (16-CH2); 77.9 (14-CH); 134.0 (2-C); 135.3 (3-CH); 171.8 (9-CO); 173.5 
(13-CO); 194.1 (1-COS). ES-MS: m/z (%): 383 [M]Na
+
 (8%), 361 [M]H
+
 (58%), 343 [M-H2O]H
+
 (88%), 
231 [M -C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 383.1617, found 383.1618. 
 
2RS-2-Methylhexanoylpantetheine (265).
[129]
 
 
0.13 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 
7.4, 3H, 6-CH3); 0.93 (s, 3H, 19-CH3); 1.02 (s, 3H, 20-CH3); 1.16 (d, J = 7.6, 3H, 7-CH3); 1.23-1.31 (m, 
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4H, 4-5-CH2); 1.42 (m, 1H, 3-CH2); 1.64 (m, 1H, 3-CH2); 2.41 (t, J = 5.9, 2H, 12-CH2); 2.65 (q, J = 6.2, 
1H, 2-CH); 2.96-3.09 (m, 2H, 8-CH2); 3.33-3.59 (m, 6H, 9-13-18-CH2); 4.00 (s, 1H, 16-CH); 6.20 (bt, J = 
5.7, 1H, 10-NH); 7.37 (bt, J = 5.9, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.9 (6-CH3), 17.6 
(7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 22.6 (5-CH2); 28.3 (8-CH2); 29.3 (4-CH2); 33.8 (3-CH2); 35.1 
(12-CH2); 35.5 (13-CH2); 39.4 (17-C); 39.8 (9-CH2); 48.8 (2-CH); 70.9 (18-CH2); 77.7 (16-CH); 171.6 
(11-CO); 173.4 (15-CO); 204.8 (1-COS). ES-MS: m/z (%): 389 [M]H
-
 (38%), 371 [M-H2O]H
+
 (100%). 
HR-MS: m/z (%): calculated 413.2092, found 413.2093. 
 
2E-Hex-2-enoylpantetheine (90).
[129]
 
 
0.003 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.93 (s, 3H, 
6-CH3); 0.95 (t, J = 7.8, 3H, 18-CH3); 1.04 (s, 3H, 19-CH3); 1.46-1.56 (m, 2H, 5-CH2); 2.20 (dq, J = 1.3, 
J = 6.7, 2H, 4-CH2); 2.41 (t, J = 6.1, 2H, 11-CH2); 3.03-3.18 (m, 2H, 7-CH2); 3.36-3.65 (m, 6H, 8-12-17-
CH2); 3.99 (s, 1H, 15-CH); 6.13 (m, 1H, 2-CH); 6.17 (dt, J = 1.8, J = 15.7, 1H, 9-NH); 6.93 (dt, J = 6, 7, 
J = 15.3, 1H, 3-CH); 7.32 (bt, J = 6.
1
, 1H, 13-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.7 (6-CH3), 20.4 
(18-CH3); 21.1 (19-CH3); 21.7 (5-CH2); 28.1 (7-CH2); 34.3 (4-CH2); 35.1 (11-CH2); 35.5 (12-CH2); 39.4 
(16-C); 39.8 (8-CH2); 70.9 (17-CH2); 77.8 (15-CH); 128.3 (2-CH); 147.0 (3-CH); 171.6 (10-CO); 173.3 
(14-CO); 190.6 (1-COS). ES-MS: m/z (%): 375 [M]H
+
 (100%), 357 [M-H2O]H
+
 (32%). HR-MS: 
m/z (%): calculated 397.1773, found 397.1774. 
 
2E-2-Methylhex-2-enoylpantethine (91).
[129]
 
 
0.02 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.93 (s, 3H, 
1-CH3); 0.95 (t, J = 7.4, 3H, 19-CH3); 1.02 (s, 3H, 20-CH3); 1.46-1.55 (m, 2H, 5-CH2); 1.88 (d, J = 1.4, 7-
CH3) 2.20 (dq, J = 1.3, J = 7.0, 2H, 4-CH2); 2.41 (t, J = 5.9, 2H, 12-CH2); 3.00-3.13 (m, 2H, 8-CH2); 
3.35-3.59 (m, 6H, 9-13-18-CH2); 3.99 (s, 1H, 16-CH); 6.23 (bt, J = 5.7, 1H, 10-NH); 6.77 (tq, J = 1, 4, 
J = 7.4, 1H, 3-CH); 7.38 (bt, J = 5.9, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.5 (6-CH3), 13.9 
(7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 21.8 (5-CH2); 28.3 (8-CH2); 30.8 (4-CH2); 35.1 (12-CH2); 35.5 
(13-CH2); 39.4 (17-C); 39.8 (9-CH2); 70.9 (18-CH2); 77.7 (16-CH); 135.7 (2-C); 142.5 (3-CH); 171.6 
(11-CO); 173.4 (15-CO); 194.2 (1-COS). ES-MS: m/z (%): 411 [M+Na]H
+
 (28%), 389 [M]H
+
 (31%), 
371 [M-H2O]H
+
 (88%), 259 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 411.1930, found 
411.1931. 
 
  
 
166 
 
2EZ-2-Ethylhex-2-enoylpantetheine (95).
[129]
 
 
0.027 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.85-0.99 
(m, 12H, 6-8-20-21-CH3); 1.38-1.53 (m, 2H, 5-CH2); 2.16-2.35 (m, 4H, 4-7-CH2); 2.41 (t, J = 6.4, 2H, 
13-CH2); 2.97-3.06 (m, 2H, 9-CH2); 3.33-3.56 (m, 6H, 10-14-19-CH2); 3.98 (s, 1H, 17-CH); 5.63 (t, J = 
7.6, 1H, 3-CHZ); 6.56 (bt, J = 5.7, 1H, 11-NH); 6.70 (t, J = 7.6, 1H, 3-CHE); 7.46 (bt, J = 5.9, 1H, 
15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.4 (6-CH3), 13.9 (8-CH3), 20.4 (20-CH3); 21.5 (21-CH3); 22.0 
(7-CH2); 22.8 (5-CH2); 28.2 (9-CH2); 30.4 (4-CH2); 35.1 (13-CH2); 35.5 (14-CH2); 39.4 (18-C); 39.8 
(10-CH2); 70.9 (19-CH2); 77.7 (17-CH); 136.1 (2-C); 140.5 (2-C); 142.2 (3-CHE); 171.6 (12-CO); 173.4 
(16-CO); 193.9 (1-COS). ES-MS: m/z (%): 425 [M+Na]H
+
 (78%), 403 [M]H
+
 (13%), 385 [M-H2O]H
+
 
(56%), 273 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 425.2086, found 425.2086. 
 
4RS-4-Methylhex-2-enoylpantetheine (92).
[129]
 
 
0.02 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 
7.5, 3H, 6-CH3); 0.98 (s, 3H, 19-CH3); 1.01 (s, 3H, 20-CH3); 1.05 (d, J = 6.9, 7-CH3); 1.38-1.47 (m, 2H, 
5-CH2); 2.19-2.27 (m, 1H, 4-CH); 2.41 (t, J = 5.8, 2H, 12-CH2); 2.94-3.15 (m, 2H, 8-CH2); 3.33-3.58 (m, 
6H, 9-13-18-CH2); 4.00 (s, 1H, 16-CH); 6.08 (dd, J = 1.4, J = 15.4, 1H, 2-CH); 6.40 (bt, J = 5.4, 1H, 
10-NH); 6.83 (dd, J = 7.4, J = 15.4, 1H, 3-CH); 7.40 (bt, J = 5.4, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 11.6 (6-CH3), 18.7 (7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 28.2 (5-CH2); 28.8 (8-CH2); 35.1 
(12-CH2); 35.8 (13-CH2); 38.2 (4-CH); 39.4 (16-C); 39.7 (9-CH2); 70.8 (18-CH2); 77.6 (16-CH); 126.7 
(2-CH); 152.1 (3-CH); 171.7 (11-CO); 173.6 (15-CO); 190.8 (1-COS). ES-MS: m/z (%): 411 [M+Na]H
+
 
(8%), 389 [M]H
+
 (65%), 371 [M-H2O]H
+
 (88%), 259 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): 
calculated 411.1930, found 411.1930. 
 
4RS-2-4-Dimethylhex-2-enoylpantetheine (94).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 
7.4, 3H, 6-CH3); 0.92 (s, 3H, 20-CH3); 1.03 (s, 3H, 21-CH3); 1.03 (d, J = 2.3, 3H, 7-CH3); 1.30-1.51 (m, 
4H, 5-CH2); 1.88 (d, J = 1.1, 8-CH3), 2.41 (t, J = 5.6, 2H, 13-CH2); 2.40-2.49 (m, 1H, 4-CH); 2.99-3.14 
(m, 2H, 9-CH2); 3.35-3.59 (m, 6H, 10-14-19-CH2); 3.99 (s, 1H, 17-CH); 6.19 (bt, J = 5.7, 1H, 11-NH); 
6.54 (dq, J = 1, 3, J = 9.8, 1H, 3-CH); 7.36 (bt, J = 5.9, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 
11.9 (6-CH3), 12.7 (7-CH3), 19.5 (8-CH3), 20.4 (20-CH3); 21.7 (21-CH3); 28.3 (9-CH2); 29.6 (5-CH); 
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35.1 (13-CH2); 35.6 (14-CH2); 39.4 (18-C); 39.8 (10-CH2); 71.0 (19-CH2); 77.7 (17-CH); 134.4 (2-C); 
147.8 (3-CH); 171.4 (11-CO); 173.3 (15-CO); 194.5 (1-COS). ES-MS: m/z (%): 425 [M+Na]H
+
 (12%), 
403 [M]H
+
 (28%), 385 [M-H2O]H
+
 (88%), 273 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 
425.2086, found 425.2085. 
 
(2E, 4S)-Dimethylhex-2-enoylpantetheine (93).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 
7.4, 3H, 6-CH3); 0.92 (s, 3H, 20-CH3); 1.03 (s, 3H, 21-CH3); 1.03 (d, J = 2.3, 3H, 7-CH3); 1.30-1.51 (m, 
2H, 5-CH2); 1.88 (d, J = 1.1, 8-CH3), 2.41 (t, J = 5.6, 2H, 13-CH2); 2.40-2.49 (m, 1H, 4-CH); 2.99-3.14 
(m, 2H, 9-CH2); 3.35-3.59 (m, 6H, 10-14-19-CH2); 3.99 (s, 1H, 17-CH); 6.19 (bt, J = 5.7, 1H, 11-NH); 
6.54 (dq, J = 1, 3, J = 9.8, 1H, 3-CH); 7.36 (bt, J = 5.9, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): 
δ 11.9 (6-CH3), 12.7 (7-CH3), 19.5 (8-CH3), 20.4 (20-CH3); 21.7 (21-CH3); 28.3 (9-CH2); 29.6 (5-CH); 
35.1 (13-CH2); 35.6 (14-CH2); 39.4 (18-C); 39.8 (10-CH2); 71.0 (19-CH2); 77.7 (17-CH); 134.4 (2-C); 
147.8 (3-CH); 171.4 (11-CO); 173.3 (15-CO); 194.5 (1-COS). ES-MS: m/z (%): 425 [M+Na]H
+
 (11%), 
403 [M]H
+
 (26%), 385 [M-H2O]H
+
 (88%), 273 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 
425.2086, found 425.2085. 
 
2E-Hept-2-enoylpantetheine (96).
[129]
 
 
6 mg of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.94 (t, J = 
7.1, 3H, 7-CH3); 0.95 (s, 3H, 19-CH3); 1.06 (s, 3H, 20-CH3); 1.28-1.42 (m, 4-H, 5-6-CH2); 2.24 (dq, J = 
1.6, J = 7.2, 2H, 4-CH2); 2.43 (t, J = 7.2, 2H, 12-CH2); 3, 05-3.25 (m, 2H, 8-CH2); 3.38-3.62 (m, 6H, 
9-13-18-CH2); 4.01 (s, 1H, 16-CH); 6.13 (m, 1H, 2-CH); 6.15 (dt, J = 1.5, J = 15.4, 1H, 10-NH); 6.96 (dt, 
J = 7, 0, J = 15.5, 1H, 3-CH); 7.34 (bt, J = 6.0, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.8 
(7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 22.3 (6-CH2); 28.1 (8-CH2); 29.9 (5-CH2); 31.9 (4-CH2); 35.1 
(12-CH2); 35.6 (13-CH2); 39.3 (17-C); 39.9 (9-CH2); 70.9 (18-CH2); 77.8 (16-CH); 128.1 (2-CH); 147.3 
(3-CH); 171.6 (11-CO); 173.2 (15-CO); 190.6 (1-COS). ES-MS: m/z (%):778 [M2]H
+
 (28 %), 389 [M]H
+
 
(100 %). HR-MS: m/z (%): calculated 411.1930, found 411.1929. 
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2E-2-Methylhept-2-enoylpantetheine (97).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 (s, 3H, 
1-CH3); 0.93 (t, J = 7.2, 3H, 20-CH3); 1.03 (s, 3H, 21-CH3); 1.31-1.49 (m, 4H, 5-6-CH2); 1.88 (d, J = 1.1, 
8-CH3) 2.22 (q, J = 6.8, 2H, 4-CH2); 2.41 (t, J = 5.9, 2H, 13-CH2); 3.00-3.14 (m, 2H, 9-CH2); 3.35-3.59 
(m, 6H, 10-14-19-CH2); 3.99 (s, 1H, 17-CH); 6.16 (bt, J = 5.6, 1H, 11-NH); 6.78 (tq, J = 1, 3, J = 7.5, 1H, 
3-CH); 7.36 (bt, J = 5.9, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.5 (8-CH3), 13.9 (7-CH3), 20.4 
(20-CH3); 21.8 (21-CH3); 22.5 (6-CH2); 28.3 (4-CH2); 28.5 (9-CH2); 30.6 (5-CH2); 35.1 (13-CH2); 35.5 
(14-CH2); 39.4 (18-C); 39.8 (10-CH2); 70.9 (19-CH2); 77.7 (17-CH); 135.6 (2-C); 142.5 (3-CH); 171.6 
(12-CO); 173.3 (16-CO); 194.2 (1-COS). ES-MS: m/z (%): 425 [M+Na]H
+
 (7%), 403 [M]H
+
 (81%), 385 
[M-H2O]H
+
 (88%), 273 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 425.2086, found 
425.2084. 
 
2E-6RS-6-Methylhept-2-enoylpantetheine (98).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.86-0.92 (m, 
9H, 7-19-CH3); 1.01 (s, 3H, 20-CH3); 1.14-1.38 (m, 2H, 5-CH2); 1.47-1.62 (m, 1H, 6-CH); 2.22 (q, J = 
7.0, 2H, 4-CH2); 2.41 (t, J = 6.2, 2H, 12-CH2); 3.01-3.15 (m, 2H, 8-CH2); 3.35-3.58 (m, 6H, 9-13-18-
CH2); 3.99 (s, 1H, 16-CH); 6.13 (dt, J = 1.5, J = 15.2, 1H, 2-CH); 6.39 (bt, J = 5.6, 1H, 10-NH); 6.93 (dt, 
J = 6.5, J = 15.5, 1H, 3-CH); 7.39 (bt, J = 5.9, 1H, 14-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 20.4 
(19-CH3); 21.7 (20-CH3); 22.4 (7-2xCH3); 27.6 (6-CH); 28.1 (8-CH2); 30.2 (4-CH2); 35.1 (12-CH2); 35.6 
(13-CH2); 36.9 (5-CH2); 39.4 (17-C); 39.8 (9-CH2); 70.9 (18-CH2); 77.7 (16-CH); 128.0 (2-CH); 147.4 
(3-CH); 171.7 (10-CO); 173.5 (14-CO); 190.6 (1-COS). ES-MS: m/z (%): 425 [M+Na]H
+
 (12%), 403 
[M]H
+
 (30%), 385 [M-H2O]H
+
 (88%), 273 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 
425.2086, found 425.2089. 
 
2E-Oct-2-enoylpantetheine (99).
[129]
 
 
6 mg of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 
6.7, 3H, 8-CH3); 0.95 (s, 3H, 20-CH3); 1.06 (s, 3H, 21-CH3); 1.28-1.61 (m, 6H, 5-6-7-CH2); 2.21 (dq, J = 
1.4, J = 7.3, 2H, 4-CH2); 2.43 (t, J = 6.0, 2H, 13-CH2); 3, 05-3.20 (m, 2H, 9-CH2); 3.38-3.62 (m, 6H, 
10-14-19-CH2); 4.01 (s, 1H, 17-CH); 6.13 (t, J= 4.07, 1H, 2-CH); 6.17 (dt, J = 1.4, J= 15.4, 1H, 11-NH); 
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6.96 (dt, J = 6, 9, J = 15.4, 1H, 3-CH); 7.34 (bt, J = 5.82, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): 
δ 13.9 (8-CH3), 20.4 (20-CH3); 21.7 (21-CH3); 22.4 (7-CH2); 27.6 (6-CH2); 28.1 (9-CH2); 31.7 (5-CH2); 
32.3 (4-CH2); 35.1 (13-CH2); 35.5 (14-CH2); 39.3 (18-C); 39.9 (10-CH2); 70.9 (19-CH2); 77.8 (17-CH); 
128.1 (2-CH); 147.3 (3-CH); 171.6 (12-CO); 173.2 (16-CO); 190.6 (1-COS). ES-MS: m/z (%): 806 
[M2]H
+
 (14%), 403 [M]H
+
 (100%). HR-MS: m/z (%): calculated 425.2086, found 425.2089. 
 
2E-2-Methyloct-2-enoylpantetheine (100).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.90 (tr, J = 
6.9, 3H, 8-CH3); 0.91 (s, 3H, 21-CH3); 1.01 (s, 3H, 22-CH3); 1.25-1.36 (m, 4H, 6-7-CH2); 1.41-1.50 (m, 
2H, 5-CH2); 1.85 (s, 3H, 9-CH3); 2.20 (q, J = 7.5, 2H, 4-CH2); 2.41 (t, J = 6.6, 2H, 14-CH2); 2.99-3.12 
(m, 2H, 10-CH2); 3.35-3.58 (m, 6H, 11-15-20-CH2); 3.99 (s, 1H, 18-CH); 6.37 (bt, J = 5.7, 1H, 12-NH); 
6.77 (tq, J = 1.3, J = 7.6, 1H, 3-CH); 7.41 (bt, J = 6.2, 1H, 16-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.5 
(9-CH3); 14.1 (8-CH3); 20.4 (21-CH3); 21.6 (22-CH3); 22.5 (7-CH2); 28.1 (5-CH2); 28.2 (4-CH2); 28.8 
(10-CH2); 31.6 (6-CH2); 35.1 (14-CH2); 35.6 (15-CH2); 39.4 (19-C); 39.8 (11-CH2); 70.9 (20-CH2); 77.8 
(18-CH); 135.6 (2-C); 142.7 (3-CH); 171.7 (13-CO); 173.2 (17-CO); 194.2 (1-COS). ES-MS: m/z (%): 
439 [M+Na]H
+
 (2%), 417 [M]H
+
 (41%), 399 [M-H2O]H
+
 (85%), 287 [M-C6H11O3]H
+
 (100%). HR-MS: 
m/z (%): calculated 439.2243, found 439.2240. 
 
2EZ-2-Ethyloct-2-enoylpantetheine (103).
[129]
 
 
0.027 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.85-0.99 
(m, 12H, 8-10-22-23-CH3); 1.28-1.51 (m, 4H, 5-6-7-CH2); 2.16-2.35 (m, 4H, 4-9-CH2); 2.41 (t, J = 6.4, 
2H, 15-CH2); 2.97-3.06 (m, 2H, 11-CH2); 3.33-3.56 (m, 6H, 12-16-21-CH2); 3.98 (s, 1H, 19-CH); 5.63 (t, 
J = 7.6, 1H, 3-CHZ); 6.56 (bt, J = 5.7, 1H, 13-NH); 6.70 (t, J = 7.6, 1H, 3-CHE); 7.46 (bt, J = 5.9, 1H, 
17-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.4 (8-CH3), 13.9 (10-CH3), 20.4 (22-CH3); 21.5 (23-CH3); 
22.0 (7-CH2); 22.8 (6-CH2); 28.2 (11-CH2), 29.5 (5-CH2); 31.4 (4-CH2); 35.1 (15-CH2); 35.5 (16-CH2); 
39.4 (20-C); 39.8 (12-CH2); 70.9 (21-CH2); 77.7 (19-CH); 136.1 (3-CHZ); 140.5 (2-C); 142.2 (3-CHE); 
171.6 (14-CO); 173.4 (18-CO); 193.9 (1-COS). ES-MS: m/z (%): 453 [M+Na]H
+
 (8%), 431 [M]H
+
 
(65%), 413 [M-H2O]H
+
 (88%), 301 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 453.2396, 
found 453.2396. 
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6RS,4RS-2E-Dimethyloct-2-enoylpantetheine (104).
[129]
 
 
0.027 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.81-0.90 
(m, 6H, 8-9-CH3), 0.92 (s, 3H, 22-CH3 ), 1.03 (s, 3H, 23-CH3), 1.00-1.07 (m, 3H, 10-CH3 ), 1.07-1.44 (m, 
7H, 5-6-7-CH2), 2.41 (t, 2H, J = 6.0, 15-CH2), 2.34-2.46 (m, 1H, 4-CH), 2.95-3.17 (m, 2H, 11-CH2), 
3.33-3.66 (m, 6H, 12-16-21-CH2), 3.99 (s, 1H, 19-CH), 6.08 (dt, 1H, J = 1.4, J = 15.6, 2-CH), 6.23 (bt, 
J = 6.0, 1H, 13-NH), 6.75-6.88 (m, 1H, 3-CH); 7.36 (bt, J = 6.0, 1H, 17-NH). 
13
C-NMR (CDCl3, 100 
MHz): 11.3 (8-9-CH3), 19.2 (10-CH3 ), 20.5 (22-CH3), 21.9 (23-CH3), 28.3 (11-CH2), 29.5 (7-CH2), 31.9 
(6-CH), 34.3 (4-CH), 35.3 (15-CH2), 35.7 (16-CH2), 39.5 (20-C), 40.0 (12-CH2), 71.1 (21-CH2), 77.9 
(19-CH), 126.2 (2-CH), 152.5 (3-CH), 171.8 (14-CO), 173.5 (18-CO), 190.9 (1-CO). ES-MS: m/z (%): 
453 [M+Na]H
+
 (11%), 431 [M]H
+
 (62%), 413 [M-H2O]H
+
 (85%), 301 [M-C6H11O3]H
+
 (100%). HR-MS: 
m/z (%): calculated 453.2396, found 453.2396. 
 
6S,4S-2E-Dimethyloct-2-enoylpantetheine (102).
[129]
 
 
0.027 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.81-0.90 
(m, 6H, 8-9-CH3), 0.92 (s, 3H, 21-CH3 ), 1.03 (s, 3H, 22-CH3), 1.05 (m, 3H, 10-CH3 ), 1.10-1.44 (m, 6H, 
5-7-CH2, 6-CH), 2.42 (t, 2H, J = 6.0, 15-CH2), 2.37-2.41 (m, 1H, 4-CH), 3.03-3.17 (m, 2H, 11-CH2), 
3.36-3.58 (m, 6H, 12-16-21-CH2), 3.99 (s, 1H, 19-CH), 6.08 (dd, 1H, J = 1.4, J = 15.6, 2-CH), 6.23 (bt, 
J = 6.0, 1H, 13-NH), 6.79 (dd, J = 7.6, 1H, 3-CH); 7.37 (bt, J = 6.0, 1H, 17-NH). 
13
C-NMR (CDCl3, 100 
MHz): 11.3 (8-CH3), 18.8 (9-CH3), 20.2 (10-CH3), 20.5 (21-CH3), 21.9 (22-CH3), 28.3 (11-CH2), 29.7 
(7-CH2), 31.9 (6-CH2), 34.3 (4-CH), 35.1 (15-CH2), 35.9 (16-CH2), 39.5 (18-C), 39.8 (12-CH2), 43.3 
(5-CH2), 71.1 (21-CH2), 77.9 (19-CH), 126.2 (2-CH), 152.5 (3-CH), 171.8 (14-CO), 173.5 (18-CO), 
190.9 (1-CO). ES-MS: m/z (%): 453 [M+Na]H
+
 (8%), 431 [M]H
+
 (65%), 413 [M-H2O]H
+
 (88%), 301 
[M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 453.2399, found 453.2392. 
 
2E-7-Methyloct-2-enoylpantetheine (101).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.86 (d, J = 
6.6, 6H, 8-CH3); 0.93 (s, 3H, 20-CH3); 1.03 (s, 3H, 21-CH3); 1.14-1.30 (m, 2H, 5-6-CH2); 1.42-1.60 (m, 
1H, 7-CH); 2.22 (q, J = 7.4, 2H, 4-CH2); 2.41 (t, J = 5.8, 2H, 13-CH2); 3.01-3.18 (m, 2H, 9-CH2); 
3.35-3.59 (m, 6H, 10-14-19-CH2); 3.99 (s, 1H, 17-CH); 6.13 (dt, J = 1.5, J = 15.5, 1H, 2-CH); 6.18 (bt, 
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J = 5.8, 1H, 11-NH); 6.93 (dt, J = 6.9, J = 15.5, 1H, 3-CH); 7.34 (bt, J = 5.8, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 20.4 (20-CH3); 21.7 (21-CH3); 22.5 (8-2xCH3); 27.8 (7-CH); 28.1 
(9-CH2); 30.1 (5-CH2); 32.6 (4-CH2); 35.1 (13-CH2); 35.6 (14-CH2); 38.5 (6-CH2); 39.4 (18-C); 39.8 
(10-CH2); 70.9 (19-CH2); 77.8 (17-CH); 128.1 (2-CH); 147.3 (3-CH); 171.6 (12-CO); 173.3 (16-CO); 
190.6 (1-COS). ES-MS: m/z (%): 417 [M]H
+
 (15%), 399 [M-H2O]H
+
 (60%), 287 [M-C6H11O3]H
+
 
(100%). HR-MS: m/z (%): calculated 439.2243, found 439.2242. 
 
2E-Dec-2-enoyl-pantetheine (105).
[129]
 
 
6 mg of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 
7.1, 3H, 10-CH3); 0.95 (s, 3H, 22-CH3); 1.06 (s, 3H, 23-CH3); 1.28-1.33 (m, 8H, 6, 7, 8, 9-CH2); 
1.45-1.53 (m, 2H, 5-CH2); 2.23 (dq, J = 1.6, J = 7.2, 2H, 4-CH2); 2.43 (t, J = 7.2, 2H, 15-CH2); 3, 05-3.20 
(m, 2H, 11-CH2); 3.37-3.62 (m, 6H, 12-16-21-CH2); 4.01 (s, 1H, 19-CH); 6.13 (m, 1H, 2-CH); 6.17 (dt, 
J = 1.5, J = 15.4, 1H, 13-NH); 6.96 (dt, J = 7, 0, J = 15.5, 1H, 3-CH); 7.34 (bt, J = 6.0, 1H, 17-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 14.1 (10-CH3), 20.4 (22-CH3); 21.7 (23-CH3); 22.6 (9-CH2); 27.9 
(5-CH2); 28.6 (11-CH2); 29.1 (7-CH2); 29.2 (6-CH2); 31.7 (8-CH2); 32.3 (4-CH2); 35.1 (15-CH2); 35.6 
(16-CH2); 39.3 (20-C); 39.9 (12-CH2); 70.9 (21-CH2); 77.8 (19-CH); 128.1 (2-CH); 147.7 (3-CH); 171.6 
(14-CO); 173.3 (18-CO); 190.9 (1-COS). ES-MS: m/z (%): 863 [M2]H
+
 (28%), 431 [M]H
+
 (100%), 413 
[M-H2O]H
+
 (1%). HR-MS: m/z (%): calculated 453.2399, found 453.2399. 
 
2E-2-Methyldec-2-enoylpantetheine (106).
[129]
 
 
0.01 g of the product were purified by HPLC (acetonitrile). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (tr, J = 
7.2, 3H, 10-CH3); 0.93 (s, 3H, 23-CH3); 1.04 (s, 3H, 24-CH3); 1.28-1.31 (m, 8H, 6-7-8-9-CH2); 1.43-1.48 
(m, 2H, 5-CH2); 1.87 (s, 3H, 11-CH3); 2.22 (q, J = 7.2, 2H, 4-CH2); 2.41 (t, J = 6.2, 2H, 16-CH2); 
3.00-3.14 (m, 2H, 12-CH2); 3.35-3.63 (m, 6H, 13-17-22-CH2); 3.99 (s, 1H, 20-CH); 6.09 (bt, J = 5.6, 1H, 
14-NH); 6.78 (tq, J = 1.3, J = 7.4, 1H, 3-CH); 7.38 (bt, J = 6.6, 1H, 18-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 12.5 (11-CH3); 14.1 (10-CH3); 20.4 (23-CH3); 21.7 (24-CH3); 22.6 (9-CH2); 28.3 (5-CH2); 28.5 
(12-CH2); 29.1 (7-CH2); 29.4 (6-CH2); 31.8 (8-CH2); 35.1 (16-CH2); 35.6 (17-CH2); 39.4 (21-C); 39.8 
(13-CH2); 70.9 (22-CH2); 77.8 (19-CH); 135.6 (2-C); 142.8 (3-CH); 171.7 (15-CO); 173.2 (19-CO); 
194.2 (1-COS). ES-MS: m/z (%): 467 [M+Na]H
+
 (12%), 445 [M]H
+
 (27%), 427 [M-H2O]H
+
 (67%), 315 
[M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 467.2556, found 467.2556. 
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3-Oxobutanoylpantetheine (224a).  
 
3-oxobutanepantetheine dimethyl ketal (0.96 g, 2.0 mmol was solved in dichloromethane and 10% TFA 
for 20 minutes. The reaction was followed by TLC and LCMS. After that the solvents were evapurated. 
The product was purified by HPLC (0.26 g, 0.7 mmol, 30%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.92 (s, 3H, 
16-CH3); 1.02 (s, 3H, 17-CH3); 1.95 (s, 1H, 4-CH3); 2.27 (s, 2H, 4-CH3); 2.44 (t, J = 5.7, 2H, 9-CH2); 
3.09 (t, J = 6.5, 2H, 5-CH2); 3.37-3.65 (m, 6H, 6-10-15-CH2); 3.73 (s, 2H, 2-CH2); 4.00 (s, 1H, 13-CH); 
6.49 (bt, J = 5.7, 1H, 7-NH); 7.38 (bt, J = 5.9, 1H, 11-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 20.4 
(16-CH3); 21.6 (17-CH3); 27.4 (5-CH2); 30.4 (4-CH3), 35.2 (10-CH2); 35.6 (9-CH2); 39.4 (13-C); 39.8 
(6-CH2); 57.9 (2-CH2); 70.8 (15-CH2); 77.6 (13-CH); 171.2 (8-CO); 174.2 (12-CO); 192.4 (1-CO); 200.3 
(3-CO). ES-MS: m/z (%): 385 [M+Na]H
+
 (65%), 363 [M]H
+
 (100%). HR-MS: m/z (%): calculated 
363.1590, found 363.1586. 
 
2-Methyl-3-oxobutanoylpantetheine (225a). 
 
Potassium tert-butanolate (0.31 g, 2.8 mmol) in 20 mL THF was added to 3-oxobutanepantetheine 
dimethyl ketal (1.1 g, 2.4 mmol) and the mixture stirred for further 45 min at room temperature. After that 
methyliodide (0.39 g, 2.8 mmol) was added and stirred for 5 hours. Ether and water was given to the 
mixture and the aqueous phase extracted three times with diethyl ether (20 mL). Finally the combined 
organic layers were washed with brine, dried over MgSO4 and concentrated. The residue was solved in 
dichloromethane and 10 % TFA for 20 minutes. The reaction was followed by TLC and LCMS. After that 
the solvents were evapurated. The product was purified by HPLC (0.28 g, 0.7 mmol, 30%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.93 (s, 3H, 17-CH3); 1.02 (s, 3H, 18-CH3); 1.40 (d, 3H, J = 7.6, 5-CH3); 
2.02 (s, 1H, 4-CH3); 2.25 (s, 2H, 4-CH3); 2.43 (t, J = 5.3, 2H, 10-CH2); 2.99-3.09 (m, 2H, 6-CH2); 
3.32-3.59 (m, 6H, 7-11-16-CH2); 3.77 (q, 1H, J = 6.5, 2-CH2); 4.05 (s, 1H, 14-CH); 6.34 (bt, J = 5.7, 1H, 
8-NH); 7.36 (bt, J = 5.9, 1H, 12-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.5 (5-CH3); 20.4 (17-CH3); 21.6 
(18-CH3); 28.5 (4-CH3); 28.8 (6-CH2); 30.4 (4-CH3), 35.2 (11-CH2); 35.6 (10-CH2); 39.2 (15-C); 39.4 
(7-CH2); 61.8 (2-CH); 70.9 (16-CH2); 77.7 (14-CH); 171.6 (9-CO); 173.6 (13-CO); 197.4 (1-CO); 203.3 
(3-CO). ES-MS: m/z (%): 399 [M+Na]H
+
 (5%), 377 [M]H
+
 (88%), 359 [M-H2O]H
+
 (73%), 247 
[M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 399.1566, found 399.1566. 
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3-Oxohexanoylpantetheine (224b). 
 
Butanoyl meldrums acid (1.6 g, 7.4 mmol) stirred in toluene with pantetheine dimethyl ketal (2.4 g, 
7.8 mmol) under nitrogen at 90 °C. After 6 hours the reaction was stopped and the mixture concentrated 
under vacuum. The mixture was then solved in 2 M HCl/ MeOH 1:5 and stirred for further 4 hours. After 
that the product was purified by HPLC to give a yellow oil (0.32 g, 0.7 mmol, 10%). 
1
H-NMR (CDCl3, 
400 MHz): δ 0.93 (t, J = 7.4, 3H, 6-CH3); 0.95 (s, 3H, 18-CH3); 1.03 (s, 3H, 19-CH3); 1.60-1.65 (m, 2H, 
5-CH2); 2.43 (t, J = 5.9, 2H, 11-CH2); 2.51 (t, J = 6.9, 2H, 4-CH2); 3.05-3.15 (m, 2H, 7-CH2); 3.36-3.59 
(m, 6H, 8-12-17-CH2); 3.70 (s, 2H, 2-CH2); 4.00 (s, 1H, 15-CH); 6.39 (bt, J = 5.7, 1H, 10-NH); 7.35 (bt, 
J = 5.9, 1H, 13-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 13.5 (6-CH3), 16.9 (5-CH2), 20.4 (18-CH3); 21.7 
(19-CH3); 29.0 (7-CH2); 35.1 (11-CH2); 35.6 (12-CH2); 39.1 (16-C); 39.4 (8-CH2); 45.4 (3-CH2); 57.1 
(2-CH2); 70.9 (17-CH2); 77.6 (15-CH); 171.9 (11-CO); 173.5 (14-CO); 192.2 (1-CO); 202.9 (3-CO). 
ES-MS: m/z (%): 413 [M+Na]H
+
 (49%), 391 [M]H
+
 (98%), 373 [M-H2O]H
+
 (73%), 261 [M-C6H11O3]H
+
 
(100%). HR-MS: m/z (%): calculated 413.1720, found 413.1720. 
 
2-Methyl-3-oxohexanoylpantetheine (225b). 
 
Potassium tert-butanolate in 20 mL THF was added (0.31 g, 2.8 mmol) to 3-oxohexanepantetheine 
dimethyl ketal (1.1 g, 2.4 mmol) and the mixture stirred for further 45 min at room temperature. After that 
methyliodide (0.4 g, 2.8 mmol) was added and stirred for 5 hours. Ether and water was given to the 
mixture and the aqueous phase extracted three times with diethyl ether (20 mL). Finally the combined 
organic layers were washed with brine, dried over MgSO4 and concentrated. The residue was solved in 
dichloromethane and 10% TFA for 20 minutes. The reaction was followed by TLC and LCMS. After that 
the solvents were evapurated. The product was purified by HPLC (0.28 g, 0.7 mmol, 30%). 
1
H-NMR 
(CDCl3, 400 MHz): δ 0.91 (t, J = 6.7, 3H, 6-CH3); 0.93 (s, 3H, 19-CH3); 1.03 (s, 3H, 20-CH3); 1.39 (d, 
J = 6.7, 3H, 7-CH3); 1.61 (q, J = 7.4, 2H, 5-CH2); 2.43 (t, J = 5.7, 2H, 12-CH2); 2.53 (t, J = 7.1, 2H, 
4-CH2); 3.05-3.15 (m, 2H, 8-CH2); 3.36-3.59 (m, 6H, 9-13-178-CH2); 3.79 (q, J = 7.1, 1H, 2-CH); 4.01 
(s, 1H, 16-CH); 6.31 (bt, J = 5.7, 1H, 10-NH); 7.37 (bt, J = 5.9, 1H, 15-NH). 
13
C-NMR (CDCl3, 100 
MHz): δ 13.6 (6-7-CH3), 16.9 (5-CH2), 20.4 (19-CH3); 21.7 (20-CH3); 28.8 (8-CH2); 35.1 (12-CH2); 35.6 
(13-CH2); 39.3 (17-C); 39.4 (9-CH2); 43.5 (4-CH2); 61.1 (2-CH2); 70.7 (18-CH2); 77.7 (16-CH); 171.8 
(11-CO); 173.5 (15-CO); 197.4 (1-CO); 205.6 (3-CO). ES-MS: m/z (%): 427 [M+Na]H
+
 (65%), 405 
[M]H
+
 (100%), 387 [M-H2O]H
+
 (68%), 275 [M-C6H11O3]H
+
 (100%). HR-MS: m/z (%): calculated 
427.1879, found 427.1879. 
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6.2.7 Synthesis of Pantetheine Glycine Substrates. 
 
General Procedure: Step 1 
Corresponding pantetheine and boc-glycine-OH were dissolved in dichloromethane (8 mL). The mixture 
was cooled to 0 °C. Then N, N-dimethylaminopyridine and N-(3-Diethylaminopropyl)-N-
ethylcarbodiimide were added. The mixture was warmed to 25 °C and stirred for 8 hours. After that the 
mixture was quenched with 2 M HCl (10 mL) and extracted with dichloromethane (3 × 25 mL). The 
organic layer was washed with saturated NaHCO3 (25 ml) and brine (25 mL). The product was dried over 
MgSO4 and concentrated under vacuo. In the last step dichloromethane and 20% TFA and 10% water was 
added and stirred for further 20 min. The crude product was purified by HPLC.
[192]
  
 
3-Oxo-butyrylpantetheine-glycine (210). 
 
The obtained product was a yellow oil (18 mg, 0.04 mmol, 6%). 
1
H-NMR (D2O, 400 MHz): δ 0.98 (s, 
3H, 16-CH3); 0.99 (s, 3H, 17-CH3); 2.23 (s, 1H, 4-CH3); 2.29 (s, 2H, 4-CH3); 2.48 (t, J = 6.3, 2H, 9-CH2); 
3.10 (t, J = 5.9, 2H, 5-CH2); 3.40 (t, J = 7.0, 2H, 10-CH2); 3.48-3.52 (m, 2H, 6-CH2); 3.98 (s, 2H, 
19-CH2); 4.01 (s, 1H, 13-CH) 4.09 (d, J = 11.4, 1H, 15-CH2); 4.19 (d, J = 11.4, 1H, 15-CH2). 
13
C-NMR 
(D2O, 100 MHz): δ 19.4 (16-CH3); 20.3 (17-CH3); 28.5 (5-CH2); 29.9 (4-CH3); 35.1 (13-C); 35.4 
(9-CH2); 37.6 (10-CH2); 38.4 (6-CH2); 39.9 (19-CH2); 53.8 (2-CH2); 71.6 (15-CH2); 74.6 (13-CH); 168.0 
(18-CO); 174.0 (8-CO); 174.5 (12-CO); 195.8 (1-CO); 206.3 (3-CO). ES-MS: m/z (%): 442 [M+Na]H
+
 
(16%), 420 [M]H
+
 (100%), 402 [M-H2O]H
+
 (6%). HR-MS: m/z (%): calculated 442.1624, found 
442.1628.
[192]
 
 
3-Oxo-2-methyl-butyrylpantetheine-glycine (211). 
 
The obtained product was a yellow oil (33 mg, 0.08 mmol, 11%). 
1
H-NMR (D2O, 400 MHz): δ 0.98 (s, 
3H, 17-CH3); 0.99 (s, 3H, 18-CH3); 1.35 (s, 3H, 5-CH3); 2.30 (s, 3H, 4-CH3); 2.48 (t, J = 6.3, 2H, 
10-CH2); 3.10 (t, J = 5.9, 2H, 6-CH2); 3.40 (t, J = 7.0, 2H, 11-CH2); 3.48-3.52 (m, 2H, 7-CH2); 3.98 (s, 
2H, 20-CH2); 4.01 (s, 1H, 14-CH) 4.09 (d, J = 11.4, 1H, 16-CH2); 4.19 (d, J = 11.4, 1H, 16-CH2). 
13
C-NMR (D2O, 100 MHz): δ 13.1 (5-CH3); 19.4 (17-CH3); 20.3 (18-CH3); 28.4 (4-CH3); 28.5 (6-CH2); 
35.1 (15-C); 35.4 (10-CH2); 37.6 (11-CH2); 38.4 (7-CH2); 39.9 (20-CH2); 53.8 (2-CH2); 71.6 (16-CH2); 
74.6 (14-CH); 168.0 (19-CO); 173.9 (9-CO); 174.5 (13-CO); 200.1 (1-CO); 208.9 (3-CO). ES-MS: m/z 
(%): 462 [M+Na]H
+
 (31%), 434 [M]H
+
 (100%), 416 [M-H2O]H
+
 (2%). HR-MS: m/z (%): calculated 
434.1961, found 434.1960.
[192]
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3R-Hydroxy-2R-methylbutyrylpantetheine-glycine (212). 
 
The obtained product was a yellow oil (14 mg, 0.03 mmol, 10%). 
1
H-NMR (D2O, 400 MHz): δ 0.98 (s, 
3H, 17-CH3); 0.99 (s, 3H, 18-CH3); 1.12 (d, J = 7.1, 3H, 5-CH3); 1.20 (d, J = 6.4, 3H, 4-CH3); 2.47 (t, J = 
6.5, 2H, 10-CH2); 2.76-2.83 (m, 1H, 2-CH); 2.98-3.13 (m, 2H, 6-CH2); 3.39 (t, J = 7.0, 2H, 11-CH2); 
3.47-3.53 (m, 2H, 7-CH2); 3.95 (m, 1H, 3-CH), 3.98 (s, 2H, 20-CH2); 4.01 (s, 1H, 14-CH) 4.09 (d, J = 
11.4, 1H, 16-CH2); 4.19 (d, J = 11.4, 1H, 16-CH2). 
13
C-NMR (D2O, 100 MHz): δ 13.8 (5-CH3); 19.3 
(4-CH3); 19.4 (17-CH3); 20.3 (18-CH3); 27.9 (6-CH2); 35.1 (15-C); 35.4 (10-CH2); 37.6 (11-CH2); 38.6 
(7-CH2); 39.9 (20-CH2); 55.6 (2-CH); 69.4 (3-CH); 71.6 (16-CH2); 74.6 (14-CH); 168.0 (19-CO); 174.0 
(9-CO); 174.5 (13-CO); 206.3 (1-CO). ES-MS: m/z (%): 458 [M+Na]H
+
 (12%), 436 [M]H
+
 (100%). 
HR-MS: m/z (%): calculated 436.2117, found 436.2118 
 
Tigloylpantetheine-glycine (213). 
 
The obtained product was a yellow oil (27 mg, 0.06 mmol, 2%). 
1
H-NMR (CDCl3, 400 MHz): δ 0.88 (s, 
3H, 17-CH3); 0.97 (s, 3H, 18-CH3); 1.82 (m, 6H, 4-5-CH3); 2.43 (t, J = 5.2, 2H, 10-CH2); 2.99 (t, J = 5.6, 
2H, 6-CH2); 3.29-3.56 (m, 4H, 7-11-CH2); 3.80-4.03 (m, 3H, 14-20-CH2); 4.16 (m, 2H, 16-CH2); 6.56 
(bt, J = 5.7, 1H, 8-NH); 6.84 (m, 1H, 3-CH); 7.41 (bt, J = 5.7, 1H, 12-NH); 7.71 (bt, J = 7.3, 1H, 21-NH). 
13
C-NMR (CDCl3, 100 MHz): δ 12.1 (5-CH3), 14.5 (4-CH3), 19.8 (17-CH3); 21.1 (18-CH3); 27.9 
(6-CH2); 35.2 (15-C); 35.6 (10-CH2); 37.4 (101-CH2); 38.5 (7-CH2); 39.9 (20-CH2); 71.6 (14-CH2); 74.6 
(14-CH); 136.1 (2-C); 136.8 (3-CH); 167.8 (19-CO); 172.0 (9-CO); 173.7 (13-CO); 193.7 (1-COS). 
ES-MS: m/z (%): 440 [M+Na]H
+
 (8%), 418 [M]H
+
 (100%), 400 [M-H2O]H
+
 (12%), 343 [M-C2H4NO]H
+
 
(100%). HR-MS: m/z (%): calculated 440.1831, found 440.1833.
[192]
 
 
Methylbutyrylpantetheine-glycine (214). 
 
The obtained product was a yellow oil (80 mg, 0.2 mmol, 50%) 
1
H-NMR (D2O, 400 MHz): δ 0.87 (t, J = 
7.6, 3H, 4-CH3); 0.98 (s, 3H, 17-CH3); 0.99 (s, 3H, 18-CH3); 1.14 (d, J = 7.4, 3H, 5-CH3); 1.44-1.71 (m, 
2H, 3-CH2); 2.47 (t, J = 7.0, 2H, 10-CH2); 2.67-2.76 (m, 1H, 2-CH); 3.05 (t, J = 7.6, 2H, 6-CH2); 3.39 (t, 
J = 7.0, 2H, 11-CH2); 3.47-3.53 (m, 2H, 7-CH2); 3.98 (s, 2H, 20-CH2); 4.01 (s, 1H, 14-CH) 4.09 (d, J = 
11.4, 1H, 16-CH2); 4.19 (d, J = 11.4, 1H, 16-CH2). 
13
C-NMR (D2O, 100 MHz): δ 10.8 (4-CH3); 16.6 
(5-CH3); 19.4 (17-CH3); 20.3 (18-CH3); 26.9 (3-CH2); 27.7 (6-CH2); 35.1 (15-C); 35.4 (10-CH2); 37.6 
(11-CH2); 38.5 (7-CH2); 39.8 (20-CH2); 49.9 (2-CH); 71.6 (16-CH2); 74.6 (14-CH); 168.1 (19-CO); 173.8 
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(9-CO); 174.5 (13-CO); 209.2 (5-CO). ES-MS: m/z (%): 442 [M+Na]H
+
 (23%), 420 [M]H
+
 (100%), 402 
[M-H2O]H
+
 (4%). HR-MS: m/z (%): calculated 442.1988, found 442.1989.
[192]
 
 
3-Oxohexanoylpantetheine-glycine (215). 
 
The obtained product was a yellow oil (13 mg, 0.03 mmol, 20%). 
1
H-NMR (D2O, 400 MHz): δ 0.87 (t, 
J = 7.6, 3H, 6-CH3); 0.98 (s, 3H, 18-CH3); 1.00 (s, 3H, 19-CH3); 1.54-1.62 (m, 2H, 5-CH2); 2.48 (t, J = 
7.1, 2H, 11-CH2); 2.62 (t, J = 7.3, 2H, 4-CH2); 3.11 (t, J = 6.4, 2H, 7-CH2); 3.40 (t, J = 7.0, 2H, 12-CH2); 
3.49-3.52 (m, 2H, 8-CH2); 3.99 (s, 2H, 21-CH2); 4.02 (s, 1H, 15-CH) 4.09 (d, J = 11.4, 1H, 17-CH2); 4.19 
(d, J = 11.4, 1H, 17-CH2). 
13
C-NMR (D2O, 100 MHz): δ 13.5 (6-CH3); 16.5 (5-CH2); 19.4 (18-CH3); 20.3 
(19-CH3); 28.5 (7-CH2); 35.1 (16-C); 35.4 (11-CH2); 37.6 (12-CH2); 38.5 (8-CH2); 39.8 (21-CH2); 46.1 
(4-CH2); 71.6 (17-CH2); 74.6 (15-CH); 168.1 (20-CO); 173.9 (10-CO); 174.5 (14-CO); 195.9 (1-COS); 
208.8 (3-CO). ES-MS: m/z (%): 470 [M+Na]H
+
 (8%), 448 [M]H
+
 (100%). HR-MS: m/z (%): calculated 
484.2093, found 484.2094. 
 
3-Oxo-2-methyl-hexanoyl-pantetheine-glycine (216). 
 
The obtained product was a yellow oil (30 mg, 0.06 mmol, 10%). 
1
H-NMR (D2O, 400 MHz): δ 0.87 (t, 
J = 7.6, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 0.99 (s, 3H, 20-CH3); 1.44 (s, 3H, 7-CH3); 1.51-1.60 (m, 2H, 
5-CH2); 2.46 (t, J = 7.1, 2H, 12-CH2); 2.66 (t, J = 7.1, 2H, 4-CH2); 3.09 (t, J = 6.2, 2H, 8-CH2); 3.39 (t, 
J = 6.3, 2H, 13-CH2); 3.47-3.51 (m, 2H, 9-CH2); 3.98 (s, 2H, 22-CH2); 4.01 (s, 1H, 16-CH) 4.09 (d, J = 
11.4, 1H, 18-CH2); 4.19 (d, J = 11.4, 1H, 18-CH2). 
13
C-NMR (D2O, 100 MHz): δ 12.7 (7-CH3); 13.5 
(6-CH3); 16.6 (5-CH2); 19.4 (19-CH3); 20.3 (20-CH3); 27.6 (8-CH2); 35.1 (17-C); 35.4 (12-CH2); 37.6 
(13-CH2); 38.5 (9-CH2); 39.8 (22-CH2); 43.7 (4-CH2); 71.6 (18-CH2); 74.6 (16-CH); 168.1 (21-CO); 
173.9 (11-CO); 174.5 (15-CO); 199.9 (1-COS); 211.8 (3-CO). ES-MS: m/z (%): 484 [M+Na]H
+
 (9%), 
462 [M]H
+
 (100%). HR-MS: m/z (%): calculated 484.2093, found 484.2094.
[192]
 
 
2E-2-Methylhex-2-enoylpantetheine-glycine (218). 
 
The obtained product was a yellow oil (14 mg, 0.03 mmol, 60%). 
1
H-NMR (D2O, 400 MHz): δ 0.91 (t, 
J = 7.2, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 0.98 (s, 3H, 20-CH3); 1.44-1.53 (m, 2H, 5-CH2); 1.86 (s, 3H, 
7-CH3); 2.24 (q, J = 7.2, 2H, 4-CH2); 2.46 (t, J = 6.7, 2H, 12-CH2); 3.08 (t, J = 6.1, 2H, 8-CH2); 3.40 (t, 
J = 6.5, 2H, 13-CH2); 3.44-3.53 (m, 2H, 9-CH2); 3.98 (s, 2H, 22-CH2); 4.00 (s, 1H, 16-CH) 4.09 (d, J = 
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11.4, 1H, 18-CH2); 4.19 (d, J = 11.4, 1H, 18-CH2); 6.80 (dt, J = 1.4, J = 7.6, 1H, 3-CH). 
13
C-NMR (D2O, 
100 MHz): δ 11.7 (7-CH3); 13.1 (6-CH3); 19.4 (19-CH3); 20.3 (20-CH3); 21.2 (5-CH2); 27.9 (8-CH2); 
30.3 (4-CH2); 35.1 (17-C); 35.4 (12-CH2); 37.6 (13-CH2); 38.7 (9-CH2); 39.8 (22-CH2); 71.6 (18-CH2); 
74.6 (16-CH); 135.7 (2-C); 143.9 (3-CH); 168.1 (21-CO); 173.7 (11-CO); 174.3 (15-CO); 197.5 (1-COS). 
ES-MS: m/z (%): 468 [M+Na]H
+
 (22%), 446 [M]H
+
 (100%). HR-MS: m/z (%): calculated 468.2144, 
found 468.2144.
[192]
 
 
2RS-2-Methyl-hexanoylpantetheine-glycine (219). 
 
The obtained product was a yellow oil (23 mg, 0.05 mmol, 12%). 
1
H-NMR (D2O, 400 MHz): δ 0.86 (t, 
J = 7.7, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 0.99 (s, 3H, 20-CH3); 1.14 (d, J = 6.8, 3H, 7-CH3); 1.26-1.30 
(m, 4H, 4-5-CH2); 1.41-1.66 (m, 2H, 3-CH2); 2.47 (t, J = 6.8, 2H, 12-CH2); 2.72-2.78 (m, 1H, 2-CH); 
3.04 (t, J = 6.3, 2H, 8-CH2); 3.38 (t, J = 6.5, 2H, 13-CH2); 3.45-3.54 (m, 2H, 9-CH2); 3.98 (s, 2H, 
22-CH2); 4.00 (s, 1H, 16-CH) 4.09 (d, J = 11.4, 1H, 18-CH2); 4.19 (d, J = 11.4, 1H, 18-CH2). 
13
C-NMR (D2O, 100 MHz): δ 13.1 (6-CH3); 17.2 (7-CH3); 19.4 (197-CH3); 20.3 (20-CH3); 22.2 (5-CH2); 
27.9 (8-CH2); 28.7 (4-CH2); 33.4 (3-CH2); 35.1 (17-C); 35.4 (12-CH2); 37.6 (13-CH2); 38.7 (9-CH2); 39.8 
(22-CH); 48.3 (2-CH); 71.6 (18-CH2); 74.6 (16-CH); 168.1 (21-CO); 173.6 (11-CO); 174.5 (15-CO); 
208.5 (1-COS). ES-MS: m/z (%): 470 [M+Na]H
+
 (13%), 448 [M]H
+
 (100%). HR-MS: m/z (%): 
calculated 448.2481, found 448.2481.
[192]
 
 
6.2.8 Synthesis of DH Domain substrates  
 
(2R, 3R)-3-(tert-Butyldimethylsilyloxy)-2-methyl-ethylbutanoate (184). 
 
Anhydrous THF (40 mL) was cooled down to -78 °C under nitrogen. Then LDA (21 mL, 2 mol/L) and 
3-hydroxy-ethylbutanoate (2.5 g, 18.9 mmol) were added dropwise. The solution stirred for 30 min. Then 
methyl iodide (50 mL, 2 mol/L) was added dropwise at -78 °C. The reaction stirred for 1.5 h and was then 
warmed up to 20 °C. It was quenched with 1 M HCl (30 mL). The phaseswere separated and the aqueous 
phase was adjusted to pH 1 with 1 M HCl and extracted with ethyl acetate (3 × 50 mL). The organic 
phaseswere combined, dried (MgSO4), filtered and concentrated in vacuo. A brown solution was 
obtained. This was used in the next step without further purification. The resulting residue was dissolved 
in dry dichloromethane (60 mL) under nitrogen. Then pyridine (3.2 mL, 39.7 mmol) was added and the 
solution was cooled to 0 °C. tert-butyldimethylsilyl triflate (5.2 mL, 22.7 mmol) was added dropwise. A 
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white solid was precipitated. The reaction stirred at 20 ◦C for 1 hour. Then it was quenched with NaHCO3 
(20 mL). The solid dissolved in the aqueous phase, which was extracted with dichloromethane (2 × 
50 mL). The organic phaseswere combined, dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified two times by flash column chromatography (hexane/ethyl acetate 97/3), which 
afforded 40 as a yellow oil (0.45 g, 1.8 mmol, 10.7% over two steps). Rf: 0.3 (hexane/ethyl acetate 97/3). 
1
H-NMR (400 M, CDCl3): δ (ppm) = 0.02 (s, 3H, 6-CH3), 0.05 (s, 3H, 7-CH3), 0.85 (s, 9H, 8-9-10-CH3), 
1.08 (d, J= 7.05, 3H, 4-CH3 ), 1.11 (d, J= 6.16, 3H, 5-CH3 ), 2.50 (m, 1H, 2-CH ), 3.66 (s, 3H, 12-CH3), 
4.00 (m, J= 6.15, 1H, 3-CH). 
13
C-NMR (100 M, CDCl3): δ (ppm) = −5.1 (6-CH3), −4.3 (7-CH3), 12.7 
(4-CH3), 17.9 (11-C), 20.6 (5-CH3), 25.7 (8-9-10-CH3), 48.1 (2-CH), 51.4 (12-CH3), 70.2 (3-CH), 125.6 
(1-CO). ES-MS: m/z (%): 261 [M]H
+
 (60%), 284 [M+Na]H
+
 (10%), 302 [M+CH3CN]H
+
 (100%), 259 
[M]H
+
 (20%).
[150]
 
 
(2R, 3R)- (3-(tert-Butyldimethylsiloxy)-2-methylbutanoic acid (185).  
 
The methyl Ester (0.45 g, 1.8 mmol, ) was dissolved in THF (5 mL) and MeOH (12 mL). Then LiOH 
(0.15 g, 3.6 mmol) in water (2 mL) was added. The reaction mixture was heated to 60 °C overnight. Then 
it was diluted with water (10 mL). The aqueous phase was extracted with Et2O (2 × 20 mL). Then it was 
acidified to pH 3 with H2SO4 (6 M) and further extracted with ethyl acetate (3 × 15 mL). The organic 
layers were combined, dried (MgSO4), filtered and concentrated in vacuo. The yellow residue was 
purified by column chromatography (10% ethyl acetate/ hexane/ 0.5% acetic acid). A yellow oil was 
afforded (0.38 g, 1.6 mmol, 89%). Rf: 0.3. 
1
H-NMR (400 M, CDCl3): δ (ppm) = 0.10 (s, 3H, 6-CH3), 0.12 
(s, 3H, 7-CH3), 0.9 (s, 9H, 8-9, -10-CH3), 1.22 (d, J= 7.21, 3H, 4-CH3), 1.24 (d, J= 6.24, 3H, 5-CH3), 2.53 
(m, 1H, 2-CH), 3.98 (m, 1H, 3-CH). 
13
C-NMR (100 M, CDCl3): δ (ppm) = −5.1 (6-CH3), −4.4 (7-CH3), 
14.4 (4-CH3), 17.9 (11-C), 21.5 (5-CH3), 25.7 (8-9-10-CH3), 47.4 (2-CH), 70.6 (3-CH). IR ( = cm
-1
): 
2955 (C-H), 2930 (C-H), 2886 (C-H), 2857 (C-H), 1707 (C=O). ES-MS: m/z (%): 233 [M]H
+
 (90%), 215 
[M+H2O]H
+
 (10%), 256 [M+Na]H
+
 (20%), 231 [M]H
+
 (100%). HR-MS: m/z (%): calculated: 231.1407, 
found: 231.1416.
[150]
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(2R, 3R)-3-(tert-Butyldimethylsilyloxy)-2-methylbutyl pantetheine dimethyl ketal (186). 
 
The protected acid (0.38 g, 1.6 mmol) was mixed with EDCI (0.31 g, 1.6 mmol), DMAP (0.1 eq, 11.5 
mg, 0.1 mmol) and pantetheine dimethyl ketal (0.51 g, 1.6 mmol) and dissolved in dichloromethane (8 
mL). The reaction mixture stirred for 22 hours. It was quenched with 2 M HCl (20 mL). The aqueous 
phase was extracted with dichloromethane (3 × 25 mL). The organic phaseswere combined, dried 
(MgSO4), filtered and concentrated in vacuo. Flash chromatography (ethyl acetate) afforded a colourless 
oil (0.64 g, 1.2 mmol, 75%). Rf :0.5 (ethyl acetate). 
1
H-NMR (400 M, CDCl3): δ (ppm) = 0.00 (s, 3H, 
6-CH3), 0.04 (s, 3H, 7-CH3), 0.85 (s, 9H, 8-9-10-CH3), 0.91 (s, 3H, 23-CH3), 0.97 (s, 3H, 22-CH3), 1.09 
(m, 3H, 5-CH3), 1.11 (m, 3H, 4-CH3), 1.42 (s, 3H, 27-CH3), 1.46 (s, 3H, 26-CH3), 2.41 (t, 2H, 16-CH2), 
2.68 (m, 2H, 12-CH2), 2.95 (m, 1 H, 2-CH), 3.27 (d, J= 11.67, 1H, 24b-CH2), 3.42 (m, 2H, 17-CH2), 3.57 
(m, 2H, 13-CH2), 3.67 (d, J= 11.75, 1H, 24a-CH2), 4.02 (m, 1H, 3-CH), 4.07 (s, 1H, 20-CH), 6.09 (t, J = 
5.63, 1H, 14-NH), 7.03 (t, J= 5.85, 1H, 18-NH). 
13
C-NMR (100 M, CDCl3): δ (ppm) = −5.2 (6-CH3), 
−4.3 (7-CH3), 14.2 (4-CH3), 18.0 (11-C), 18.7 (22-CH3), 19.0 (23-CH3), 21.7 (5-CH3), 25.7 (8-9-10-CH3), 
28.3 (12-CH2), 29.5 (27-CH3), 30.0 (26-CH3), 33.0 (17-CH2), 34.8 (16-CH2), 36.0 (21-C), 39.7 (13-CH2), 
56.7 (2-CH), 70.1 (3-CH), 71.0 (24-CH2), 77.7 (20-CH), 99.1 (25-C), 170.1 (15-CO), 171.1 (19-CO), 
202.7 (1-COS). IR ( = cm-1): 2953 (C-H), 2930 (C-H), 2857 (C-H), 1655 (C=O). ES-MS: m/z (%): 533 
[M]H
+
 (100%), 556 [M+Na]H
+
 (5%), 531 [M]H
+
 (10%). HR-MS: m/z (%): calculated: 555.2900, found: 
555.2897.
[150]
 
  
(2R, 3R)- 3-Hydroxy-2-methylbutyrylpantetheine (187).  
 
The compound (0.64 g, 1.2 mmol) was dissolved in dichloromethane (1 mL). Then trifluoroacetic acid 
(0.2 mL) was added and the reaction stirred for 10 min. Water (1 mL) was added and it stirred for further 
10 min. The product was purified by HPLC, which afforded a colourless oil (0.13 g, 0.3 mmol, 25%). 
1
H-NMR (400 M, CDCl3): δ (ppm) = 0.92 (s, 3H, 17-CH3), 1.02 (s, 3H, 16-CH3), 1.13 (d, J= 7.03, 3H, 
4-CH3), 1.24 (d, J= 6.26, 3H, 5-CH3), 2.40 (m, 2H, 10-CH2), 2.66 (m, 2H, 6-CH2), 2.85 (m, 1H, 2-CH), 
3.25 (m, 1H, 18b-CH2), 3.48 (m, 2H, 11-CH2), 3.59 (m, 2H, 7-CH2), 3.73 (m, 2H, 18-CH2), 3.95 (m, 1H, 
3-CH), 4.02 (s, 1H, 14-CH), 6.43 (t, J= 5.08, 1 H, 8-NH), 7.40 (t, J= 6.00, 1 H, 12-NH). 
13
C-NMR (100 M, CDCl3): δ (ppm) = 14.9 (4-CH3), 20.3 (5-CH3), 21.2 (17-CH3), 21.7 (16-CH3), 28.8 
(6-CH2), 35.4 (11-CH2), 35.7 (10-CH2), 38.8 (15-C), 39.3 (7-CH2), 56.6 (C2 ), 70.3 (3-CH), 70.9 
(18-CH2), 77.7 (14-CH), 171.9 (9-CO), 174.2 (13-CO), 203.8 (1-COS). HR-MS: m/z (%): calculated: 
401.1722, found: 401.1718.
[150]
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6.2.9 Synthesis of AT Domain Substrates  
 
[1S-[1(4R, 5S)3, 4, 5, 6, 7]]-1-(4-Hydroxy-5-methyl-3-methylene-6-phenyl-hexyl)-4, 6, 7-
trihydroxy-2, 8-dioxabicyclo[3.2.l]octane-3, 4, S-tricarboxylic-acid (Full hydrolysis of Squalestatin 
S1) (245).
[97] 
 
To a solution of Squalestatin S1 (0.10 g, 0.14 mmol) in ethanol/water 5:1 (5 ml/ 1 ml) potassium 
hydroxide (0.66 g, 11.00 mmol) was added. After stirring under reflux for 3 hours diethyl ether was 
added. The mixture was washed with NaHCO3 (3x 10 ml). The aqueous layer was acidified with 2M HCl 
until pH 1 and extracted with ethyl acetate (3x 10 ml). The organic layer was dried over MgSO4 and 
concentrated under vacuo. 0.01 g (0.02 mmol, 14%) of the product were purified by HPLC. 
1
H-NMR (CD3CN, 400 MHz): δ 0.82 (d, 3H, J = 6.9, 20-CH3), 1.98-2.50 (m, 5H, 9-10-14-CH2); 2.75 (m, 
1H, dd, J = 5, 13, CH2Ph), 3.93 (d, 1H, J = 4.9, 12-CH), 4.05 (d, 1H, J = 2.0, 7-CH); 4.95-4.99 (m, 2H, 
19-CH2); 5.05-5.09 (m, 1H, 6-CH); 5.12 (s, 1H, 3-CH); 7.10-7.23 (m, 2H, 16-18-CH); 7.27-7.32 (m, 1H, 
17-CH). ES-MS: m/z (%): 519 [M+Na]H
+
 (12%), 497 [M]H
+
 (27%). 
 
[1S-[1(4R, 5S)3, 4, 5, 6, 7]]-1-(4-Hydroxy-5-methyl-3-methylene-6-phenyl-hexyl)-4, 6, 7-
trihydroxy-2, 8-dioxabicyclo[3.2.l]octane-3, 4, S-tricarboxylic-acid (Full hydrolysis of Squalestatin 
S1) (244).
[97]
 
 
To A solution of Squalestatin S1 (0.10 g, 0.14 mmol) in ethanol/water 5:1 (5 ml/ 1 ml) potassium 
hydroxide (0.044 g, 0.08 mmol) was added. After stirring under reflux for 3 hours diethyl ether was 
added. The mixture was washed with NaHCO3 (3x 10 ml). The aqueous layer was acidified with 2M HCl 
until pH 1 and extracted with ethyl acetate (3x 10 ml). The organic layer was dried over MgSO4 and 
concentrated under vacuo. 0.01 g (0.018 mmol, 13%) of the product were purified by HPLC. 
1
H-NMR (CD3CN, 400 MHz): δ 0.85 (d, 3H, J = 7.6, 20-CH3), 1.96-2.38 (m, 4H, 9-10-CH2); 2.08 (s, 
3H, 35-CH3), 2.48 (dd, 1H, J = 5, 13, 14-CH2), 2.68 (dd, 1H, J = 5, 13, 14-CH), 4.04 (d, 1H, J = 2.1, 
7-CH); 4.92-5.11 (m, 3H, 6-12-19-CH/CH2); 5.11 (s, 1H, 1-CH), 7.19-7.22 (m, 2H, 16-18-CH); 7.28-7.32 
(m, 1H, 17-CH). ES-MS: m/z (%): 556 [M+H2O]H
+
 (12%), 539 [M]H
+
 (27%), 497 [M-C2H3O] 100%. 
 
181 
 
[1S-[1(4R, 5S)3, 4, 5, 6, 7]]-1-(4-Hydroxy-5-methyl-3-methylene-6-phenyl-hexyl)-4, 6, 7-
trihydroxy-2, 8-dioxabicyclo[3.2.l]octane-3, 4, S-tricarboxylic-acid (Full hydrolysis of Squalestatin 
S1) (246).
[97]
 
 
To A solution of Squalestatin S1 (0.10 g, 0.14 mmol) in ethanol/water 5:1 (5 ml/ 1 ml) potassium 
hydroxide (0.044 g, 0.08 mmol) was added. After stirring under reflux for 3 h diethyl ether was added. 
The mixture was washed with NaHCO3 (3x 10 ml). The aqueous layer was acidified with 2M HCl until 
pH 1 and extracted with ethyl acetate (3x 10 ml). The organic layer was dried over MgSO4 and 
concentrated under vacuo. 0.01 g (0.015 mmol, 11%)  of the product were purified by HPLC. 
1
H-NMR (CD3CN, 400 MHz): δ 0.85 (m, 9H, 20-31-33-CH3), 1.03 (d, 3H, J = 6.4, 32-CH3), 1.10-1.15 
(m, 2H, 28-30-CH2); 1.24-1.42 (m, 3H, 28-29-30-CH2/CH); 1.99-2.23 (m, 4H, 9-10-13-CH2/CH); 
2.35-2.51 (m, 3H, 10-14-27-CH2/CH), 2.72 (dd, 1H, J = 5, 13, 14-CH), 3.92 (d, 1H, J = 4.9, 12-CH), 4.12 
(d, 1H, J = 2.0, 7-CH), 4.96 (s, 1H, 19- CH2); 5.08 (s, 1H, 19-CH2); 5.75 (dd, 1H, J = 1.0, 16.0, 25-CH); 
6.74-6.85 (m, 1H, 26-CH); 7.16-7.22 (m, 2H, 16-18-CH); 7.26-7.30 (m, 1H, 17-CH). ES-MS: m/z 
(%):649 [M]H
+
 (27%), 631 [M-H2O]H
+
 (100%), 613 [M-2x H2O]H
+
 (62%).
 
 
Preparation of 4-6-dimethyloct-2-enoyl-CoA (248).  
 
To a solution of (4S, 6S)- Dimethyloctenoic acid (10 mg, 0.05 mmol) in fresh destillated THF (1mL) was 
added carbonyldiimidazole (10 mg, 0.06 mmol). This solution was controlled by LCMS to a complete 
activation of the acid (nearly 1 h). After that Coenzyme A (47 mg, 0.06 mmol) in 1 mL water was added 
to the solution and controlled by LCMS. The product was only analysed by LCMS and directly used 
reasoned on the instability of the compound.
[97]
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Preparation of 2-methylhex-2-enoyl-CoA (263).  
 
To a solution of 2-methylhexenoic acid (10 mg, 0.07 mmol) in fresh destillated THF (1mL) was added 
carbonyldiimidazole (12 mg, 0.08 mmol). This solution was controlled by LCMS to a complete activation 
of the acid (nearly 1 h). After that Coenzyme A (60 mg, 0.08 mmol) in 1 mL water was added to the 
solution and controlled by LCMS. The product was only analysed by LCMS and directly used reasoned 
on the instability of the compound.
[97]
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7.0 Biochemical and Biophysical Investigations 
7.1 SQTKS-ER domain 
 
Transformation of pET28-SQTKS-ER into E. coli Top10 
50 μL chemically competent E. coli Top10 cells were thawed on ice and incubated on ice for 30 min with 
1 μL of the appropriate vector. For the heat shock transformation, the cells were incubated at 42 °C for 
30 s, then immediately chilled on ice for 2 min. 250 μL SOC medium were added. The transformed cells 
were shaken (200 rpm) for 1 h at 37 °C. Positive clones were selected by plating 50 - 150 μl of the cells 
on solid LB medium containing the appropriate antibiotic. The cells were grown over night at 37 °C. 
 
Transformation of pET28-SQTKS-ER into E. coli BL21 
50 μL chemically competent E. coli BL 21 cells were thawed on ice and incubated on ice for 30 min with 
1 μL of the SQTKS-ER domain. For the heat shock transformation, the cells were incubated at 42 °C for 
10 s, then immediately chilled on ice for 2 min. 800 μl SOC medium were added. The transformed cells 
were shaken (200 rpm) for 1 h at 37 °C. Positive clones were selected by plating 50 - 150 μL of the cells 
on solid LB medium containing the appropriate antibiotic. The cells were grown over night at 37 °C. 
 
Protein expression and purification 
A starter culture was prepared by scraping the surface of a glycerol stock of E.coli BL21 transformed 
with pET28-ER. The cells were grown in LB media with kanamycin (50 mg/mL) and incubated at 37 °C, 
200 rpm, over night. 1 ml of the starter culture was added to 100 mL 2TY media. The cells were 
incubated to an OD600 of 0.6, then the flask was cooled down to 16 °C and induced with 50 µl 1M IPTG 
solution. This solution was incubated over night at 16 °C, 200rpm. 
 To isolate the protein, the media was centrifuged at 7000 rpm for 15 min and the pellet was 
collected. The cells could be used immediately or frozen at -80 °C. The cells were suspended in 50 ml of 
nickel column wash buffer (50 mM Tris pH 8, 150 mM NaCl, 20% glycerol (v/v) and 20 mM imidazole) 
and sonicated on ice for 6.5 minutes. Every 30 second the sonicator was switched on and of. The rest of 
the solution was centrifuged at 8500 rpm for 30 min, filtered and purified by a nickel column*. For this a 
linear gradient of elution buffer (50 mM Tris pH 8, 150 mM NaCl, 20% glycerol (v/v) and 0.5 M 
imidazole) was used. The fractions were checked by SDS gel and the fractions with the correct mass were 
combined and concentrated. A second purification was done by a size exclusion column 
chromatography**. The protein solution was loaded onto the column and eluted with size exclusion 
elution buffer (Buffer: 50 mM Tris pH 8, 150 mM NaCl, 20% glycerol (v/v)). The fractions were 
analyzed again by SDS gel and the protein with the correct mass and high purity was combined and 
concentrated. The concentration of protein was estimated by a calculated absorption coefficient  = 0.69 
at 280 nm. After that the protein was divided into several aliquots and stored at - 80 °C.
[104]
 
 
*Nickel column Protino Ni-NTA Columns 5 mL  
**Size exclusion column- HiLoad 26/600 Superdex 200pg (GE Healthcare), 320 ml. 
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SQTKS-ER Domain Comparison SNAC/Pantetheine Assays
 
Assays with acyl-SNAC substrates were performed using stocks of acyl-SNAC (10 mM), NADPH (10 
mM), Tris pH 8.5 (1 M), glycerol (50% v/v) and SQTKS-ER (0.2 mU/µl). Assays were conducted at 
(final concentration, volume of stock): acyl-SNAC (0.5 mM, 10 µl), NADPH (0.75 mM, 15 µl), Tris 
buffer pH 8.5 (50 mM, 10 µL), glycerol (20% v/v, 80 µL), SQTKS-ER (4 mU, 20 µL) and water (65 µL), 
to a total volume of 200 µL.  
 Assays with acyl PANT substrates were performed using stocks of acyl PANT (10 mM), 
NADPH (10 mM), Tris pH 8.5 (1 M), glycerol (50% v/v) and SQTKS-ER (0.2 mU/µL). Assays were 
conducted at (final concentration, volume of stock): acyl PANT (0.5 mM, 10 µL), NADPH (0.75 mM, 
15 µL), Tris buffer pH 8.5 (50 mM, 10 µL), glycerol (20% v/v, 80 µl), SQTKS-ER (1 mU, 5 µL) and 
water (80 µL), to a total volume of 200 µL.  
 
SQTKS-ER Domain Kinetic Assays 
Assays were run in 500 µL quartz cuvettes with a path length of 1 cm and the absorption was measured at 
340 nm against a standard cuvette at 25 ˚C. Assays with acyl PANT substrates were performed using 
stocks of acyl PANT (5 mM), NADPH (10 mM), Tris pH 8.5 (1 M), glycerol (50% v/v) and SQTKS-ER 
(0.08 U/µl). Assays were conducted at (final concentration, volume of stock): acyl PANT (62.5 µM – 
500 µM, 5 - 40 µl); NADPH (250 µM, 10 µl); SQTKS-ER (20 µL, 4 mU); Buffer (330 - 365 µl) in a total 
volume 400 µl. Reactions were run in triplicate. Initial rates were plotted vs substrate concentration.*  
*10 LTris pH 8.5 (1 M), 80 L glycerol (50% v/v), 100 L water  
 
Polymerase-chain-reaction (PCR)  
The successful transformation of BL21 cells was configured by PCR. For standard PCR amplification the 
Taq DNA polymerase NEB was used according to the manufacturer’s instruction. For a colony PCR the 
template was added by transferring a small part of a single E.coli colony into the reaction mixture using a 
sterile toothpick. For each primer pair the specific annealing temperature was determined in a PCR 
temperature gradient. For efficient DNA amplification 30 PCR cycles were applied.  
 
Bradford assay 
Standard solutions of bovine serum albumin (0.1-2 ml/ml) in size exclusion buffer [50 mM Tris pH 8, 
150 mM NaCl, 20% glycerol (v/v)] were prepared by serial dilution. 100 μl of the standards were mixed 
with Bradford dye reagent (1 ml) and incubated for 15 mins at RT. The absorption of each sample was 
measured at 595 nm against a standard (size exclusion buffer 100 μl, Bradford dye reagent, 1 ml) to 
construct a standard concentration curve. A sample of the protein to be quantified (20 μl) was diluted in 
size exclusion buffer (80 μl) and treated with Bradford dye reagent (1ml). This was incubated at room 
temperature for 15 mins and then the absorption was measured at 595 nm. This was compared to the 
previously prepared concentration curve to calculate the amount of protein that had been produced. 
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7.2 SQTKS-DH Domain 
 
Transformation of pET28-SQTKS-DH into E. coli BL21 
50 μL chemically competent E. coli BL 21 cells were thawed on ice and incubated on ice for 30 min with 
1 μl of the SQTKS-DH domain. For the heat shock transformation, the cells were incubated at 42 °C for 
10 s, then immediately chilled on ice for 2 min. 800 μl SOC medium were added. The transformed cells 
were shaken (200 rpm) for 1 h at 37 °C. Positive clones were selected by plating 50 - 150 μl of the cells 
on solid LB medium containing the appropriate antibiotic. The cells were grown over night at 37 °C. 
 
Protein expression and purification 
A starter culture was prepared by scraping the surface of a glycerol stock of E.coli BL21 transformed 
with pET28-DH. The cells were grown in LB media with carbenicillin (stock 50 mg/mL concentration 
50 L / 50 mL) and incubated at 37 °C, 200 rpm, over night. 1 ml of the starter culture was added to 
100 mL LB media. The cells were incubated to an OD600 of 0.6, then the flask were cooled down to 14 °C 
and induced with 50 µl 1M IPTG solution. This solution was incubated over night at 14 °C, 200rpm. 
 To isolate the protein, the media was centrifuged at 7000 rpm for 15 min and the pellet was 
collected. The cells could be used immediately or frozen at -80 °C. The cells were suspended in 50 ml of 
nickel column wash buffer (20 mM Tris pH 8, 150 mM NaCl, 10% glycerol (v/v), 5 mM imidazole, 
25 mM L-Arginine and L-Glutamic acid) and sonicated on ice for 6.5 minutes. Every 30 second the 
sonicator was switched on and of. The rest of the solution was centrifuged at 8500 rpm for 30 min, 
filtered and purified by a nickel column*. For this a linear gradient of elution buffer (20 mM Tris pH 8, 
150 mM NaCl, 10% glycerol (v/v), 0.4 M imidazole, 25 mM L-Arginine and L-Glutamic acid) was used. 
The fractions were checked by SDS gel and the fractions with the correct mass were combined and 
concentrated to 14 mL. Reasoned on precipitation in the present of imidazole the protein was desalted 
with a HiPrepTM 26/10 desalting column. One and a half column volumes were used (20 mM Tris-HCl 
pH 8, 150 mM NaCl, 10 % glycerol, 25 mM L-Arginine and L-Glutamic acid) and collected in fractions. 
These fractions were analysed by SDS gel and concentrated. 
 
SQTKS-DH Domain Assays: Assays were run in 500 µl quartz cuvettes with a path length of 1 cm and 
the absorption was measured at 260 nm against a standard cuvette at 25 ˚C. Assays with acyl PANT 
substrates were performed using stocks of acyl PANT (5 mM), Tris pH 8.5 (1 M), glycerol (50% v/v) and 
SQTKS-DH (0.01 U/min).  
Assays were conducted at (final concentration, volume of stock): acyl PANT (62.5 µM - 500 µM, 
5-40 µl); SQTKS-DH (20 µL); Buffer (340– 375 µl) in a total volume 400 µl. Reactions were run in 
triplicate. Initial rates were plotted vs substrate concentration.*  
*10 LTris pH 8.5 (1 M), 80 L glycerol (50% v/v), 100 L water 
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7.3 SPR investigation 
 
Sensorchip installation 
SPR sensor chip HC1000m was installed under a continuous flow of 10 L/min at 20 °C on the SPR 
equipment. During this installation, double destilled water was used as standard buffer. After successful 
installation, the whole system was washed for 20 min with double destilled water. The flow rate was 
settled to 250L/min to remove inpurities and air bubbles out of the system. 
Surface modification 
Modification of the surface was performed in a 10 mM maleate solution that was calibrated to pH 7. A re-
buffering of the system with 250L/min was performed at 20 °C.  
After that modification of the surface was started with an activation mix that contains 100 mM 
EDCI. The flow rate was settled down to 10 L/min and an incubation over 15 min was performed. This 
step was repeated 3 times. The incubated surface was overflowed with the cross linked material at the 
same flow rate. This step was repeated 3 times. The concentration of the used cross linkers was 10 mmol. 
Additionally the whole surface was washed with ethanolamine (25 mmol solution) to block possible 
active residues of the surface that did not interact with the substrate. Finally, several wash runs with 
double destilled water were processed to clean the surface from potential residues that could influence the 
final measuring of the system. 
Surface plasmon resonance spectroscopy 
 A re-buffering was performed for the final investigations. Investigations of the ER domain were 
executed in 50 mM Tris pH 8, 150 mM NaCl, 20% glycerol (v/v), DH domain in 20 mM Tris-HCl pH 8, 
150 mM NaCl, 10 % glycerol, 25 mM L-Arginine and L-Glutamic acid.  
An overflow of the surface was performed with different protein concentrations (0.25 mg/mL, 
0.5 mg/mL, 1 mg/mL, 2 mg/mL, 4 mg/mL, 6 mg/mL and 10 mg/mL). Constant flow rates were used of 
10L/min and 25 L/min at 20 °C. Regeneration of the surface was performed with 1.5 M NaCl solution 
in the same buffer that was used for the loaded protein. Finally the analysis of the interactions was 
determined with an internal software of the SPR instrument. 
7.4 Isothermal Titration Calorimetry 
 
Reference and sample cell were adjusted to 20 °C. In both cells 150 L reference 0.1 mM solution of 
SQTKS-ER was added. For the protein stock solution a buffer of 50 mM Tris pH 8, 150 mM NaCl and 
20% glycerol (v/v) was used. Same buffer that showed good properties in stability and activity for the 
enzyme. The ligand tigloylpantetheine (1.4 M) was titrated in the sample cell. Twenty injections were 
performed over a time of 7000 seconds. The volume of each injection was 2.69 L of the ligand 
tigloylpantetheine. Final results were calculated with internal software of the ITC equipment. 
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9.0 Appendix 
9.1 DH Domain: 
Further SPR results with DH domain 
 
A1: DH overflow of 209. Protein concentrations are shown by the different colours: 1 mg/ mL, black, 
2 mg/ mL, green, 4 mg/ mL, yellow, 6 mg/ mL, purple, 10 mg/ mL, blue. 
 
 
A2: DH overflow of 210. Protein concentrations are shown by the different colours: 1 mg/ mL, black, 
2 mg/ mL, red, 4 mg/ mL, blue, 6 mg/ mL, purple, 10 mg/ mL, green. 
 
A3: DH overflow of 212. Protein concentrations are shown by the different colours: 1 mg/ mL, green, 
2 mg/ mL, black, 4 mg/ mL, red; 6 mg/ mL, yellow, 10 mg/ mL, blue. 
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A4: DH overflow of 213. Protein concentrations are shown by the different colours: 1 mg/ mL, purple, 
2 mg/ mL, green, 4 mg/ mL, red; 6 mg/ mL, blue, 10 mg/ mL, green. 
 
9.2 ER domain: 
Further SPR results of ER domain 
 
A5: ER overflow of 215. Protein concentrations are shown by the different colours: 1 mg/ mL, black, 
2 mg/ mL, yellow, 4 mg/ mL, blue; 6 mg/ mL, dark blue, 10 mg/ mL, purple. 
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A6: ER overflow of 216. Protein concentrations are shown by the different colours: 1 mg/ mL, green, 
2 mg/ mL, blue, 4 mg/ mL, yellow; 6 mg/ mL, turquoise, 10 mg/ mL, purple. 
 
A7: ER overflow of 217. Protein concentrations are shown by the different colours: 1 mg/ mL, blue, 
2 mg/ mL, purple, 4 mg/ mL, brown; 6 mg/ mL, green, 10 mg/ mL, red. 
 
A8: ER overflow of 209. Protein concentrations are shown by the different colours: 0.5 mg/ mL, green, 
1 mg/ mL, yellow, 2 mg/ mL, brown, 4 mg/ mL, purple; 6 mg/ mL, blue, 10 mg/ mL, red. 
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A9: ER overflow of 211. Protein concentrations are shown by the different colours: 1 mg/ mL, green, 
2 mg/ mL, black, 4 mg/ mL, red; 6 mg/ mL, yellow, 10 mg/ mL, blue. 
 
A10: ER overflow of 213. Protein concentrations are shown by the different colours: 1 mg/ mL, red, 
2 mg/ mL, blue, 4 mg/ mL, purple; 6 mg/ mL, green, 10 mg/ mL, black.
 
196 
 
Wissenschaftlicher Werdegang 
 
Christoph Bartel, geboren am 07.04.1986 in Salzgitter-Bad 
 
-Schulbesuch von 1992 bis 2005; Abschluss der allgemeinen Hochschulreife am 
Gymnasium in Salzgitter Bad im Juni 2005. 
 
-Oktober 2006 bis November 2010; Bachelorstudium der Chemie an der Gottfried 
Wilhelm Leibniz Universität, Abschlussarbeit im Bereich der Metallorganischen 
Chemie 
 
-Oktober 2010 bis Dezember 2012; Masterstudium an der Technischen Universität 
Braunschweig, Vertiefung im Bereich der Biologischen Chemie 
 
-Mai 2013- Februar 2017, Promotionsstudent an der Gottfried Wilhelm Leibniz 
Universität 
 
 
Veröffentlichungen, Publikationen 
 
(1) B. Bonsch, V. Belt, C. Bartel, N. Duensing, M. Koziol, C. M. Lazarus, T. J. 
Simpson and R. J. Cox; Chem. Commun., 2016, 52, 6777-6780.  
(2) D. M. Roberts, C. Bartel, A. Scott, D. Ivison, T. J. Simpson, R. J. Cox; Chem. 
Sci., 2017, 8, 1116-1126. 
 
